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Background/aims: Testicular cancer (TC) is the most common cancer among young men aged 20-
40 years. The cure rates are excellent, an important factor being the chemotherapeutic agent 
cisplatin. This thesis aimed to investigate how TC treatment influenced the subsequent risk for 
metachronous contralateral (second) TC, non-TC second cancer (SC) and non-TC mortality.  
Methods: The Cancer Registry of Norway (CRN) identified all men diagnosed with TC 1980-2009. 
Complete TC treatment information was retrieved from medical journals for all eligible men 
(n=5724), and linked with the CRN and the Norwegian Cause of Death Registry. Crude cumulative 
incidences were estimated, and standardized incidence ratios (SIRs) and standardized mortality 
ratios (SMRs) were calculated to compare rates with the general population. Adjusted hazard ratios 
(HRs) were estimated to investigate the effect of treatment intensity. 
Results: Median follow-up time in the three papers was 16.6-18.7 years. Second TC developed in 
218 (3.9%) men, and the 20-year cumulative incidence was 4% (95% CI 3.5-4.6). Treatment with 
cisplatin-based chemotherapy (CBCT) at first TC was associated with a significantly reduced 
second TC risk compared with surgery (HR 0.55). A dose-dependent relationship was observed, 
with a risk reduction for each additional CBCT cycle after 3, 4 and >4 cycles (HRs 0.53, 0.41 and 
0.21, respectively). Additionally, older age at first TC was associated with a reduced second TC 
risk. Overall, 572 (10.2%) men developed a non-TC SC, and compared with the general population 
the risk was increased after treatment with surgery (SIR 1.28, 95% CI 1.05-1.56), CBCT (SIR 1.62, 
95% CI 1.39-1.88) and radiotherapy (SIR 1.64, 95% CI 1.46-1.85). In total, 665 (12%) men died 
due to non-TC causes during follow-up, and the risk was increased after CBCT (SMR 1.23, 95% CI 
1.07-1.43) and radiotherapy (SMR 1.28, 95% CI 1.15-1.43), but not after surgery. Compared with 
the general population, increased risk for suicide was observed after treatment with CBCT. The 
highest risk for SC and non-TC mortality was observed in those with young age at TC diagnosis. 
Compared with surgery, treatment with 1 CBCT cycle was not associated with increased risks, 
while increased risks were observed after ≥2 (SC) and ≥3 (mortality) CBCT cycles in those with 
>10 years follow-up.  
Conclusions: Previous TC treatment as well as age at diagnosis influenced the subsequent risks for 
second TC, SC and premature non-TC mortality. This information is important for all TC survivors 





Bakgrunn: Testikkelkreft er den vanligste kreftsykdommen blant unge menn. Heldigvis kureres de 
aller fleste, og cellegiften cisplatin er en viktig årsak til dette. Målsetninga med denne avhandlinga 
var å undersøke hvordan testikkelkreftbehandling påvirker den seinere risiko for å utvikle metakron 
kontralateral testikkelkreft (ny testikkelkreft), sekundærkreft (ikke testikkelkreft) og risiko for død 
av andre årsaker enn testikkelkreft. 
Metode: Kreftregisteret identifiserte alle menn diagnostisert med testikkelkreft i perioden 1980-
2009. Komplett informasjon om behandling ble samla fra medisinske journaler for alle menn 
inkludert i studien (n=5724) og koblet med data fra Kreftregisteret og Dødsårsaksregisteret. 
Kumulativ insidens ble estimert. For å sammenligne med den generelle befolkning kalkulerte vi 
standardisert insidensratio (SIR) og standardisert mortalitetsratio (SMR). Justerte hasard ratio (HR) 
ble estimert for å undersøke effekten av behandlingsintensitet. 
Resultater: Median oppfølgingstid i de tre arbeidene var 16.6-18.7 år. Det var 218 (3.9%) menn 
som utviklet en ny testikkelkreft, og 20 års kumulativ insidens var 4% (95% konfidensintervall (KI) 
3.5-4.6). Behandling med cisplatin-basert cellegift (CBCT) ved første testikkelkreft var assosiert 
med en signifikant reduksjon i risiko for ny testikkelkreft sammenligna med kirurgi (HR 0.55). Vi 
observerte en dose-respons-sammenheng med en risikoreduksjon for hver påfølgende kur med 
CBCT etter 3 (HR 0.53), 4 (HR 0.41), >4 (HR 0.21). Alder >30 år ved første testikkelkreft var også 
assosiert med redusert risiko for en ny testikkelkreft. Totalt var det 572 (10.2%) menn som utviklet 
sekundærkreft, og sammenligna med den generelle befolkning var risikoen økt etter kirurgi (SIR 
1.28, 95% KI 1.05-1.56), CBCT (SIR 1.62, 95% KI 1.39-1.88) og strålebehandling (SIR 1.64, 95% 
KI 1.46-1.85). Det var 665 (12%) menn som døde av andre årsaker enn testikkelkreft, og risikoen 
var forhøyet etter behandling med CBCT (SMR 1.23, 95% KI 1.07-1.43) og strålebehandling (SMR 
1.28, 95% KI 1.15-1.43), men ikke etter kun kirurgi. Sammenligna med generell befolkning fant vi 
en økt risiko for selvmord etter behandling med CBCT. Den høyeste risikoen for sekundærkreft og 
død (ikke testikkelkreft) ble observert blant de som var yngst ved testikkelkreftdiagnosen.  
Konklusjon: Testikkelkreftbehandling og alder ved diagnose påvirker den seinere risikoen for ny 
testikkelkreft, sekundærkreft og for tidlig død. Dette er viktig informasjon for testikkelkreft-







The study has used data from the Cancer Registry of Norway. The interpretation and reporting of 
these data are the sole responsibility of the authors, and no endorsement by the Cancer Registry of 
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1 Introduction  
1.1 Background and epidemiology of germ cell testicular cancer 
(TC) 
Germ cell testicular cancer (TC) is a rare malignancy as it represents only 1-2% of all malignancies 
in Norway, corresponding to about 300 new TC cases annually. Despite this, it is the most common 
cancer in men aged 15-49 years in Norway.1 Without a clear explanation, the TC incidence in 
Norway increased gradually from 1965, with a plateau reached in 2007 with an age-adjusted (world 
standard) incidence rate of 12.8/100.000 (Figure 1).1,2 In 2019, the incidence rate was 
10.7/100.000.1 Europe has the highest incidence of TC in the world, and the incidence has been 
increasing since at least mid-20th century.3 Northern European countries, with Norway and 
Denmark as the countries with the highest incidences, have had the topmost incidence rates, but it 
has stabilized somewhat in recent years. Both the rising incidence and the stabilization are largely 
unexplained.3 During the last decades, a rising incidence has been observed in Eastern and Southern 
Europe, and the incidence has also been increasing in some Middle Eastern countries as well as 
countries in Latin America and the Caribbean.3 
 
Figure 1. Age-adjusted incidence, mortality and 5-year relative survival of testicular cancer in 







Fortunately, the survival rates are excellent with 15-year relative survival rates exceeding 
98% in Norway (Figure 1), and TC now has the highest five-year relative survival among all 
cancers in Norway.1 In Europe, the age-standardized 5-year relative survival has been around 90% 
from 1999-2007, and the 5-year relative survival conditional to surviving one year is 95% in most 
countries.4 However, mortality rates vary across different countries.5 
As demonstrated in Figure 1, the survival improved dramatically during the late 1970s, the 
most important reason being the introduction of cisplatin in the treatment of metastatic TC.6 
Additionally, treatment according to a risk stratification system with serum tumor markers elevation 
and half-life to guide diagnosis and treatment effect, improvements of diagnostic imaging, timing of 
surgery of residual masses, potent salvage chemotherapy and multimodal therapy are important co-
factors for the high cure rates.7-10  
As a consequence of the increased incidence and the exceptionally high survival, the number 
of long-term TC survivors (TCS) has been growing. The number of Norwegian TCS alive more 
than 10 years after diagnosis have increased from 3400 in 2009 to 5221 in 2019.1,11 Likewise, the 
prevalence of men alive in Norway with a history of TC has doubled during the last two decades as 
demonstrated in Figure 2.  
Figure 2. Number of men alive in Norway with a history of testicular cancer diagnosis in 1999, 






























1.2 Risk factors and pathogenesis of germ cell TC 
The two main functions of the testicles are the sperm cell production (by Sertoli cells) and the 
testosterone production (by Leydig cells).12 Several traits are associated with TC; atrophic testis 
(<12 mL), cryptorchidism, hypospadias, microlithiasis, infertility or low sperm count, as well as a 
family history of TC.13-15 These features often co-exist in the same individuals, and the associations 
between them led to the hypothesis of a testicular dysgenesis syndrome (TDS), which can be 
thought of as a form of sex development disorder, with TC as the most serious condition (Figure 
3).13,14  
 
Figure 3. The hypothesis of the testicular dysgenesis syndrome and signs that might be linked to 
it.13 Permission obtained from The American Physiological Society.  
 




A complex interaction of environmental influences in fetal and early life, specific single 
nucleotide polymorphisms (SNPs) and epigenetic changes are involved in TC development.13,14,16-21 
The familial clustering of TC, as well as the increased risk of developing a metachronous 
contralateral TC, supports the hypothesis of a strong genetic component.22,23 Among all cancers, TC 
is associated with one of the highest familial risks.14 Brothers of TC patients have a 4 to 10-fold 
increased TC risk, while sons of TC patients have a 2 to 6-fold increased risk.24-26 A family history 
of other cancers are also associated with an increased TC risk, supporting a component of 
hereditary cancer syndromes.27,28  
The contribution of genome-wide association studies and the identification of SNPs have 
been crucial for the current understanding of the complex genetic susceptibility of TC.16,18,20,29-32 
Multiple susceptibility loci, associated with chromosome segregation, DNA repair mechanisms, 
maturation and differentiation of male germ cells and KIT-MAPK signaling, have been 
identified.18,21 A strong association with TC has been found in the KITLG (12q21) locus.30,32 The 
KIT/KITLG pathway is critical for germ cell migration to the gonads.13 Many of the identified 
genes associated with TC are important for gonadal development and germ cell function,13 further 
supporting the hypothesis of TDS.20 Ethnic differences in frequencies of the KITLG variant,14,30 as 
well as the higher TC incidence in Caucasians than Afro-Americans living in the same area, further 
supports a genetic contribution to TC development.13 Adult height has been associated with 
increased TC risk, but genome-wide association studies has not confirmed such associations.33 
Currently, 39% of the familial risk can be explained by independent SNPs,18 but the understanding 
within this field is constantly evolving.  
 The presumed fetal origin of the malignant process is supported by the peak of TC incidence 
in young adults,13,14 and the role of environmental risk factors affecting the fetus is supported by the 
near doubling of TC incidence during the late 20th century in Northern Europe.34 A birth cohort 
effect of TC incidence, and the changing TC risk in second-generation immigrants that has been 
observed in epidemiological studies, also supports in utero or early-life environmental risk 
factors.35-37 Exogenous risk factors are, however, not well understood.14 It is suspected that 
mother`s exposure to persistent chemicals, like organochlorines, that impair fetal androgen 
signalling are associated with increased TC risk.38 The importance of impaired fetal androgen 
stimulation is further underscored by the increased TC risk in sex development disorders caused by 




Germ cell neoplasia in situ (GCNIS) is the precursor of TC,14,40 and if left untreated for 5 
years, GCNIS will develop into an invasive cancer in 50% of patients.41 A theoretical model for the 
pathogenesis starts with genetic mutations and in utero environmental exposures, together causing 
an insufficient masculinization of the gonocytes.13,14 This results in a delayed gonocyte, also called 
a pre-GCNIS, in the prepubertal testis. Further genetic aberrations strongly associated with TC, 
including polyploidization and amplification of chromosome 12p,42 are acquired before and after 
onset of adulthood, resulting in a malignant transformation from GCNIS to an invasive tumour.13,14 
This process is illustrated in Figure 4, and although it is not yet demonstrated experimentally, the 
support for this theory is convincing.43 Further understanding of TC genomics might identify 
potential targets for novel therapies including immunotherapy in cisplatin-resistant TC.16 
 
Figure 4. Pathogenesis of testicular cancer.13 Permission obtained from The American 
Physiological Society. 
 
Note: The green background illustrates normal germ cell development. 





1.3 Diagnosis of germ cell TC 
1.3.1 Presentation and histopathology 
Germ cell TC often presents with a painless, unilateral, scrotal tumor.44 Some degree of pain is 
however experienced by 10-20% of patients.44 Further confirmed suspicion of the TC diagnosis is 
done by scrotal ultrasound and measurement of tumor markers. The confirmation of TC diagnosis is 
done through a radical inguinal orchiectomy, which also serves as the primary treatment. In some 
cases, symptoms from metastatic sites initiate the diagnostic process, for instance abdominal pain 
due to large retroperitoneal metastases.45 It is import to offer cryopreservation of sperm and to 
discuss testicular prothesis with the patient before orchiectomy. 
The surgical specimen is sent for histopathological examination. Germ cell TC derived from 
GCNIS accounts for 95% of all testicular malignancies.40,46 The remaining 5% (lymphoma, 
spermatocytic tumors, sex-cord stromal tumors, sarcoma, prepubertal non-GCNIS related tumors) 
are out of scope of this thesis and thus will not be further described.14,40  
Germ cell TC is divided into two distinct histopathological subgroups; pure seminomas and 
nonseminomas as defined by the 2016 World Health Organization (WHO) classification.40 About 
55-60% of patients are diagnosed with pure homogenous seminoma histology, which resembles the 
gonocyte arrested at a pre-differentiated stage.14,45 Nonseminomas, on the other hand, are 
heterogenous tumors that may contain a variety of cell types including embryonal carcinoma 
(resembling undifferentiated stem cells), choriocarcinoma and yolk-sac (both with extraembryonic 
differentiation), and teratoma.14,45 Teratomas can in rare cases display a somatic differentiation, 
histologically resembling sarcoma or adenocarcinoma.46 Nonseminomas may also contain 
components of seminoma. 
Additional current pathological evaluation includes tumor staging according to the TNM 
classification 8th edition, and information regarding tumor vascular invasion, stromal rete testis 
invasion, invasion of tunica albuginea, tunica vaginalis, epididymis or the spermatic cord invasion, 
and whether GCNIS is present or absent.15 
 There are several clinical differences between the two subgroups. Seminoma patients are 
generally 10 years older at diagnosis than patients with nonseminoma, with a peak incidence at 35 




nonseminomas.46,47 With no adjuvant treatment, recurrence will develop in 10-20% of stage I 
seminoma, and the risk might be influenced by tumor size and whether invasion in rete testis is 
present.9 Seminomas metastasize in a predictable, stepwise and relatively indolent manner via the 
lymphatic system in the retroperitoneum, and visceral metastases are very uncommon.48,49 
Recurrences are generally diagnosed within the first 3 years of follow-up.50 In stage I 
nonseminoma, the presence of lymphovascular invasion in the tumor predicts the risk of occult 
metastases and the risk of recurrence.51,52 About one-third of tumors are diagnosed with 
lymphovascular invasion, and if present, the risk of recurrence is 50% in stage 1 nonseminoma if no 
adjuvant treatment is administered.47,53,54 Recurrences most commonly occur in the retroperitoneum 
within 2 years after orchiectomy,50,53,55as nonseminomas most commonly metastasize through the 
lymphatics to the retroperitoneum, and may also continue to supradiaphragmatic lymph nodes.56 
Hematogenous spread of nonseminomas to lung, bone or brain may occur, but is relatively 
infrequent.56   
In 2-5% of cases, germ cell cancer presents with an extragonadal localization without a 
testicular tumor.57 Extragonadal germ cell cancers were excluded from this study.   
 
1.3.2 Tumor markers 
Serum tumor markers include Alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin 
(beta-hCG). At diagnosis, 50-70% of patients with nonseminoma have elevated serum AFP.58 AFP 
is secreted by some yolk sac and embryonal carcinomas, while not by pure seminomas or 
choriocarcinoma. Thus, an elevated AFP is inconsistent with a seminoma diagnosis. Beta-hCG is 
produced by all choriocarcinomas, 40-60% of embryonal carcinomas and 10-20% of seminomas.58 
The level of beta-hCG produced by seminomas is generally lower than the levels produced by 
nonseminomas. In nonseminoma, normal tumor markers are more common in stage 1 vs. metastatic 
disease; In stage I, 45% have normal levels of AFP or beta-hCG pre-orchiectomy, and both markers 
are negative in 33%. In metastatic disease, only about 15% have one or both tumor markers 
normal.58 The peak levels of tumor markers and the half-life kinetics are important for final staging 
and treatment evaluation.46 
Additionally, elevation of lactate dehydrogenase is present in 40-60% of TC patients. It is 




For the last decade, new microRNA-based tumor markers have yielded promising results in 
TC.59 The most promising is microRNA (miR)-371a-3p, expressed by both TC and GCNIS tissues, 
and superior to the classic TC tumor markers with a sensitivity and specificity of >90% in all 
histological subtypes except teratoma.60,61 Further studies to validate this marker for clinical use are 
ongoing. 
 
1.3.3 Clinical staging 
The clinical staging of TC is based on histopathological information, serum tumor markers and 
computed tomography scans of thorax, abdomen and pelvis (preferably done before orchiectomy). 
According to the modified Royal Marsden Hospital Staging system as first described by Peckham et 
al.62 and later modified by the Swedish and Norwegian Testicular Cancer Group (SWENOTECA),15 
patients are designated to clinical stage I-IV (Table 1).  
Table 1. Clinical staging of testicular cancer according to the Royal Marsden Hospital Staging 
System.62 
Stage Description 
I No metastases 
Mk+ No metastases, but persistent elevation of serum tumor markers 
II Metastases involving abdominal lymph-nodes. 
 A: <2 cm 
 B: 2-5 cm 
 C: >5-10cm 
 D: >10 cm 
III Metastases involving supradiaphragmatic lymph-nodes.  
Abdominal lymph-nodes according to stage II (A-D) 
IV Metastases involving extra-lymphatic tissue/organ 





From 1997, the prognostic group classification according to The International Germ Cell 
Cancer Collaborative Group has also been used to decide upon treatment strategy in metastatic 
disease (Table 2).10 According to an update of this classification, 5-year overall survival for 
nonseminoma patients is 96% in good prognosis group, 89% in intermediate and 67% in poor 
prognosis group.63 For seminoma, updated 5-year overall survival is 95% for good prognosis group 
and 88% in intermediate prognosis group.64 The inclusion in our study cohort started 16 years 
before the prognostic group classification was introduced, and information regarding tumor markers 
was not included in our clinical database. Thus, it was not possible for us to allocate the study 
cohort according to this classification.  
 
Table 2. Prognostic classification according to the Germ Cell Consensus Classification10  
Prognosis Nonseminoma Seminoma 
Good Primary tumor in testis or retroperitoneum, 
No non-pulmonary visceral metastases, 
and good markers (beta-hCG <5000 IU/L, 
AFP <1000 µg/L and LDH <1.5 x ULN) 
Any primary site, no-non-
pulmonary visceral 
metastases, and normal AFP, 
any beta-hCG and any LDH 
Intermediate  Primary tumor in testis or retroperitoneum, 
No non-pulmonary visceral metastases, 
and any intermediate markers (beta-hCG 
≥5000 - ≤ 50000 IU/L or AFP ≥1000 - 
≤10000 µg/L or LDH ≥1.5 - ≤10 x ULN) 
Non-pulmonary visceral 
metastases 
Poor Primary tumor in mediastinum or non-
pulmonary visceral metastases or any poor 
markers (beta-hCG >50000 IU/L or AFP 
>10000 µg/L or LDH >10 x ULN) 
No seminomas have poor 
prognosis 
Abbreviations: beta-hCG, beta-human chorionic gonadotropin; IU, international units; AFP, alpha-fetoprotein, LDH, 





1.4 Treatment of germ cell TC 
1.4.1 General treatment principles during the study period 
In Norway, management of TC is centralized to four university Hospitals. The study participants 
have been treated in line with the recommendations by the SWENOTECA collaboration,15,65-67 or 
according to protocols by the European Organization for Research and Treatment of Cancer and 
Medical Research Council.68-76 SWENOTECA treatment protocols have been available for 
nonseminoma patients from 1980 and for seminoma patients from 2000.15 
The initial treatment for most participants was an orchiectomy. For stage I nonseminoma, a 
post-orchiectomy retroperitoneal lymph node dissection (RPLND) was routinely performed as a 
staging procedure until the early 1990s,77 when 1-3 cycles of adjuvant cisplatin-based 
chemotherapy (CBCT) or the surveillance strategy (orchiectomy followed by close monitoring with 
clinical examinations, diagnostic imaging and measurement of serum tumor markers) were 
introduced as treatment options (Table 3).47,65,67,70,75 Abdominal radiotherapy (RT), with gradually 
reduced target dose from 36-40 Gy to 25.2-27 Gy,78,79 was the standard treatment for stage I 
seminoma until the early 2000s,76 when surveillance or 1 cycle of adjuvant carboplatin became the 
recommended treatment strategies.47,80-82 
In case of metastatic disease, CBCT has been the standard treatment for both nonseminoma 
and seminoma during the entire study period, as it still is today (Table 3).6,66,83,84 In line with 
expanding insights regarding treatment efficacy and side effects, the number of CBCT cycles were 
reduced from ≥4 cycles to 3 cycles for patients with good prognosis (the majority) and 4 cycles for 
patients with intermediate and poor prognosis from the early 2000s.7,15,74 For small volume 
metastatic seminoma, abdominal RT continued to be a treatment option during the entire study 





Table 3. General initial treatment principles for TC patients in Norway by decade of diagnosis 
Decade Stage I-IIA Stage IIB-IV 
1980 to 1989 Nonseminomas: staging RPLND 
(unilateral RPLND only if stage I) 
followed by CBCT if metastases were 
histologically verified.77 
Seminomas: adjuvant RT towards 
paraaortal and ipsilateral iliacal 
lymph nodes by the L-field 
technique.78 The target dose was 
gradually reduced from 36-40 Gy to 
25.2-27 Gy.78,79 One institution 
offered RT restricted to the para-
aortic area only from 1989.76 
 
Cisplatin in combination with bleomycin and 
vinblastine (CVB), and from 1987 etoposide 
(BEP), has since the late 1970s been the standard 
treatment of metastatic nonseminoma and 
seminoma.6,66,83,84 Generally ≥4 cycles 
administered. Some treated according to 
experimental regimens within research 
protocols.68,69,71-74 
Nonseminomas: Post-chemotherapy RPLND and 
surgical removal of additional residual tumors if 
present in all patients with initial metastatic 
disease.66 Further CT if malignant cells present 
upon histological examination. RT was a treatment 
option if residual masses persisted after CBCT 
and/or surgery. Nerve-sparing RPLND from 
1989.77  
Seminomas: post-chemotherapy RT of residual 
masses (until 1986) or surgical removal.84 
1990 to 1999 Nonseminomas: Primary staging 
RPLND was abandoned for all 
patients. Stage I: offered surveillance 
or 1-3 cycles of adjuvant 
CBCT.47,65,67,70,75 Stage Mk+ and IIA: 
BEP x 3-4 followed by RPLND if 
residual masses.85  
Seminomas: adjuvant abdominal RT 
continued as above, target dose 
usually <30 Gy. 
The BEP-regimen remained standard first-line 
therapy in metastatic disease. From 1995, high-
dose chemotherapy with autologous stem cell 
support was available. Some treated according to 
experimental regimens within research 
protocols.68,69,71-74 
Nonseminomas: From 1995 post-chemotherapy 
RPLND was performed if abdominal metastases >2 
cm at diagnosis or in case of residual masses.85 
Seminomas: Surgical removal of residual masses 
often performed.84,86-88  
2000 to 2009 Nonseminomas: Stage I: surveillance 
or one adjuvant BEP cycle.47,89 Stage 
Mk+ and IIA: continued as above. 
Seminomas: Stage I: RT was 
gradually abandoned. Patients 
increasingly offered surveillance or 1 
cycle of adjuvant carboplatin 
monotherapy.47,80-82 Stage IIA: RT 
still a treatment option.78 
The number of CBCT cycles was reduced to 3 
cycles for patients with good prognosis (the 
majority of patients) and 4 cycles for patients with 
intermediate and poor prognosis.7,74 Seminoma 
patients offered EP instead of BEP.78,82,90 
Nonseminomas: Post-chemotherapy RPLND 
continued as above. 
Seminomas: Post-chemotherapy surgery not 
recommended.78,82,87 88 
Note: Clinical stage as described by Peckham et al.62 Abbreviations: TC, testicular cancer; RPLND, retroperitoneal lymph 





1.4.2 Platinum compounds and the retention of platinum 
The metal platinum is the most fundamental component of the cytotoxic drugs cisplatin and 
carboplatin.91 For 40 years, cisplatin and its analogs have had a considerable impact on the 
treatment of a number of solid cancers, and it made TC a model of a curable malignancy.6,91 
Genomic features that can explain the chemosensitivity of TC have been identified. Through whole-
genome sequencing and functional measurement of apoptotic signaling, primary TCs have been 
found to have high mitochondrial priming, a trait that facilitates chemotherapy-induced apoptosis.42  
Cisplatin is a highly-potent cancer drug that interacts with and modifies DNA through 
intrastrand (>90%) crosslinks in addition to interstrand crosslinks, DNA-protein crosslinks and 
DNA monoadducts, ultimately leading to apoptosis of cancer cells. 92-94 Germ cell TC is highly 
sensitive for cisplatin, presumably because of an overexpression of some crucial proteins, decreased 
repair of DNA-crosslinks and a hypersensitive apoptotic response.93,95 However, multiple dose-
limiting acute side effects are related to cisplatin, such as nephrotoxicity, ototoxicity, neurotoxicity, 
and nausea.91 To reduce the risk of renal damage, high fluid intake and sufficient diuresis during 
treatment is important. Modern antiemetic treatment is effectively minimizing cisplatin-induced 
nausea. The elimination of cisplatin compounds is mainly renal.96 Although 50% of cisplatin is 
eliminated within the first 5 days after infusion, the elimination of cisplatin requires several half-
lives that increases with follow-up time.97,98 
 The cytotoxic mechanism of carboplatin is similar to that of cisplatin, although carboplatin 
requires a much higher drug concentration and longer incubation time to induce the same amount of 
DNA changes.99 Carboplatin is considered 4-fold less potent than cisplain.100,101 The acute toxicity 
following carboplatin is less frequent and milder than that of cisplatin, except for a larger degree of 
myelosuppression.92 Carboplatin is generally excreted as an unchanged drug in the urine.92  
 Traces of platinum have been detected in several organs months after administration,102,103 
and in 2000, Gietema et al. discovered that platinum metabolites could be detected in plasma for up 
to 20 years after treatment with CBCT.104 Moreover, serum concentrations up to a 1000 times 
higher than in unexposed controls have been detected in TCS >5 years after treatment,96 and up to 
10% of the long-term circulating platinum remains reactive.105 Likewise, adducts have been 




the development of adverse health outcomes after treatment with platinum-based chemotherapy 
(PBCT).  
 
1.4.3 Other important cytotoxic drugs in the treatment of TC 
Cisplatin has been used in combination with other cytotoxic drugs during the study period. From 
the late 1970s to 1987, cisplatin in combination with bleomycin and vinblastine (CVB) was the 
standard treatment.6,66 Because of less acute neurotoxicity when cisplatin and bleomycin was 
combined with etoposide (BEP), this has been the standard treatment combination from 1987.83 
From the early 2000s, metastatic seminoma patients were offered cisplatin and etoposide (EP) 
instead of BEP.90  
Bleomycin, a glycopeptide antibiotic, acts by forming free radicals that induces DNA 
cleavage.91 The elimination of bleomycin is renal. Pulmonary toxicity is the most important dose-
limiting toxicity.91 
Vinblastine is a vinca alkaloid that exerts its anticancer effect by acting upon microtubules, 
leading to cell cycle arrest in metaphase.91 The elimination is hepatobiliary, and the most important 
dose-limiting toxicity is neutropenia.91 Peripheral neurotoxicity may occur, but milder than for 
some other vinca alkaloids.91 
Etoposide is a DNA topoisomerase II inhibitor.91 DNA topoisomerases are enzymes 
involved in the transient DNA breaks essential for fundamental biological processes. By poisoning 
this process, etoposide inhibits the re-ligation of DNA ultimately leading to apoptosis.91,106 The 
elimination of etoposide is renal, and myelosuppression is the most important dose-limiting 
toxicity.91  
 
1.5 Follow-up procedures of germ cell TC 
The close follow-up after treatment for TC aims to detect relapses as early as possible, and to 
identify and attempt to ameliorate side-effects after cancer and cancer treatment. Clinical 




intervals at the centralized treatment centers in Norway have been recommended by 
SWENOTECA, with modifications, throughout the study period.15  
During the study period, all patients were generally followed with controls for a total of 10 
years.15 Due to the usual patterns of relapse,50 a shorter time interval between controls of 2 months 
were recommended for the 2 first years after orchiectomy for nonseminoma patients and intervals 
of 2-4 months for the first 3 years for seminoma patients, followed by longer time intervals between 
controls for the rest of the follow-up. Towards the end of the study period, a shorter follow-up of 5 
years was recommended for nonseminoma stage I treated with adjuvant CBCT, while a total 
follow-up length of 6 years was recommended for seminoma stage I treated with adjuvant RT, also 
including longer control intervals and fewer abdominal scans. By the end of the study period, 
magnetic resonance imaging-scans were recommended in the follow-up of TCS, as concerns grew 
about an increased second cancer risk after multiple computed tomography-scans.107,108 Results 
from a clinical trial concluded that magnetic resonance imaging was noninferior to computed 
tomography scans in the follow-up of stage I seminoma.109 As a result of the increased knowledge 
regarding cardiovascular disease (CVD) risk after CBCT,110,111 screening for CVD risk factors was 
recommended in the follow-up guidelines from 2007.112,113 
Today, follow-up for the majority of patients ends at 5 years after orchiectomy.15 The 
recommended control interval for nonseminoma patients is every 3 months for most patients, except 
stage I with lymphovascular infiltration and intermediate or poor prognosis groups for which 2 
month intervals are recommended during the first year of follow-up. For seminoma, 6-month 
control intervals are recommended from the start of follow-up for the majority of patients. For some 
seminoma patients the follow-up length is extended to 10 years.  
 
1.6 Surivorship issues for TC survivors 
1.6.1 General aspects 
Survivorship research seeks to identify and investigate the adverse effects of cancer and cancer 
treatment aiming to reduce and control these effects in order to enhance the health and quality of 
life of cancer survivors.114 In the strictest technical term, adverse treatment effects are defined as 




years after end of treatment. However, these concepts tend to be somewhat intertwined in the 
literature. Individuals alive more than 5 years after the primary cancer diagnosis are defined as 
long-term cancer survivors. 
 Because of the young age at TC diagnosis and the excellent cure rates even for men with 
advanced disease, the expected lifespan post diagnosis is 40-60 years.8,115 Consequently, knowledge 
regarding survivorship issues is highly relevant in this group of cancer survivors. Research has 
shown that the survival of TC comes at a cost, and that numerous possibly life-threatening late 
adverse effects may follow TC treatment.115 In this chapter I will describe important survivorship-
issues faced by TCS, with focus on late effects relevant for this thesis. The chapter is based on the 
knowledge available at the beginning of the research period for this thesis. 
 
1.6.2 Metachronous contralateral testicular cancer 
After a diagnosis of a primary unilateral germ cell TC, the risk of a metachronous contralateral 
(second) TC is increased with estimated 15 to 20-year cumulative incidences of 1.9-3.9%.23,116-118 
Compared with the general population, the risk of a second TC is 12.4 to 35.7-fold increased.23,116-
121 A second TC is usually treated with orchiectomy, and thus a life-long dependency of 
testosterone substitution follows this diagnosis.122,123  
The increased risk for a second TC is presumably explained by shared etiological factors for 
the first and second TC.13,19 Based on previous studies, there is an association between young age at 
diagnosis of the first TC and an increased risk of developing a second TC. 23,116-118,124 Results 
regarding first TC histology and subsequent second TC risk are inconclusive. 23,118,121,125,126 
Cisplatin has been hypothesized to reduce or delay the incidence of a second TC, but literature 
investigating this association is lacking. Existing literature is either based on public registries 
without details regarding TC treatment,23,116 involves individuals treated in the pre-cisplatin era,117-
119 or populations screened for GCNIS.127,128 
Andreassen et al. investigated the second TC risk in 7102 Norwegian TCS treated during 
1953-2007,116 and they concluded with a 50% risk reduction of a second TC in men with metastatic 
vs. localized disease in those treated after 1980. This implies a risk reduction related to CBCT. 




and they concluded that future studies should investigate the potential dose-response relationship 
between cisplatin and eradication of GCNIS.23 
 
1.6.3 Neurotoxicity, ototoxicity and Raynaud’s phenomenon 
By degeneration of dorsal root ganglion, cisplatin can cause peripheral neuropathy that is most 
often sensory with paraesthesia as the main symptom.8 Cumulative cisplatin dose is related to 
incidence and severity, and symptoms of peripheral neuropathy is reported by 20-40% after 
CBCT.7,129,130 The neuropathy may become persistent.7,129,130 Peripheral neuropathy may also 
develop after treatment with carboplatin, but it is infrequent with symptoms in only 3% of 
patients.92 Vinblastine is also associated with some degree of peripheral neuropathy, causing 
paraesthesia in 7-31% of patients.91  
By damaging of the outer hair cells of the cochlea, cisplatin can induce tinnitus and hearing 
loss.131 Persistent hearing impairment has been reported in 20% of TCS after standard cisplatin 
doses with increasing prevalence after higher cumulative doses.130,132  
Raynaud`s phenomenon is characterized by white discoloration, coldness and stiffness of 
digits caused by an abnormal vasoconstriction of digital arteries.133 This long-term adverse effect is 
reported by 15-45% after treatment with CBCT, and it is presumed to be a vascular complication 
brought about mainly by bleomycin,130,134-136 but cumulative cisplatin also seems important.130 
 
1.6.4 Hypogonadism, fertility and sexuality 
Gonadal dysfunction in TCS can be observed by lowered testosterone levels (endocrine 
hypogonadism) and/or oligo -or azoospermia (exocrine hypogonadism).12 A compensatory increase 
in serum luteinizing hormone (LH) often accompanies lowered testosterone, while increased 
follicle-stimulating hormone (FSH) indicate reduced sperm production. Thus, increased levels of 
serum LH and/or FSH may be the first laboratory sign of hypogonadism.137 Levels of testosterone 
below the reference range was observed in 10-17% of long-term TCS with median age of 50 years, 
depending on treatment, and 50% had levels outside the reference range for either testosterone, LH 




including hypogonadism as a feature of TDS (Figure 3).13,142 Furthermore, in TCS, the gonadal 
function is based on only one testicle, and physiological decline of testosterone levels is associated 
with ageing.143 Additionally, treatment with CBCT is associated with both endocrine and exocrine 
hypogonadism.137-139,144  
In a Norwegian study, long-term TCS treated with CBCT were five times more likely than 
age-matched controls to have testosterone levels outside the reference range,138 and increasing 
Leydig cell deficiency has been observed with higher cumulative doses of CBCT.137 Endocrine 
hypogonadism is associated with reduced sexual functioning, loss of energy, muscle weakness, 
depression, osteoporosis, metabolic syndrome and cardiovascular disease (CVD).8,115,139,145 
Testosterone substitution should be considered for TCS presenting symptoms of hypogonadism 
together with serum testosterone below the normal range.9  
Poor semen quality is related to TDS and TC. A more pronounced reduction of sperm 
quality and concentration, and also changes of sperm DNA, has however been observed in TCS 
treated with CBCT compared with those treated with surgery.146,147 One adjuvant cycle of BEP or 
carboplatin does not seem to influence sperm count.148 The recovery of spermatogenesis, and thus 
the ability to father children, has been associated with number of administered CBCT cycles.147,149-
151 Overall, the 15-year actuarial post-treatment paternity rate without the use of cryopreserved 
sperm was 48% (95% confidence interval (CI) 30%-69%) in TCS treated with high doses of CBCT 
vs. 92% (95% CI 78%-98%) in the surgery group.144 Fertility can also be affected by retrograde 
ejaculation, a possible side effect of RPLND.8 Offering cryopreservation of sperm is mandatory 
before starting any TC treatment. 
Some TCS experience a reduced sexual functioning compared with controls, and reduced 
drive, erectile and ejaculatory dysfunction have been observed,139,152,153 In a Norwegian study, 
sexual problems was reported by 39% of long-term TCS compared with 36% of controls,152 
however the youngest TCS in this study actually reported a better sexual satisfaction compared with 
controls.152 A Danish study did not observe differences in sexual functioning in different treatment 





1.6.5 Fatigue, mental health and lifestyle 
Chronic fatigue is a subjective feeling of physical, cognitive or emotional tiredness not relieved by 
rest and sleep, and with a duration >6 months.154 Chronic fatigue has been reported by 17% of 
Norwegian long-term TCS compared with 10% in the general population,155 and the prevalence has 
been found to increase with increasing follow-up time.156 Higher levels of circulating interleukin-1 
receptor antagonist and c-reactive protein in TCS with fatigue compared with TCS without fatigue 
has indicated an association with inflammation,157 but the underlying mechanisms causing fatigue 
are still not well understood.158 
Long-term memory problems was reported by 36% of TCS treated with CBCT compared 
with only 4.3% treated with surgery only, and significantly lower cognitive performance was also 
observed in the CBCT group.159 An association between PBCT dose and cognitive decline has also 
been observed.160  
 Anxiety was more frequent in long-term TCS (19%, 95% CI 17%-21%) compared with age-
matched normative controls (14%, 95% CI 13%-14%) in a Norwegian study, and there was a 
significant association between young age and anxiety.161 Prevalence of depression was however 
not higher in TCS compared with controls in the Norwegian study,161 while an Australian study 
reported a small, but significant higher prevalence of both anxiety and depression in TCS compared 
with controls.162Increased anxiety has also been observed in TCS after >5 CBCT cycles compared 
with a lower number of CBCT cycles or surgery.163 However, a Danish study observed equal long-
term quality of life in TCS compared with the general population, and no statistically significant 
differences were observed between the treatment groups.134 A Norwegian study observed that a 
considerable degree of fear of cancer recurrence was common in TCS, and it may persist for many 
years after the diagnosis.164 No difference was however observed for the different treatment 
modalities.164 Alarmingly, a Surveillance, Epidemiology and End Results (SEER) study including 
23381 TCS reported a 20% excess of suicides compared with the general population.165 
Problem drinking and low intake of fruit and vegetables were reported as more common in 
TCS than in their age-matched relatives in a US study.166 Smoking prevalence did however not 
differ from controls, while engagement in regular physical exercise was higher. Similarly, a 
Norwegian study, using a sub-population from the current study, also reported comparable smoking 




TCS.111 Another US study reported a very low smoking prevalence in TCS of 8%.167 However, a 
study involving 7384 cancer survivors, reported a higher prevalence of smoking among younger 
cancer survivors compared with noncancer controls.168 
 
1.6.6 Cardiovascular disease 
Atherosclerotic disease was observed in 8% of long-term TCS treated with CBCT compared with a 
frequency of 3.6% in those treated with surgery in a Norwegian study.111 This study also reported a 
significant 3-fold excess risk of myocardial infarction in TCS treated with CBCT compared with 
age-matched controls.111 TCS treated with CBCT have been identified as having 1.5 to 2.6 
increased long-term relative risks for developing CVD, compared with TCS treated with 
surgery.111,169,170 The association between RT and CVD risk has been more conflicting,111,169 but the 
combination of CBCT and RT has been found especially harmful in studies with complete TC 
treatment details.111,170  
The increased CVD risk after CBCT is presumably caused both by direct endothelial 
damage and also indirectly by increasing cardiovascular risk factors,171 e.g. hyperlipidemia172, 
hypertension110,111, obesity,110 and the metabolic syndrome.173 RT has been linked with increased 
risk for diabetes, a possible explanation being radiation injury of the pancreas function.111 
Testosterone deficiency might also contribute to the increase of CVD risk factors.174  
 
1.6.7 Non-TC second cancer 
It is relatively well documented that TCS have a 1.6 to 1.9-fold increased risk of developing 
hematological and solid non-germ cell second cancer (SC) compared with age-matched general 
populations.119,121,169,175-177 Increased SC risk has been observed after CBCT and RT, but not after 
surgery only. There is a considerable latency after cancer treatment before SC occur; subsequent 
hematological malignancies develop within 10 years after cancer treatment,178,179 while solid 
neoplasms generally develop beyond 10 years after TC treatment, with risks remaining significantly 
elevated for at least 35 years.177 Furthermore, the cumulative risk at any given attained age 




Based on major etiological influences, second primary cancers can be divided in three 
categories: 1) therapy-related, 2) syndromic, 3) shared exposures.180 However, multiple factors are 
usually involved, and the SC risk is often related to the co-existence and interaction of several 
etiologic influences i.e. previous cancer treatment together with continued tobacco use (Figure 5).180  
 
Figure 5. Risk factors for second cancer development. Adapted with permission from Travis, 
2002.181   
 
TC has been associated with other familial cancers, as mentioned in chapter 1.2, supporting 
a hypothesis that TC to some extent is related to hereditary cancer syndromes.27,28 However, genetic 
and epigenetic factors related to SCs are complex with individual penetrance of cancer 
susceptibility genes and their interaction with other etiological factors for SC.29,182  
Adverse health behaviors are associated with increased cancer mortality in general 
populations,183-185 and lifestyle behaviors like smoking and alcohol has been suggested to contribute 





Therapy-related cancers are defined as SCs that develops after previous chemotherapy 
and/or RT, and they serve as a potential life-threatening late effect after cancer treatment.187 
Exposure to chemotherapy or RT can induce DNA damage in normal tissue, and if DNA repair 
mechanisms are affected this may lead to genomic instability which in turn can result in cancer 
development (Figure 6).187 For therapy-related SCs, a dose-dependent relationship often exists, and 
a proliferative state at the time of treatment exposure may influence the SC risk.187 
Figure 6. The pathogenesis of therapy-related cancers187 Permission obtained from Springer 
Nature. 
 
 In TCS, there is an established association between treatment with RT and subsequent 
excess risk of SC.127,169,177,188 The SCs following RT are often localized in relation to the previous 
RT field (colon, stomach, pancreas, bladder and the urinary tract).127,177,188-191 
Experimental data and animal studies have suggested cisplatin as a carcinogen.192,193 A 
mechanism found to be involved in cisplatin-related carcinogenesis and resistance, is selection of 
cells with DNA-mismatch repair deficiency causing genomic instability.187 Selection of DNA-
mismatch repair deficient cells have been observed even after only one exposure to cisplatin in vitro 




Four decades have now passed since the first TC patients were treated with CBCT, which 
makes it possible to study very late adverse health outcomes such as SC. Two recent studies have 
investigated SC risk after modern-era CT in TCS. In 2013, Fung et al. were the first to report of an 
increased solid SC risk after CBCT in a SEER-based study involving 12691 nonseminoma 
survivors diagnosed with TC after 1980.195 Compared with the general population, treatment with 
CBCT was associated with a 40% overall increased risk of solid SC (standardized incidence ratio 
(SIR) 1.43, 95% CI 1.18-1.73), and significantly increased risks appeared for cancers of the kidney, 
thyroid and soft tissue. No increased risk appeared after surgery only (SIR 0.93; 95% CI, 0.76 to 
1.14). Details regarding type and dose of initial and subsequent CT were, however, not available for 
the study population. Kier et al. were the first to include complete information on TC treatment in 
their study involving 5190 Danish TCS diagnosed 1984-2007.127 Compared with a control group, 
they reported significantly 70-80% increased risks of SC after CBCT (hazard ratio (HR) 1.7, 95% 
CI 1.4-2.0) and RT (HR 1.8, 95% CI 1.5-2.3), but not after surveillance, after median 14.4 years. 
Three to four BEP cycles were associated with increased risks for SCs of the lung, bladder, 
oesophagus, soft tissue and for myeloid leukaemia.127 However, instead of calculating SIRs, Kier et 
al. estimated cumulative incidences of SC and HRs by using a control group from the general 
population matched 10:1 on age at diagnosis. Because the majority of available literature are based 
on outdated TC treatment, studies evaluating SC risk after CBCT are needed.8,115,196 
 
1.6.8 Mortality  
Mortality due to TC generally occur within the first 5 years after diagnosis, and thus 10- and 15-
year relative survival for TC overlaps with rates for 5-year relative survival.197 Mortality due to TC 
was not the scope of this thesis. Despite exceptionally high cure rates after TC,4 long-term relative 
survival beyond 20 years is inferior in TCS (Figure 7).198 Compared with general population rates, 
previous studies have observed an increased non-TC mortality after TC,198-200 with reported overall 
1.3 to 1.6-fold increased mortality risk after PBCT,127,201,202 and 1.23 to 1.59-fold increased overall 
mortality risk after RT 127,203,204 while no increased risk has been observed after surgery 
only.127,201,202 In line with the increased risk of developing a SC after treatment for TC described 
previously, deaths due to non-TC SCs have been identified as an important cause of death. After 




group, and after RT the SC mortality has been reported as 1.6 to 2.4-fold increased, compared with 
the general population.188,200,203,204  
 
Figure 7. Relative survival (RS) of Norwegian TCS by cohort of diagnosis and follow-up time.198 
Permission obtained from American Association for Cancer Research. 
 
Increased risk of non-cancer deaths have also been observed after TC.127,201,202 Fosså et al. 
investigated non-cancer causes of deaths in 38907 1-year TCS.201 They reported an overall 
standardized mortality ratio (SMR) for total non-cancer mortality of 1.06 (95% CI 1.01-1.10), and 
significant excess of deaths due to infections, digestive diseases, hypertensive disorders and other 
respiratory diseases compared with the general population. Further, they reported significantly 
increased deaths due to circulatory diseases in those <35 years at TC diagnosis (SMR1.23, 95% CI 
1.09-1.39) and in TCS initially treated with CT in 1975 or later (SMR 1.44, 95% CI 1.06-1.91).201 
Increased suicide risk after TC has been observed in some previous studies.165,204 Based on 15006 
nonseminoma patients registered in the SEER-database, Fung et al. reported significantly increased 
overall non-cancer deaths after initial PBCT (SMR 1.60, 95% CI 1.40-1.82), while no increased risk 
was observed after surgery (SMR 0.96, 95% 0.84-1.11) compared with the general population.202 




2.65-9.51) restricted to the first year after diagnosis. Kier et al. reported significantly increased risk 
of mortality due to infection after CBCT.127  
However, the majority of the available literature investigating mortality after TC lacked 
complete information on previous TC treatment,199-202,204 included only patients with localized 
seminoma treated with RT,188,203 or included patients treated in the pre-cisplatin era.201 Despite the 
complete information on total treatment burden, Kier et al. did not investigate the effect of 







2 Aims of the thesis 
The overall aim of this thesis was to study the associations between TC treatment, with emphasis on 
cisplatin-based chemotherapy (CBCT), and the subsequent risk of non-TC SC, metachronous 
contralateral TC and non-TC mortality and causes of death. More specifically the objectives of this 
thesis were to: 
  
i. Assess the total risk of non-germ cell SC, and the incidence of specific non-TC SCs, 
among 1-year TCS compared with the general population, with emphasis on the impact 
of previous TC treatment. Investigate how follow-up time, age at first treatment, 
histology and treatment intensity, in particular number of CBCT cycles, influenced the 
SC risk. 
 
ii. Assess the crude and relative risk of developing a metachronous contralateral TC among 
TCS followed from >2 months after TC diagnosis, with emphasis on the impact of 
previous TC treatment. Examine how age at diagnosis, follow-up time, histology and 
treatment intensity, in particular number of CBCT cycles, influenced the second TC risk. 
 
iii. Assess total non-TC mortality and causes of death in TCS followed from TC diagnosis 
and compared with general population rates, with emphasis on the impact of previous 
TC treatment. Investigate how follow-up time, age at diagnosis, histology and treatment 






3.1 Study cohort and data assembly  
The Cancer Registry of Norway (CRN) identified 6354 males diagnosed with TC between January 
1, 1980 and December 31, 2009 based on the International Classification of Diseases (ICD) 7, 
localization code 178.x (Figure 8). Based on data from the CRN, we excluded individuals coded 
with an extragonadal localization, or localization in ductus deferens, funicle or epididymis as well 
as males <16 years at diagnosis (n=274). Of the remaining 6080 individuals, all men alive at the 
start of the study (n= 5117), received an information letter where they were given the opportunity to 
withdraw from study participation. Only 23 (0.38%) men declined to participate. 
 Clinical data were assembled for the remaining 6057 TCS (Table 4). Detailed information 
regarding initial disease stage, histology, and complete information on all TC treatment, including 
relapse treatment (Appendix I), was retrieved from medical journals at all four hospitals involved in 
the post-orchiectomy treatment in Norway. We included all men >16 years diagnosed with germ 
cell TC from January 1, 1980 and with clinical treatment data available. All men diagnosed with a 
prior malignancy including TC before January 1, 1980 were excluded. Based on medical journals, a 
total of 333 men were excluded (Figure 8). The final study cohort comprised 5724 TCS with 
complete treatment information. 
Based on previous studies, clinical data had already been assembled for 2959 participants by 
the start of this study, and were updated for the present project (Table 3). Clinical data for the 
remaining 3098 participants were retrieved for this project. Finally, all datasets with clinical data 




















Excluded, based on data from the CRN (n=274, 4.3%) 
 Extragonadal localization (ICD-7 178.4) (n=180) 
 Localization ductus deferens or funicle (ICD-
7 178.3) (n=24) 
 Localization epididymis (ICD-7 178.2) (n=4) 
 Age < 16 years (n=66) 
   
  
Males diagnosed with germ cell TC in the CRN (coded with localization 
ICD-7 178.x) between 01/01/1980-12/31/2009 (n=6354) 
Excluded, based on clinical data (n=333, 5.5%) 
 Previous diagnosis of non-TC cancer (n=58) 
 TC before 1980 (n=27) 
 Extragonadal localization (n=51) 
 Clinical data missing (n=55) 
 Other histology than GC cancer (n=99) 
 Treated abroad (n=11) 
 Clinical diagnosis only/histology not performed 
(n=11) 
 Other causes (n=2) 
 Synchronous non-TC cancer diagnosis (n=19) 
 
 
Study cohort for n=5620 (88.4%) 
Paper II 
Dataset used as basis for study information letter (n=6080, 95.7%) 
Excluded from Paper II (n=104, 1.8%) 
due to the following events <2 months 
after first primary TC-diagnosis: 
 Synchronous bilateral TC 
(n=61)  
 Death (n=35 (of which 7 
were also diagnosed with 
synchronous bilateral TC))  
 Emigration (n=8 (of which 3 
were also diagnosed with 
bilateral TC)) 
Cohort of TCS with complete clinical data (n=5724, 90.1%) 
Abbreviations: TC, testicular cancer; CRN, the Cancer Registry of Norway; ICD-7, International Classification of Diseases 
version 7, GC, germ cell; TCS, testicular cancer survivors. 
 
Excluded from Paper I 
(n=99, 1.7%) due to the 
following events less than 
12 months after TC-
diagnosis: 
 Non-TC SC (n=14)  
 Death (n=77)  
 Emigration (n=8) 
Study cohort n=5625 (88.5%) 
Paper I 
Excluded from Paper III 





 Post mortem 
diagnosis of TC 
(n=11)  
 Emigration before 
diagnosis of TC 
(n=5) 
Study cohort n=5707 (90%) 
Paper III 
 
Declined participation (n=23, 0.38%) 
   




Table 4. Assembly of the clinical database 
Time 
period 
N (total 6057)  Details 
1980-1994 2365 Clinical data complete at the beginning of study, n = 2067  
• Participation in the national follow-up survey (all TCS alive 
minimum 5 years, and no extragonadal germ cell TC, previous 
malignancy or mental retardation were invited, n= 1814). 
Responders, n= 1463110,144,173,205-207  
• Included in other projects, n = 604  
 
Assembly of clinical data for this project n= 298  
The missing clinical data were retrieved by Hege Haugnes and 
collaborators 
 
1995-2009 3692 Clinical data were complete at the beginning of this project as part of 
various study protocols initiated by the SWENOTECA collaboration 
for n = 892 
• Swenoteca III Nonseminoma stage I 1995-200389 
• Swenoteca IV Nonseminoma metastatic 1995-2012208 
• Swenoteca V Seminoma all stages 2000-200682 
• Swenoteca VI Nonseminoma stage I 2004-201255 
• Swenoteca VII Seminoma all stages 2007-2012 
 
Assembly of clinical data for this project, n = 2800  
• Oslo University Hospital was not part of the Swenoteca 
collaboration 1995-2010. Missing clinical data n =1902 (The 
Norwegian Radium Hospital n = 1519, Ullevål 383) 
• Seminoma 1995-2000 missing data 
• Some Swenoteca-data were missing and were retrieved and/or 
were updated for this project.  
 
The missing clinical data were retrieved by Ragnhild Hellesnes 
and collaborators. 
 
Abbreviations: N, number; SWENOTECA, the Swedish and Norwegian Testicular Cancer Group 
 
3.2 Exposure assessments 
Treatment modality and intensity as previously described (chapter 1.4) were the main exposure 
assessments in all three papers. Further, age at diagnosis/treatment, attained age, follow-up time, 




3.2.1 Treatment modality 
Based on total treatment burden for the first and possibly second TC (paper I and III) or total 
treatment burden for the first TC only (paper II), the study participants were categorized into four 
treatment groups, applied in all three papers:  
1) Surgery only (including surveillance and, if applicable, additional RPLND) 
2) Platinum-based chemotherapy (PBCT). In papers I and II, this group was labeled as the 
chemotherapy (CT) group. However, for paper III, this group was relabeled the PBCT-
group, because only two men of the total study cohort received non-PBCT. In this thesis, the 
designation PBCT is used when referring to the chemotherapy group as a whole in all three 
papers.  
3) Radiotherapy (RT) 
4) Both PBCT and RT (PBCT + RT) 
 
3.2.2 Treatment intensity 
In our study, the chemotherapy group as a whole is labeled PBCT, while the label cisplatin-based 
chemotherapy (CBCT) is used when referring to cisplatin treatment intensity. CBCT is based on 
total number of CBCT cycles received. In this variable, all chemotherapy cycles containing 
cisplatin were summarized and accounted for. Thus, participants may have received additional non-
CBCT regimens that were not included in this variable. Adjuvant carboplatin monotherapy for stage 
I and other carboplatin-based chemotherapy were also excluded from this number, but they were 
included in the statistical models (as separate categories of treatment). The number of CBCT cycles 
included CBCT administered for the first and second TC in papers I and III, and for the first TC 
only in paper II.  
In paper I, a variable was also constructed based on CBCT regimens containing vinca alkaloids, 
etoposide or both. For paper II, cumulative doses of CBCT, PBCT and bleomycin administered for 
the first TC were estimated based on the type of chemotherapy regimen and number of 
chemotherapy cycles. The cumulative PBCT dose contained cumulative doses of cisplatin and/or 
carboplatin. For carboplatin, the corresponding cisplatin-equivalent doses were estimated by 




RT treatment was categorized and investigated according to first abdominal RT field and 
corresponding dose categories (1-20 Gray (Gy), 20-29 Gy, 30-39 Gy, 40 Gy) for the first or 
possibly second TC (papers I and III) or for the first TC only (paper II). Ten participants received 
scrotal RT of a total of 16-20 Gy because of GCNIS or a new tumor that underwent partial 
orchiectomy. Scrotal RT was not included in the RT group in our analyses. 
 
3.2.3 Age-matched controls 
Mortality rates and cancer incidence rates in the general male population of Norway were provided 
by the CRN and the Norwegian Institute of Public Health. The study cohort was matched with the 
general Norwegian male population by 5-year age groups and calendar year of follow-up to 
compare events in the study cohort with general population expected risks. In paper I, a TC-free 
male general population was used. In paper II, individuals diagnosed with TC was included in the 
background data, because the diagnosis of second TC was compared with the TC incidence in the 
general population (see chapter 3.4 for more information). In paper III, TC deaths were not 
excluded from the background data when examining total mortality due to the nature of data 
provided by the The Norwegian Cause of Death Registry (NCoDR). However, the proportion of 
men dying from TC is minimal, so this is unlikely to impact these analyses.  
 
3.3 Outcome assessments 
3.3.1 Paper I: Non-TC second cancer 
Information regarding non-TC SCs were obtained by linking the clinical database with data from 
the CRN, updated through December 31, 2016. The CRN provided information on date of diagnosis 
of subsequent cancers, localization codes (ICD-7), topography codes (ICD-O, third edition), 
morphology codes (ICD-O, third edition), ICD-10 diagnostic codes, information of metastases at 
diagnosis and the certainty of diagnosis, vital and emigration status and date of death or emigration, 
as well as treatment hospital for the primary TC diagnosis. To avoid inclusion of synchronous or SC 
not likely to be associated with treatment, follow-up started 12 months after the TC diagnosis. 
Participants who developed a SC, died or emigrated within the first year of follow-up were 




until the development of non-TC SC, emigration, death or December 31, 2016, whichever occurred 
first. A diagnosis of a metachronous TC were not included as a SC. 
 For analyses regarding specific diagnoses of SC according to the ICD-10 classification, 
participants were followed until the date the SC of interest occurred. Cancer diagnoses with few 
cases were grouped when clinically relevant.  
 
3.3.2 Paper II: Metachronous contralateral testicular cancer 
Information on metachronous contralateral (second) germ cell TC was obtained from medical 
records and by linking the clinical database with CRN data updated through December 31, 2018 to 
ensure complete incidence information. Data from the CRN included the same variables as for 
paper I. Metachronous TC was defined as a second TC occurring >2 months after the primary TC. 
Participants with a synchronous bilateral TC, or participants that died or emigrated within the first 2 
months after the first TC diagnosis, were excluded (Figure 8). Accordingly, 5620 TCS were 
included in this study and followed from 2 months after the diagnosis of the first TC until a 
diagnosis of a second TC, death, emigration or December 31, 2018, whichever occurred first. 
 
3.3.3 Paper III: Mortality and causes of death 
Information on mortality and causes of death was obtained by linking the clinical database with data 
from the NCoDR. The NCoDR provided information on death dates, causes of death for causes IA 
through II from the death certificate (coded according to ICD-8, -9, or -10), underlying cause of 
death (according to ICD-8, -9, or -10) as decided in the ICD coding rules, and underlying cause of 
death according to the European Shortlist (Appendix II), based on the WHO coding rules.209 The 
Norwegian Institute of Public Health provides death rates and causes of death according to the 
European Shortlist for the general population of Norway in the NCoDR statistics bank.210 
Consequently, for causes of death in this study, we used this same variable.  
Participants with a post-mortem TC diagnosis or those who were registered as emigrated 
before the TC diagnosis were excluded from this study (Figure 8). Likewise, one participant 




comprised 5707 TCS followed from the TC diagnosis date, until date of non-TC death or until 
censoring (date of TC-death, emigration or December 31, 2018, whichever occurred first). TC death 
was not the scope of this study. Accordingly, mortality refers to total non-TC mortality. For 
investigations regarding cause-specific mortality, non-TC mortality was divided in two main 
groups; non-TC SC mortality and non-cancer mortality.   
 
3.4 Statistical methods 
Continuous variables were summarized using median and interquartile range (IQR), and categorical 
variables were presented using absolute numbers and percent. Data were analysed using Stata 
statistical software (versions MP 14.2 and 16.1; STATA, College Station, TX). A p-value <0.5 was 
considered statistically significant, and all tests were two-sided. In paper II, differences in median 
time to second TC among those developing a second TC was tested using the K-sample median test. 
Treatment was always analysed as a time-varying covariate to avoid immortal time bias. 
Immortal time bias refers to a follow-up period during which, by design, the outcome of interest 
cannot occur.211 Such bias would occur if we e.g. were to use treatment information available after 
start of follow-up to classify patients into treatment groups from baseline. This was achieved by 
splitting follow-up time at exact treatment dates for each treatment group. For instance, a 
participant accrued observation time in the surgery only group until the date of PBCT or RT if this 
participant later received such treatment.  
 Crude cumulative incidences (probabilities) were estimated using the Aalen-Johansen 
estimator.212 Deaths of any cause (papers I and II) and TC deaths (paper III) were treated as 
competing risks. Cumulative incidences with 95% CIs were presented for the total study cohort in 
all papers and stratified by treatment group (papers II and III), histology (paper I and II) and age at 
diagnosis dichotomized as <30 or ≥30 years (paper II). 
 SIRs and SMRs were calculated to compare the observed events of interest in the study 
cohort to rates in a comparable general population. Estimates were presented with 95% CIs. In 
paper I, SIRs for total and site-specific SC incidence (if >4 cases observed) in the cohort were 
achieved by dividing the observed number of cancers in the cohort by the expected cancer incidence 




follow-up. SIRs were estimated for the total study cohort and by treatment groups, age at first 
treatment, attained age at first SC diagnosis and follow-up time. A subgroup analysis for those 
initially treated with surveillance was also performed.  
In paper II, SIRs were obtained by dividing the number of metachronous contralateral TCs 
in the study cohort by the expected number of metachronous contralateral TC, given the TC 
incidence in a male Norwegian population, matched by 5-year age groups and calendar year of 
follow-up. SIRs were presented for the total study cohort and stratified by treatment group, age at 
diagnosis, age at diagnosis dichotomized (<30 or ≥30 years), histology and follow-up time. 
 In paper III, SMRs were obtained by dividing the observed number of deaths in the cohort 
by the expected number of deaths in the general Norwegian male population, matched by 5-year 
age groups and calendar year of follow-up. SMRs were presented for the total study cohort and 
stratified by treatment group for total non-TC mortality, non-TC SCs and groups of non-cancer 
causes of deaths if >4 observed, follow-up time, age at diagnosis and attained age. In paper III, 
absolute excess risks (AERs) were calculated as the absolute difference in mortality rates using the 
following formula: [(observed number of deaths – expected number of deaths)/person-years of 
observation]*10000. 
 Cox regression models adjusted for age at first TC diagnosis, with time since diagnosis as 
time scale and the surgery group as reference, were used to evaluate the impact of treatment group, 
treatment intensity and histology in all three papers. In paper II, histology was further evaluated in a 
multivariable Cox regression model including treatment in addition to age at diagnosis, and in paper 
III, all Cox regression analyses were performed in multivariable models including histology in 
addition to age at diagnosis. Estimates were presented as HRs with 95% CIs. In paper I and II, when 
effects of number of CBCT cycles were evaluated, all participants that received RT were censored 
at the RT start date. Similarly, when investigating effects of first RT field and abdominal RT dose, 
all participants that received PBCT were censored at the date of first PBCT treatment. In Paper III, 
all treatment options were included in the model for analyses regarding treatment intensity.  
For paper I and III, time-dependent Cox regression models were applied because the 
proportional hazard assumption was violated for most analyses and, importantly, because a 10-year 
cut off was deemed clinically relevant based on previous research.177,198,201 Consequently, treatment 




was obtained by including an interaction with follow-up time dichotomized as up-to and after 10 
years. Unless otherwise specified, results were presented for those with >10 years follow-up time in 
Papers I and III, or starting 1 year from TC diagnosis (Paper I).  
In paper II, the proportional hazard assumption, judged by a nonsignificant Schoenfeld 
residuals test, was met for all analyses, except for some analyses regarding cumulative CT doses. 
For the latter, new models were fitted with an interaction effect between follow-up time and the 
affected cumulative doses, and model fits were compared using Bayesian Information Criterion. 
The best fit was provided by the simple model without interaction effects for all analyses, and 
hence, the age-adjusted Cox proportional hazard regression models were applied. Also, in paper II, 
the Cox regression model was used to investigate the effect of age at first TC diagnosis 
(dichotomized on <30 and ≥30 years). For this analysis, the Schoenfeld residuals test was 
significant (p=0.03), but the visual inspection of the log-log survival plot was judged to meet the 
proportional hazard assumption for this analysis.  
Kaplan-Meier failure curves adjusted for age at TC diagnosis centered on mean were 
estimated to illustrate the effects of number of CBCT cycles (all papers), treatment group for the 
whole study cohort (papers I and III) and treatment group according to histology (paper I). Risk 
tables presenting crude number of individuals by follow-up time accompanied the Kaplan-Meier 
plots in papers II and III. In paper III, unadjusted Kaplan-Meier curves including population 
expected (PE) risks were also included. PE risk was calculated from population lifetables 
containing mortality rates stratified by 1-year age groups and calendar year. 
 
3.5 Ethics and approvals 
The study was approved by the Data Protection Authorities at the University Hospital of North 
Norway (2015/2008) and the Regional Committee for Medical and Health Research Ethics 
(2014/1745), with the condition that all men still alive at the beginning of the study were given the 
possibility to withdraw (passive consent). Passive consent was obtained through a study information 
letter distributed to all eligible men still alive, in which they were given the possibility to withdraw 




4 Main results 
4.1 Paper I 
Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment 
in the cisplatin era (Hellesnes et al., Int J Cancer 2020) 
With information on total treatment burden available, the aim of this population-based study was to 
examine the SC risk with emphasis on the impact of previous TC treatment. 
 Median follow-up time for the total cohort of 5625 1-year TCS was 16.6 years (IQR 10.9-
23.8), median age at diagnosis was 32.9 years (27.1-40.7) and seminoma histology was present in 
52% of the participants. Over the decades from 1980-2009, the use of surgery and PBCT increased, 
and RT decreased.  
 Overall 572 (10.2%) participants developed 651 non-TC SCs. Compared with the general 
population, the TCS had an overall 58% excess risk of developing any SC (SIR 1.58, 95% CI 1.45-
1.171), and an overall 44% excess risk of developing a solid SC (SIR 1.44, 95% CI 1.32-1.57). The 
overall excess risk of all hematological malignancies was also increased (SIR 1.31, 95% CI 1.00-
1.71). The overall SC risk was significantly 1.28 to 2.00-fold increased for all treatment groups 
including surgery only. For TCS initially intended for surveillance, the total SIR was 1.34, (95% CI 
1.07-1.68). After surgery, excess risks emerged for melanoma (SIR 1.94, 95% CI 1.10-3.43) and 
cancer of the thyroid (SIR 4.95, 95% CI 1.86-13.18). After PBCT, significantly 1.86-3.73- fold 
excess risks emerged for cancers of the small intestine, lung, melanoma, kidney and bladder. After 
RT, significantly 1.47 to 4.43-fold excess risks emerged for cancers of the stomach, small intestine, 
liver, pancreas, lung, kidney and bladder. 
The overall SC risk increased with increasing follow-up time from SIR 1.28 (95% CI 1.09-
1.51) for those with <10 years follow-up time to SIR 2.12 (95% CI 1.55-2.90) for those with 
follow-up time 30-37 years. After surgery only, significantly increased SC risk was only present 
with follow-up <10 years, while the opposite was observed after PBCT and RT with significantly 
increased SC risk observed after >10 years of follow-up. The SC risk was highest in those <20 




3.17, 95% CI 1.43-7.06). It declined with increasing age at first TC treatment to SIR 1.39 (95% CI 
1.19-1.63) in those >50 years. 
 The 25-year crude cumulative SC incidence was 20% (95% CI 18%-22%) after seminoma 
and 10% (95% CI 8.7%-12%) after nonseminoma. Compared with the general population, the SC 
risk was similarly increased after both seminoma (SIR 1.59, 95% CI 1.44) and nonseminoma (SIR 
1.55, 95% CI 1.35-1.77). Compared with nonseminoma, seminoma histology was associated with 
increased SC risk in an age-adjusted model (HR 1.20, 95% CI 1.01-1.44). 
Compared with surgery, the total SC risk was significantly 1.6 to 1.7-fold increased after 
PBCT, RT and PBCT+RT after >10 years of follow-up. The hazards for solid SCs were even more 
pronounced, while hazards regarding hematological malignancies were not statistically significant. 
Significantly increased SC risks were observed after 2 (HR 1.91, 95% CI 1.01-3.59), 4 (HR 1.60, 
95% CI 1.12-2.30) and >4 (HR 2.09, 95% CI 1.23-3.53) CBCT cycles, compared with surgery after 
>10 years of follow-up. No difference in SC risks emerged when cisplatin was combined with vinca 
alkaloids vs. etoposide. Compared with surgery, both RT treatment with the L-field technique and 
paraaortic RT were associated with 1.7-fold increased SC risk, and increased SC risk was observed 
after RT doses of ≥20 Gy to first abdominal field, after >10 years of follow-up. 
In conclusion, all treatment modalities were associated with an increased non-TC SC risk 
compared with the general population, but the risks were particularly increased after PBCT and/or 
RT. Treatment with ≥2 CBCT cycles was associated with increased SC risk.   
 
4.2 Paper II 
Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study 
(Hellesnes et al., J Clin Oncol, 2021) 
Studies investigating the risk of a second TC in relation to previous TC treatment are lacking, and 
in this paper, we aimed to assess the metachronous contralateral TC risk, emphasizing the impact of 
previous TC treatment.  
 The study cohort comprised 5620 TCS with >2 months follow-up and with a median 




40.9) for the total study cohort, and 38% were <30 years. Overall, 70% were diagnosed with stage I 
at first TC, and 25% were treated with surgery while 44% were treated with PBCT at first TC. 
In total, 218 (3.9%) men were diagnosed with a second TC after median 6.2 years (IQR 3.3-
10.6), among which median age at first TC diagnosis was 28.7 years (24.6-33.5), and 57% were 
<30 years. Further, first TC histology was equally distributed with 49% seminomas and 51% 
nonseminomas, 80% were diagnosed with stage I, and as first TC treatment 33% had surgery only 
and 32% had PBCT. Histology of second TC was seminoma (72 %) in the majority of cases, and 
84% of second TCs were diagnosed with stage I.   
The overall 20-year crude cumulative incidence of a second TC was 4.0% (95% CI 3.5-4.6), 
with a lower incidence in those ≥30 years (2.8%; 95% CI 2.3-3.4) at first TC diagnosis than in those 
<30 years (6.0%; 95% CI 5.0-7.1). The incidence was also lower after treatment with PBCT (3.2%; 
95% CI 2.5-4.0) than after surgery only (5.4%; 95% CI 4.2-6.8) or RT (4.5%; 95% CI 3.6-5.6).  
Compared with the risk of developing TC in the general population, the risk of developing a 
second TC was 13-fold higher (SIR 13.1, 95% CI 11.5-15.0). Also, compared with the general 
population, the risk decreased with increasing age at first TC diagnosis and decreased with 
increasing follow-up time.  
 The second TC risk was significantly lower after treatment with PBCT at first TC (HR 0.55, 
95% CI 0.40-0.76), with surgery only as the reference group. For each additional CBCT cycle 
administered, the second TC risk decreased with significantly reduced risk after 3 (HR 0.53, 95% 
CI 0.29-0.97), 4 (HR 0.41, 95% CI 0.25-0.66), and >4 cycles (HR 0.21, 95% CI 0.07-0.66). 
Adjuvant carboplatin monotherapy was not associated with a reduction of second TC risk (HR 1.22, 
95% CI 0.62-2.39). RT treatment did not influence the second TC risk (HR 1.10, 95% CI 0.79-
1.54). 
There was no difference in second TC risk related to first TC histology when treatment at first 
TC was included in the Cox regression model (HR 0.97, 95% CI 0.65-1.45). Age ≥30 years was 
associated with a significantly decreased risk of second TC (HR 0.47, 95% CI 0.36-0.62). 
In conclusion, we observed a strong association between number of CBCT cycles and second 




diagnosis also influenced the second TC risk, while histology did not affect the second TC risk 
when adjusting for TC treatment.  
 
4.3 Paper III 
Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based 
cohort (Hellesnes et al., revised manuscript under review in J Clin Oncol) 
In this paper, we investigated the impact of modern TC treatment on cause-specific non-TC 
mortality.  
Median follow-up time for the total study cohort comprising 5707 TCS was 18.7 years (IQR 
12.7-35.0), and 46% had follow-up time beyond 20 years. Histology was equally distributed with 
52% seminoma and 48% nonseminoma. In total, there were 665 (12%) non-TC deaths. The median 
age at TC diagnosis for the whole study cohort was 33.1 years (IQR 27.0-40.8), while those 
registered with non-TC death were older (median 44.6 years, IQR 34.9-54.7).  
The overall 25-year crude cumulative non-TC mortality was 13.7% (95% CI 12.5-14.9), 
whereas the population expected (PE) risk was 11.3%. The 25-year cumulative non-TC mortality in 
the cohort and the PE risks were similar after surgery (10.1%, 95% CI 8.0-12.4 vs. PE risk 10.6%), 
while it was higher after PBCT (9.5%, 95% CI 7.9-11.3 vs. PE risk 8.1%), RT (19.0%, 95% CI 
16.8-21.2 vs. PE risk 14.9%), and PBCT+RT (18.4%, 95% CI 13.3-24.2 vs. PE risk 14.1%). 
 The overall non-TC mortality in the study cohort was significantly increased compared with 
the general population (SMR 1.23, 95% CI 1.14-1.33, AER 11.14). Significantly 1.23 to 2.04-fold 
increased excess non-TC mortality emerged after treatment with PBCT, RT and PBCT+RT, while 
no excess appeared after surgery only. The non-TC mortality risk was highest in those <20 years at 
TC diagnosis (SMR 2.27, 95% CI 1.32-3.90, AER 14.42), especially in those previously treated 
with PBCT (SMR 2.49, 95% CI 1.29-4.78, AER 16.55). The non-TC mortality risk increased with 
increasing follow-up time beyond 10 years. 
 Overall, 257 (4.5%) participants died as a result of non-TC SC. Compared with the general 
population, the TCS experienced a 53% excess non-TC SC mortality risk (SMR 1.53, 95% CI 1.35-




excess risks appeared after PBCT, RT and PBCT+RT. After PBCT, 1.69 to 6.82-fold excess SC 
mortality emerged due to cancers of the lip/oral cavity/pharynx, esophagus, lung, bladder and 
leukemia compared with the general population. After RT, 3.02 to 4.91-fold excess SC mortality 
was observed for cancers of the lip/oral cavity/pharynx, stomach, liver, pancreas and bladder.  
 In total, 408 (7.1%) participants were registered with non-cancer deaths. The risk of non-
cancer mortality was significantly increased compared with the general population (SMR 1.15, 96% 
CI 1.04 to 1.27, AER 4.71), with SMRs of 1.17 to 1.55 following PBCT, RT and PBCT+RT. PBCT 
was associated with significantly increased suicide risk (SMR 1.65, 95% CI 1.01-2.69, AER 1.39), 
and RT was associated with significantly increased mortality due to diseases of the digestive system 
(SMR 2.46, 95% CI 1.59-3.82, AER 3.29). The overall CVD mortality was not increased in the 
study cohort compared with the general population. However, within the first year of follow-up, 
death due to CVD was significantly elevated after PBCT (SMR 3.90, 95% CI 1.26-12.08, AER 
10.42). 
 Compared with surgery only, the total non-TC mortality risk was significantly 1.42 to 2.79-
fold increased following PBCT, RT and PBCT+RT after >10 years of follow-up. The risk for non-
TC SC mortality was even more pronounced with estimates 1.69 to 3.95-increased after PBCT, RT, 
and PBCT+RT. In multivariable models adjusting for histology and treatment in addition to age at 
diagnosis, the non-TC mortality risk following PBCT remained unchanged, while minimal changes 
were observed for the risks following RT and PBCT+RT. Additionally, histology did not influence 
the non-TC mortality (HR 0.93, 95% CI 0.71-1.23) in the multivariable model. Compared with 
surgery, increased non-TC mortality appeared after ≥3 CBCT cycles, with significant hazards after 
4 (HR 1.41, 95% CI 1.01-1.99) and >4 (HR 2.04, 95% CI 1.25-3.35) cycles beyond >10 years of 
follow-up. RT with the L-field technique or paraaortic RT was associated with 1.48- to 1.60-fold 
increased non-TC mortality, and abdominal RT doses of ≥30 Gy for non-TC mortality and ≥20 Gy 
for SC mortality were associated with significantly increased risks after >10 years of follow- up.  
 In conclusion, TC treatment with PBCT and/or RT is associated with significantly increased 
premature non-TC mortality, and in particular SC mortality, compared with the general population. 
The highest non-TC mortality risk was observed in the youngest TC patients. Increased risk of 





5.1 Methodological considerations 
All three papers in this thesis are based on the same population-based cohort identified by the CRN, 
diagnosed with TC 1980-2009. Thus, by referring to “the study” in the following discussion of 
methodological consideration, this applies for all three papers. If some parts of the discussion are 
only relevant for one or two papers, this is specified in the text.  
 
5.1.1 Study design 
The design of this epidemiological study is a cohort study. With this design, a group of people are 
identified, often based on exposure status or involvement in a defined population group, and then 
followed over time to capture the occurrence of health-related events.213,214 Thus, this observational 
study design is well suited to study the natural history of suspected risk factors and associate them 
with future outcomes. Both absolute and relative risks can be measured by this design, and if 
population-based, incidence rates can be deduced to similar populations elsewhere.214 Comparisons 
of incidence of within-cohort subgroups that differs in levels of exposure are common in cohort 
studies.213  
Cohort studies can be prospective (synonyms: concurrent) or retrospective (synonyms: 
historical prospective, nonconcurrent prospective, prospective study in retrospect, historical).213 In a 
prospective design, the cohort is assembled at present and then followed or traced for a period of 
time towards the future. The advantage of a prospective design is that the data collection is fitted to 
meet the study`s objective, however they are expensive and time-consuming.214 Additionally, 
prospective cohorts are very rarely based on a representative population, and a satisfactory follow-
up can be difficult to maintain as censoring can occur based on many factors other than the obvious 
factors death or emigration.215 The retrospective design, on the other hand, use existing records (i.e. 
relevant features of a population as they were at some time in the past) without regard to the 
outcome status, and trace the population forward up to, and possibly including, the present to 
investigate the occurrence of the outcome of interest.216 In other words, it is conducted by 
reconstructing data about persons at a time or times in the past.213 This design is often used in 
relation to record linkage (the combination of information from two or more records by the use of a 




for a successful register-based study.217 This design has made important contributions to scientific 
comprehension of disease causation.213 Strengths of the retrospective design is the low cost and 
speed. A main limitation is the obligatory reliance on the quality of preexisting information, i.e. the 
exposure and/or outcome information may not be suitable to fulfill the study objectives.214,215 
According to Bhopal, the difference between the retrospective and the prospective cohort study is 
minimal, it is merely the use of historical vs present records on exposure status.214 Nevertheless, the 
terms have been widely discussed and created confusion, and as a solution it has been suggested 
that describing what has been done instead of labeling the study.218 
The present study is a retrospective cohort study. However, of the many available 
synonyms, the term historical prospective cohort study best captures the design of this study. As 
already mentioned, the cohort is population-based, identified by the CRN. The cohort was 
assembled based on a common feature; the diagnosis of germ-cell TC between 1980-2009 (in the 
past), and the exposure status (TC treatment) was based on historical medical records. The study 
population was then followed until the occurrence of an event obtained by linkage with the CRN 
(papers I and II) and the NCoDR (papers III) or until emigration or the end of study. The design of 
the study made it possible to report incidence rates that can be extrapolated to similar populations 
elsewhere and also make within-group comparisons of the different exposures (treatment groups).  
The causal inference in epidemiologic research, for which Sir Bradford Hill`s considerations 
remain a cornerstone, focus on whether confounding or bias are possible alternative explanations 
for an observed statistical relationship, and if they are not, whether a cause-relationship can be 
assumed.215 The golden standard for causal inference in epidemiology research is experimental 
evidence (randomized controlled trials), however for many clinically significant research questions, 
conducting a trial is unethical or not possible. Temporality is another consideration for causal 
inference; the exposure always precedes the outcome. This is a strength of prospective cohort 
studies, and although historical, the study design of the papers in this thesis has a distinct 
temporality. Other considerations of causal inference include strength of the association, dose-
response relationship between exposure dose and risk of outcome and the existence of a biological 
plausible explanation. It is important to bear in mind that causal inference cannot be drawn based on 
results from a single observational study. Consistency of an association across epidemiological 
studies is a consideration of great importance, and it is the rationale behind the meta-analytic 






Validity refers to whether the inferences drawn from a study are valid, and as such validity relates 
to the quality, or the lack of errors, in the entire process of the study.213  
External validity refers to the degree of generalizability of results from a study to other 
populations or groups that did not participate in the study.213 Generalizability can be improved by 
conducting strict inclusion or exclusion criteria and other strategies that limits confounding.219 In 
our study, the entire Norwegian population with TC was included. Except for the 23 men (0.38%) 
that declined to participate, the population in the study was complete, and thus representable for the 
Norwegian population. We did not have information on race for our subjects, however, the 
proportion of non-white participants is probably very small.220 Thus, the results in this study is 
presumably not generalizable to non-white populations, but it is considered generalizable to white 
populations in other countries with similar availability of health care and TC treatment. Though the 
TC treatment have been modified somewhat during the last decades (discussed in chapter 1.4.1), the 
exposure variables (TC treatment) in this study are considered highly generalizable to treatment as 
it is today. Albeit adjuvant RT is no longer recommended in Norway, this treatment is still in use in 
some other countries,221 and as we expect the SCs and mortality associated with RT to persist for 
yet another decade,177,198 this exposure is also still relevant for TCS in Norway. Likewise, the 
outcomes (SC, second TC and mortality) are based on national registries with high 
completeness.222,223 Altogether, the external validity of our study can be considered as high. 
Internal validity concerns to which extent an observed association can be explained by the 
exposure rather than other alternative factors.219 Internal validity can be enhanced by minimizing 
the degree of systematic error (bias and confounding), and will be further discussed in chapters 
5.1.3 and 5.1.4. 
 
5.1.3 Bias 
Bias can be characterized as a product of systematic error in the design or conduct of a study.215 The 




of the study. Although there is an abundance of different biases, the majority of biases related to 
study design and procedures are classified in selection bias or information bias. 
Selection bias occurs if there is a systematic error in the recruitment or retention of exposed 
vs. unexposed study participants.215 Porta et al., claim that the requirement of informed consent in 
historical prospective cohort studies threaten these studies, as a large number of participants in 
reality makes it impossible to obtain an informed consent.213 The requirement made by the Regional 
Committee for Medical and Health Research Ethics that all participants still alive were to be 
informed about the study and given the possibility to withdraw from participating (passive consent), 
introduced a possible selection bias in our study. If those that withdrew their consent varied 
according to exposure (TC treatment) or probability of outcome (e.g. if the majority of those that 
withdrew from participation had experienced a SC) this could introduce a systematic deviation of 
the results in our study. As only 0.38% men declined participation, the magnitude of this error, if it 
exists, is considered too small to hamper the results.  
In cohort studies, selection bias usually relates to differential losses to follow-up, i.e. the 
study participants who are lost to follow-up differs from those that remain under observation. If 
those lost to follow-up have a different probability for the outcome, i.e. that there is not 
independence between censoring and survival, this can cause bias of the incidence estimates, in 
particular the estimates of absolute cumulative incidence. As such, independence between censoring 
and survival is one of two fundamental assumptions in survival analyses.215 Relative incidence 
estimates of within-cohort subgroups may however still be estimated if losses to follow-up are 
fairly similar between exposed and unexposed (a so-called compensating bias). Differential losses 
to follow-up mainly constitute a problem in prospective cohort studies with long-follow up time. In 
the present historical prospective cohort study censoring only occurred at death, emigration or study 
end. The distribution of TC treatment in those that emigrated (n=72 in paper III) was similar to the 
total study cohort, and thus differential losses to follow-up is negligible in our study. The second 
assumption in survival analyses is a lack of secular trends during the study`s accrual period.215 If the 
characteristics of the participants changed during the accrual period or there were significant 
changes in exposures (treatment), then bias of cumulative incidence estimates may be introduced. 
Despite the modifications in TC treatment during the study (as described in chapter 1.4), the TC 





Information bias in epidemiological research occurs when the definitions of study variables 
are inexact or when the data collection procedure is inaccurate.215 This results in misclassification, 
defined as a systematic error in the classification of exposure and/or outcome status. 
Misclassification can be non-differential (random) or differential (non-random). Non-differential 
misclassification is misclassification of exposure that is independent of the outcome or vice versa, 
while differential misclassification is misclassification of exposure or outcome that are dependent 
on status of the other.215 In our study, misclassification of exposure variables could potentially 
occur in the process of establishing the clinical database; important information in medical records 
may have been overlooked, errors might occur whilst punching data into the clinical database, or 
the information reported in the medical journals was incorrect. These potential errors would cause 
non-differential misclassification as they are independent of the status of the outcome. These errors 
may leap in all directions, i.e. information of treatment given might be exaggerated (for example 
reported as four courses of chemotherapy while in reality none were given to this patient), or it 
might be understated (for example reported as no additional treatment given while in fact the patient 
received four courses of chemotherapy). The presence of non-differential misclassification will 
generally lead to an underestimation of the association between exposure and the disease, and it is 
an important reason why epidemiological studies underestimate effects. However, unpredictable 
outcomes may follow misclassification of confounding variables.214 To minimize the chance of 
non-differential misclassification during data assembly, clinical data were plotted in a careful and 
thorough manner. As some degree of measurement error is inevitable,214 this error could to some 
degree be reduced if two independent researchers collected the same data. This was however not 
feasible in our study due to a large amount of data to be collected. From personal experience, the 
chance for the exposure information in our study (i.e. the TC treatment information) to be flawed in 
medical records is minuscule. 
The outcome information in our papers were obtained from two National Registries. The 
CRN is a cancer registry with very high completeness; through the Norwegian unique personal 
identification number, all hospital clinicians, pathology laboratories and general practitioners are 
instructed by law to report all new cases of cancer to the registry.222 Additionally, the records in the 
CRN is supplemented with data from the NCoDR for all deaths registered with a cancer diagnosis 
to ensure completeness and validity, and with the national population registry for vital status. For 
information on cancer treatment, however, the quality of the CRN data are considered unreliable.224 




discussed, in part due to the relatively high frequency of unspecified codes for the underlying cause 
of death.223 In paper III, 31(3.6% of a total mortality of 846 deaths (including TC death)) were 
registered with ill-defined or missing causes of death. Additionally, older patients usually suffer 
from comorbidity and several causes of death may thus be plausible, and autopsies are rarely done. 
Since 50 % of all deaths in the Scandinavian countries happen after age of 80 years, this is an 
important reason for why the quality of the NCoDR is questionable.217 For younger patients, the 
cause of death is often clear-cut, and autopsy rates are quite high. Errors on cause of death might 
lead to non-differential misclassification. However, it is possible that a previous medical history of 
cancer will lead to erroneous use of a cancer diagnosis on the death-certificate when in fact the 
cause of death is unknown, and this will lead to differential misclassification. 
 Surveillance bias occurs when exposed individuals are subject to a closer surveillance, and 
as a result, the detection of the study outcome is more likely in the exposed.215 In cohort studies, 
surveillance bias can be considered as a kind of information bias, but it may also be considered a 
selection bias depending on study design (i.e. case-control study). In paper I, the SC risk after 
surgery only was highest within the first 10+1years of follow-up, suggesting influence of 
surveillance bias. Further, no increase of mortality was observed after surgery in paper III, possibly 
due to early detection However, in the same manner we would then expect the SC risk after PBCT 
and RT to be increased within the first 10 years of follow up. As this was not the case, we regard 
that the increased SC risk after surgery was not the product of surveillance bias. In paper II, 
surveillance bias might have contributed to the majority of second TCs being diagnosed as stage I. 
 
5.1.4 Confounding  
Confounding occurs when the association between an exposure and an outcome is influenced by a 
third variable (a confounding variable or confounder).215 Thus, an alternative explanation exists for 
the observed association. A confounding variable must be causally associated with the outcome and 
also non-causally or causally associated with the exposure, but it is not an intermediate variable in 
the causal pathway between exposure and outcome (Figure 9). Accordingly, to identify a 
confounding variable, expert knowledge regarding pathophysiological and clinical mechanisms is 
required. The association between exposure and outcome might be induced, strengthened, 











Note: A unidirectional arrow indicates a causal relationship and a bidirectional arrow indicates a noncausal relationship.  
 
Once identified, the presence of confounding variables can be managed in two ways: at the 
planning stage through study design or at the analytical stage through statistical correctional 
methods. The study design can reduce and to some extent also help avoid confounding. 
Confounding is much more likely to happen in observational (i.e. cohort studies) than experimental 
epidemiological studies (i.e. randomized controlled trials).215 In the latter, the process of 
randomization, if successful, will produce two groups that are supposed to be similar regarding 
known confounding factors. In observational study designs, the idea of matching has been 
introduced as a strategy to try to reduce the effect of confounding factors. Matching is commonly 
used in case-control studies where cases and controls are picked in a manner so that they are alike 
regarding confounding factors.215 Matching is however infrequently used in cohort studies, the main 
reasons being the large size of most cohort studies and that a multitude of variables regarding 
exposures and outcomes often are investigated in the same study. Confounding in cohort studies are 
thus better dealt with at the analytical stage. For this to be feasible, the study must be carefully 
planned so that possible confounding factors can be accounted for. When a confounding variable is 
suspected, it can be further assessed and its effect reduced by various statistical techniques like 








Overall, in papers I and III, increasing age is the single most important risk factor for the 
outcomes (SCs and mortality).1 In paper II, age is also associated with second TC risk.23 
Additionally, age is associated with the exposure in our study, as those treated with RT 
(seminomas) are generally older than those treated with PBCT (the majority of which are 
nonseminomas). Accordingly, age is an important confounding factor in our study. The effect of 
age on the association was controlled for in all the relevant statistical analyses in the three papers. 
SIRs and SMRs are methods of indirect age adjustment, and in Cox regression, age was always 
included in the models. Additionally, in paper II, we stratified on a dichotomized age variable.  
Adverse health behaviors like smoking, alcohol abuse, physical inactivity and an unhealthy 
diet are, as mentioned in chapter 1.6.7, associated with increased cancer incidence and premature 
mortality.182-185 As much as 35% of excess SC risk is presumably related to modifiable lifestyle 
factors like smoking and alcohol.186 In addition to lifestyle risk factors,183,225-227 coronary heart 
disease is also associated with modifiable risk factors like hypertension and hyperlipidemia.228,229 
An important limitation of our study is the lack of information on lifestyle and coronary heart 
disease risk factors for all participants. Thus, the potential confounding effect of such risk factors on 
our results cannot be assessed or adjusted for using available statistical methods. The most 
important lifestyle risk factor related to both SC and mortality is smoking,182 and consequently I 
will discuss this risk factor in more detail in the following. As described, a confounding variable 
must also be related non-causally or causally to the exposure. In the smoking example, this means 
that the smoking behavior among TCS must differ across the different treatment groups and/or 
differ compared with the general population. As described in chapter 1.6.5, smoking has not been 
observed as more common in TCS compared with controls in previous studies,111,166 while younger 
cancer survivors had a higher smoking prevalence.168 However, a recent Danish study observed 
higher current smoking prevalence among TCS compared with a reference population, with the 
highest prevalence among TCSs treated with BEP.230  
It is also possible that underlying genetic aberrations or shared environmental exposures 
predispose some TCS for other cancers,27,28,182 or that epigenetic changes brought on by PBCT 
increase the morbidity in TCS.231 More research within these fields are needed before their potential 




Traits associated with TC as well as presence of GCNIS are potential confounding factors in 
paper II if they are associated with exposure status (treatment or age) in addition to being related to 
the second TC risk. The lack of this information constitutes possible limitations in paper II. 
 
5.1.5 Statistical considerations 
According to the null hypothesis which states that there is no association between an exposure and 
the outcome, a Type I error is rejecting the null hypothesis when it is true.215 This error is the most 
serious, and by tradition, the accepted probability of making a Type I error is <5% in medical 
research. A Type II error is failing to reject the null hypothesis when it is false, i.e. stating that 
there is no association between the exposure and outcome when in fact there is.215 The accepted 
probability to commit a Type II error is 10-20% in most studies. The statistical power of a study 
relates to the study`s ability to detect an association if such exists, i.e. the probability of not making 
a Type II error.213,215 The aim in most studies is a power of ≥80%, and this is influenced by factors 
like sample size, study design, and the frequency of the outcome. 
In papers I and III we conducted multiple hypothesis testing when site-specific SC incidence 
and causes of deaths were analyzed, and this increase the risk of Type I errors. 232,233 There are 
available methods to reduce the probability of Type I errors in multiple hypothesis testing, and the 
most frequent method is the Bonferroni correction.232,233 However, due to the increasing risk of 
Type II errors, we did not perform such corrections, as advised by Rothman.234 It is therefore 
important that caution is taken when interpreting results involving few events.  
In paper III, TC deaths were not excluded from the background data provided by the 
NCoDR when calculating SMRs of total SC mortality. This could potentially lead to an 
underestimation of the SMRs. However, since TC deaths constitutes a small fraction of the total, 
this bias is considered negligible.  
In regression models, collinearity is the presence of a very strong linear relationship between 
two or more independent variables or covariates.213 If included in the model, this may result in 
biased or confounded estimates. The common solution to collinearity is removal of one of the 
collinear variables from the model, although this might result in confounding if the removed 




the Cox regression model together with treatment group and age. However, all estimates changed 
dramatically, and because we suspected the reason being collinearity between stage and treatment 
group, we decided clinical stage could not be included in the model. In paper III, we included 
histology in multivariable Cox regression models. The estimates regarding RT changed a little bit in 
the multivariable model, while estimates regarding chemotherapy remained unchanged. The reason 
for this is probably the collinear relationship between seminoma histology and RT treatment, but 
because of the still unchanged estimates regarding chemotherapy, we decided to apply the 
multivariable model because we believe that it was essential to demonstrate that treatment, and not 
histology, was the most important covariate.  
   
5.2 Discussion of results 
In the following discussion of results, when referring to the results in our study, the distinction 
between PBCT and CBCT described in chapter 3.2.2 is still valid. However, when referring to other 
studies, the abbreviation CBCT was used when the studies being discussed only studied or 
mentioned cisplatin, BEP or CBCT.  
 
5.2.1 Metachronous contralateral TC (Paper II) 
The overall 20-year crude cumulative incidence of metachronous contralateral TC in the study 
cohort was 4% and the total SIR was 13.1 which is in line with previous studies.23,116-121 The 
increased risk of a second TC is probably explained by shared genetic and prenatal environmental 
predispositions, as described in chapter 1.2.13 These shared etiological factors of the first and 
second TC probably explain why young age at TC has been associated with a significantly 
increased second TC risk in both previous studies and the present one.23,117,124,235  
We observed a strong association between PBCT at first TC and a reduced second TC risk, 
concurring with the hypothesis of a protective role of cisplatin.23,116,117,119 Further, to the best of our 
knowledge, we demonstrated for the first time a dose-dependent relationship between number of 
CBCT cycles and a reduced second TC risk, with significantly reduced risk emerging after ≥3 
CBCT cycles. This dose-dependent relationship has also been confirmed by a recent Dutch study,236 




TC is preceded by GCNIS, and if left untreated, 50% of GCNIS will develop into an 
invasive cancer within 5 years.41. In previous studies, the effect of cisplatin on GCNIS eradication 
has been moderate, but possibly dose-dependent.128,238-241 Supporting our results, a Norwegian 
study involving 61 TCS with simultaneous biopsy-proven contralateral GCNIS reported 
significantly reduced second TC risk after >4 CBCT cycles compared with 1-3 CBCT cycles or no 
chemotherapy.128 The need for a sufficient cumulative dose of cisplatin before second TC risk is 
reduced may in part be explained by the blood-testis barrier`s modulating effect on the intratubular 
cisplatin concentration.242,243 The decrease in sperm concentration and changes of sperm DNA 
observed after CBCT demonstrates that the testicular function is influenced by this treatment.146,147 
Further, the recovery of testicular function is associated with number of CBCT cycles, and a higher 
probability for long-term reduced sperm count has been observed after ≥3 CBCT cycles147-151 
The risk-adapted treatment strategy in TC stage I, as recommended by SWENOTECA, 
enabled the comparison of adjuvant chemotherapy with surveillance.15 In line with a prospective 
study,244 we observed no risk reduction following 1-2 CBCT cycles. Likewise, we did not observe 
any risk reduction after 1 cycle of adjuvant carboplatin, however this result is contrasted by a 
randomized trial reporting a reduction of second TC risk after 1 cycle of adjuvant carboplatin 
compared with RT in 1477 stage I seminoma patients.80  
Some previous studies have implied that cisplatin, instead of eradicating GCNIS leading to a 
reduced second TC risk, simply delay the invasive cancer development.239,240 In line with 
Schaapveld et al.,117 our results do not support such observations. In fact, we observed a longer 
median time interval between first and second TC after surgery (7.0 years) than after PBCT (5.8 
years), although not statistically significant. The overall median latency of 6.2 years between first 
and second TC was identical with the Dutch study.236A plateau in second TC incidence has been 
reported after 15-20 years of observation.117,118 However, we demonstrate that second TCs may 
develop more than 20 years after the first TC, with the longest latency between first and second TC 
of 27 years, in line with previous observations.245 Despite an equal median follow-up time, no 
second TCs were observed after 20 years in the Dutch study.236  
The role of histology on second TC risk has been inconsistent in previous studies; some 
studies conducted in the pre-cisplatin era have reported a higher risk for metachronous contralateral 
TC after first TC nonseminoma vs. seminoma.118,126 In the cisplatin-era, on the other hand, 




reported a significantly higher risk for a second TC after first TC seminoma, even when adjusting 
for age and number of CBCT cycles.236 The significantly increased risk of the youngest TC patients 
(i.e. nonseminoma) reported in the Dutch study, is however contradictory with an increased second 
TC risk associated with seminoma histology.246 A limitation of the Dutch study was that complete 
treatment information was available only for those developing a second TC and a sub cohort, 
corresponding to 19% of the total cohort. In a multivariable model including age and first TC 
treatment, we observed no association between first TC histology and subsequent risk of second 
TC, in line with some previous studies.116,117,124 We suggest that the differences in second TC risk, 
in some studies associated with histology, merely reflects the fact that nonseminoma patients more 
frequently are treated with CBCT. Results from studies on contralateral biopsies, reporting that 
young age and testicular atrophy was associated with presence of GCNIS, whereas histology of a 
primary TC was not,247,248 further support this assumption.  
Corroborating previous studies,117,118,124 treatment with infradiaphragmatic RT did not 
influence the second TC risk. The scattered RT dose to the remaining testicle has been estimated to 
0.09-0.32 Gy in stage I seminoma,249 which is not considered sufficient for eradicating GCNIS. 
 The majority (72%) of the second TCs in our study had seminoma histology, in line with a 
review including 51 studies reporting seminoma histology in 60% of second TCs.250 We 
hypothesize that the more frequent seminoma histology is an effect of ageing.1 Robust follow-up 
procedures, centralized TC treatment, and a risk-adapted biopsy strategy of the contralateral testicle 
probably accounts for the even higher proportion (84%) diagnosed with stage I in our study, as 
compared with 73% in the review.15,250,251 Much anticipation has been associated with the new 
biomarker miR-371a-3p, however so far it has not proven successful in detection of GCNIS before 
it becomes invasive.59  
 
5.2.2 Incidence and mortality of non-TC second cancer (Paper I and III) 
The overall 58% excess SC incidence and the 44% excess solid SC incidence compared with the 
general population observed in Paper I is in line with a Swedish report investigating SC incidence 
in TCS treated in the modern era,252 while it is a little lower than the 80% excess solid SC incidence 
reported by a Dutch study.253 A recent SEER-based study reported a SIR of solid SC of only 1.06 in 




selection bias due to the hospital-based study design explained the higher SIRs in the Dutch study 
study.254 Previous reports involving TCS treated in the pre-cisplatin era reported overall SIR of 1.6 
to 1.9.119,121,169,175-177  
 Mortality due to non-TC SCs was the most important cause of death in Paper III, with a total 
SMR of 1.53. However, the AER of 7.94 was not very high. This is a little lower than the SMR for 
SC mortality of 1.9 and AER of 19.1 reported by a recent Dutch study investigating mortality in 
6042 TCS treated 1976-2006.255. In line with our results, a recent report involving 1,5 million 
cancer survivors concluded that cancer survivors have increased risk of developing or dying from 
SCs compared with the general population.256 
In line with previous studies,177,195,198,253,255 we observed a considerable latency before the 
risk of SC incidence and mortality increased. The risk of SC and mortality increased with 
increasing follow-up time, especially beyond 20 years, and this underscores that sufficient follow-
up time is required when SC incidence and mortality after TC treatment is studied.  
Importantly, in line with previous studies,177,253,255 an age-gradient emerged for SC 
incidence and non-TC mortality, with the highest risks observed in those with young age at TC 
diagnosis. A large SEER-based study identified 5-year adolescents and young adult (AYAs; 15-39 
years) cancer survivors, including TCS, as having a higher risk of developing a SC compared with 
an age-matched general population, and the absolute risk was higher for AYAs than for pediatric or 
older adult cancer survivors.257 Thus, it seems that follow-up regarding SC development is 
particularly important in AYA TCSs.  
Contrasting available studies,127,195,253,254,258 we observed an increased SC incidence after 
surgery, to our knowledge for the first time. However, no excess SC mortality appeared after 
surgery, in line with previous studies.127,255 In fact, the Danish study reported a reduced mortality 
after surgery (HR 0.9), but as participants were excluded from analysis in case of relapse, we 
believe that caution must be taken when interpreting these result. Indeed, we observed that 
participants initially intended for surveillance were associated with a significantly increased SC 
incidence compared with the general population (SIR 1.34). 
Site-specific incidence investigations demonstrated an increased risk for thyroid cancer after 




diagnosis of only 5.8 years, which might indicate surveillance bias, this is a novel finding that 
should be explored in future research. Other studies have reported an increased risk for thyroid 
cancer after PBCT,195,253 254 and after RT.177,254,258 Both thyroid and testicular cancer are associated 
with endocrine disruptors,259 suggesting a common etiology.  
In line with one previous report,169 an increased melanoma risk was observed after surgery. 
Increased melanoma risk has been reported after RT in some previous studies involving 
TCS,175,177,260 while the majority of available studies reports no such risk.127,195,253,254 Increased 
melanoma risk has been attributed to an increased medical attention during the first years after a TC 
diagnosis.260 However, as the median time to melanoma diagnosis in our cohort was 14.6 years, 
surveillance bias is not a likely explanation for this association.  
Recent studies on familial cancer risks have reported a significant association between TC 
and other cancers, including melanoma and cancer of the thyroid, suggesting the presence of 
inherited cancer susceptibility syndromes.27,28,261,262 Likewise, increased SC risk, including TC and 
thyroid cancer, has been observed in melanoma patients.263 Additionally, a common susceptibility 
to BRAF mutation has been reported in melanoma and thyroid cancer, with an observed twofold 
reciprocal increased risk of developing thyroid cancer after melanoma or vice versa.264 No TCS 
developed both melanoma and thyroid cancer in our study. Taken together, we believe the increased 
SC risk observed after surgery implies that genetic susceptibility and/or common fetal influences 
predispose for both TC and other malignancies.  
The modern era PBCT treatment of TC was associated with a 62% increased SC risk 
compared with the general population, in line with publications from Denmark, United States, 
Holland and Sweden.127,195,252-254. The Dutch study reported the highest SIR (2.25) after PBCT.253 
PBCT was associated with a 43% increased risk of SC mortality compared with the general 
population, in line with the Danish study,127 whereas another Dutch study reported a higher SC 
SMR (2.54).255 However, of the available studies, only the Danish nationwide study provided 
complete information on TC treatment, whereas the two SEER-based US studies provided first-line 
treatment only.195,254 The two Dutch multicenter studies provided complete treatment information 
only for those that developed SC or died and a randomly selected subcohort of approximately 1100 
participants, while primary treatment was registered for all participants.253,255 The Swedish study 




 Bladder cancer emerged as one of the most important SCs after PBCT with a 3-fold 
increased incidence and a 6-fold increased mortality compared with the general population. The 
increased bladder cancer incidence after PBCT has been observed in previous studies.127,169,177,195,253 
Increased mortality due to bladder cancer was however not observed in the comparable Dutch 
study.255 In line with other reports,195,252-254 we observed a two-fold increased risk for cancers of the 
kidney and upper urinary tract after PBCT compared with the general population. We did however 
not observe an increased kidney cancer mortality, contrasting the Dutch study.255 Platinum 
compounds has been detected in urine for up to 17 years after treatment.96 Thus, a continuing 
platinum exposure of the genitourinary epithelium to platinum metabolites might explain the 
increased bladder cancer incidence. As the development of superficial bladder cancer into a more 
invasive cancer takes many years, a long observation time is needed before mortality is observed.265  
We have reported that two or more CBCT cycles were associated with an increased SC 
incidence, and three or more CBCT cycles were associated with increased non-TC SC mortality, 
consistent with the two Dutch studies.253,255 A strength of the Dutch studies was the inclusion of 
smoking status at TC diagnosis in the multivariable models investigating treatment intensity. As 
demonstrated in Paper III, the follow-up time was shorter for 3 CBCT cycles, which probably 
explains why statistical significance was not reached for those estimates. In line with a previous 
study,266adjuvant treatment with one course of CBCT or Carboplatin was not associated with an 
excess SC incidence nor mortality, however the follow-up time is still short necessitating future 
studies. 
 Consistent with the increasingly extensive documentation of excess SC incidence and non-
TC SC mortality after RT in TCS, 127,169,177,188,204,253-255,267 we reported an overall SIR of 1.64 and 
SMR of 1.59 after previous treatment with RT. We observed significantly increased incidence and 
mortality due to SCs of the stomach, liver, pancreas and bladder, as well as increased incidence of 
cancers of the small intestine and kidney and upper urinary tract, i.e. within the boundaries of the 
previous RT field as described in available studies.119,127,177,188-190,204,253-255,268 Although not evident 
in paper I, a dose-dependency of the abdominal RT field emerged in the Cox regression analysis in 
paper III, in line with previous publications.191,253,255 As the use of adjuvant RT was abandoned in 
Norway during the early 2000s,15 we expect the malignancies and mortality related to RT to prevail 




Increased SIRs and SMRs of soft tissue sarcoma have been reported after PBCT and 
RT,195,253-255 however, our results could not confirm these findings. Soft-tissue sarcoma in TCS may 
reflect transformed teratomas.269,270  
 The combination of alkylating chemotherapy and RT in lymphoma survivors has increased 
the SC risk in a dose-dependent and additive manner.271-273 However, the combination of PBCT and 
RT is not well examined in TCS. In line with one previous study,169 we observed the highest risks 
of total SC incidence (SIR 2.14) and non-TC SC mortality (SMR 3.24) following the combination 
of PBCT and RT.  
Increased risk of leukemia was observed after PBCT+RT (paper I) and increased leukemia 
mortality was observed after PBCT (paper III), although based on very few cases. Increased 
leukemia mortality was also reported in the Dutch study.255 Acute myeloid leukemia (AML) is a 
rare and fatal treatment-related complication associated with both platinum compounds and 
topoisomerase II inhibitors (e.g. etoposide).179,274,275 Leukemia associated with cytotoxic agents like 
PBCT is usually preceded by myelodysplastic syndrome (MDS), involves numerous and complex 
genetic aberrations and is associated with a poor prognosis.187,274 The post-treatment latency of 
leukemia after agents like PBCT is often 2-10 years,187,274 and this is consistent with the significant 
increase in leukemia incidence after PBCT+RT within the first 10 years of follow-up. However, 
two of the three leukemia deaths after PBCT occurred >15 years after the TC treatment. Leukemia 
associated with etoposide is, on the other hand, usually not preceded by MDS, has a short latency 
period, often involves one major genetic abnormality of crucial genes, and is associated with a more 
favorable prognosis.187,274 PBCT has been associated with leukemia in a dose-dependent manner in 
TCS.179 In a recent report, Morton et al. investigated the risk of MDS or AML in 700612 survivors 
of first primary solid cancer diagnosed 2000-2013, among which 8052 TCS.276 In line with the 
expanding use of PBCT to improve survival of many solid cancers during the last two decades, the 
authors observed increased diagnoses of MDS or AML following cancers previously not associated 
with leukemia, concluding with a leukemogenicity of PBCT.276 After TC, they reported a 
significant 12% excess risk of MDS or AML compared with the general population. The leukemia 
risk following RT is less clear,274,276 however the combination of PBCT and RT is associated with 
higher risk,119,276 consistent with our results (Paper I). 
Corroborating available studies,127,195,253,255 PBCT was associated with an excess risk of 




studies,127,169,188,253,254 abdominal RT was associated with increased lung cancer incidence. 
Excessive mortality due to cancer of the esophagus was observed after PBCT and mortality due to 
cancers of the lip/oral cavity/pharynx was increased after both PBCT and RT. Smoking has been 
associated with higher number and severity of long-term adverse health outcomes in TCS.277 
Smoking-related cancers (lung, bladder, oral cavity/pharynx and esophagus) were associated with 
as much as 45% of the total SC mortality in a recent report.256 Smoking has been found to interact 
with alkylating CT and RT in an additive manner in survivors of Hodgkin`s disease.271,272 A recent 
Danish investigation involving 2395 long-term TCS, reported that prevalence of current smoking 
and overweight were higher in TCS compared with a reference population, and the smoking 
prevalence among those previously treated with BEP was particularly high.230 Lifestyle risk factors 
might reduce the risk of cancer recurrence and enhance prognosis.278  
Risk of total SC incidence and non-TC SC mortality was significantly increased for 
seminoma histology compared with nonseminoma with >10 years follow-up in age-adjusted Cox 
regression analyses. However, in the multivariable models including treatment, histology was not 
associated with a difference in mortality risk. In our opinion, this demonstrates that it is 
dissimilarity in treatment and age at diagnosis that results in the differences in risk between 
seminoma and nonseminoma in crude and relative analyses.  
Platinum levels can be detected in plasma for up to 20 years after TC treatment, and is thus a 
constant source for damage to DNA.104 It is hypothesized that cytotoxic therapy, especially during 
childhood and early adulthood, induces cellular senescence, resulting in an early ageing phenotype, 
increasing the risk of premature adverse health conditions, like development of SCs and increased 
overall mortality risk.279-282 Adverse health behaviors after the TC diagnosis may further contribute 
to the process of accelerated ageing, and thus avoidance of lifestyle stressors may possibly reduce 
cellular senescence after cytotoxic treatment.282 We hypothesize that previous TC treatment with 
PBCT and/or RT, possibly in combination with epigenetic, genetic and lifestyle factors, is the most 
important risk factor for the increased SC incidence and mortality observed in papers I and III.  
 
5.2.3 Non-cancer mortality (Paper III) 
We observed an overall 15% excess risk of non-cancer mortality compared with the expected 




reports.201,255 Compared with the general population, the overall non-TC mortality risk has been 
described as increasing with time since TC diagnosis,255 consistent with the observed risks in our 
study. Fosså et al. indicated that non-cancer mortality did not decline with increasing follow-up 
time in their study involving 38907 1-year TCS, however the median follow-up time was only 10 
years 201 Accordingly, sufficient follow-up time is crucial also when non-cancer mortality in TCS is 
studied.  
Corroborating previous studies,201,202 we did not observe an increased overall non-cancer 
mortality risk after surgery compared with the general population. Nonetheless, a significantly 
increased risk of mortality due to infections emerged after surgery in our study, supported by one 
previous study,201 while the other study observed an increased mortality due to infectious disease 
after CBCT.127 However, both studies included pneumonia in the category of infectious disease, and 
although this is clinically relevant, we followed the European Shortlist for causes of death in which 
pneumonia is grouped together with respiratory diseases.209. Kier et al. described that human 
immunodeficiency virus was the major cause of increased mortality due to infections.127 In our 
study, however, acquired immunodeficiency syndrome was the cause of death for only 3 of in total 
15 deaths due to infections.  
In line with one previous study,201 we observed an overall 23% excess risk of non-cancer 
mortality following PBCT. The AER was 4.95 per 10000. The estimates were a bit lower than the 
SMR of 1.60 and AER of 14.29 reported by a SEER-based study including 15006 nonseminona 
patients and the SMR of 1.70 reported by a Dutch multicenter study including 6042 TCS, however 
both studies included information on first-line treatment only.202,255  
We observed a 65% excess suicide risk compared with general population rates after PBCT. 
Although the AER was only 1.39, any such avoidable death is devastating. Suicide is more frequent 
in men than women, and in Norway the median age at suicide is 47 years.283 In Norway, suicide is 
the cause of 30-50% of the total mortality in men 20-35 years,210 and according to the NCoDR, the 
suicide rates in Norway are similar with suicide rates in Europe, Northern America and Australia.283 
From the literature, TCS disturbingly seems to have an increased suicide risk compared with the 
general population.165,204,284 However, studies from Holland and Denmark,127,255 and the study by 
Fosså et al.,201 report no such increased risk. In a review on psychological distress in TCS including 
36 studies, anxiety was identified as more common in TCS compared with the general 




not. Further, passive coping strategies and treatment-related adverse effects in TCS were associated 
with an inferior psychological outcome.285 Removal of a testicle may lead to feelings of loss, 
uneasiness and shame, and these negative feelings were more common in younger compared with 
older TCS.286 Further, a negative change of perceived body image (i.e. reduced masculinity) was 
reported by 17% in a study of long-term TCS.153 Additional treatment beyond orchiectomy was 
associated with significantly increased use of mental health services post-TC treatment in a recent 
population-based study from Canada.287 In our study we observed an increased mortality in those 
<20 years at TC diagnosis, particularly those treated with PBCT. As the majority of those treated 
with chemotherapy have nonseminoma histology, and because nonseminoma patients are younger 
at diagnosis than those with seminoma, the increased risk of suicide after chemotherapy also 
reflects young age at diagnosis. This is in line with the US study by Alanee et al. including 23381 
TCS diagnosed 1995-2008, reporting highest suicide rates for those <30 years at TC diagnosis. 
Taken together, we believe the increased suicide risk after PBCT observed in our study is in part 
related to bothersome long-term effects of cisplatin together with increased anxiety, negative coping 
strategies and having received cancer treatment at a vulnerable young age. The results from this 
study calls for an increased awareness of mental health issues in TCS. 
PBCT has been associated with an increased long-term risk of CVD,111,172,288 presumably 
through a combination of direct endothelial damage and indirectly through development of risk 
factors associated with CVD.8,171 PBCT+RT was observed as especially harmful.111 Possible 
genetic pathways associated with CVD risk in TCS treated with PBCT have been identified in 
genome-wide association studies.289 We did not find an association between PBCT and increased 
risk of long-term overall CVD mortality, nor from ischemic heart disease. This is line with some 
previous reports,200,202,290 but in contrast with others.172,201,255 We believe the lack of an association 
between PBCT and CVD mortality in our study can be explained by the following; Firstly, that a 
reduction in modifiable CVD risk factors combined with improved treatment options for coronary 
heart disease has led to a general decline of mortality due to coronary heart disease during the last 
two decades.229,291 Secondly, that screening for CVD risk factors was gradually included in the TC 
follow-up guidelines in Norway from 2007,112 in line with expanding insights concerning an 
increased CVD morbidity after PBCT.110  
Two studies have presented significantly increased risk of mortality due to CVD within the 




year after TC diagnosis supports this association, although based on only three cases. The CVD 
mortality happening shortly after treatment with CBCT is likely caused by acute vascular injury and 
endothelial dysfunction.171,292 
 In contrast with previous studies,201,255 we observed a 17% overall excess of non-cancer 
deaths compared with the general population following previous treatment with RT. After RT, 
significantly increased risk of mortality due to benign diseases of the digestive system emerged, as 
previously reported.201 In a previous study, gastrointestinal morbidity has been recognized as a 
possible RT-induced late toxicity.293 The risk of total non-TC mortality and non-cancer mortality 
was particularly increased after PBCT+RT, in line with previous reports.127,201 
 
 





6 Conclusions  
Previous treatment with PBCT and/or RT was associated with an increased risk of non-TC SC 
incidence and non-TC mortality. The risks increased with increasing follow-up time beyond 10 
years after TC diagnosis. Compared with the general population, the highest risks for non-TC SC 
and non-TC mortality were observed in those diagnosed with TC at a young age, particularly those 
previously treated with PBCT. Additionally, surgery only was associated with significantly 
increased risk of SC development; however, mortality risk was not increased after surgery. PBCT at 
first TC was associated with a reduced second TC risk in a dose-dependent manner, while treatment 
with RT did not influence the risk.  
More specifically, we observed the following: 
i. Compared with the general population, the risk of non-TC SC was significantly 
increased in all four treatment groups (surgery, PBCT, RT, PBCT+RT). The treatment 
groups were associated with statistically significant risks for different cancers, compared 
with general population rates. Compared with surgery, ≥2 CBCT cycles were associated 
with significantly increased SC risks in those with >10 years follow-up, whereas one 
adjuvant CBCT or carboplatin were not associated with an increased risk. In comparison 
with surgery, RT doses of ≥20 Gy to first abdominal field were associated with 
significantly increased SC risk after >10 years of follow-up, and similar risks were 
observed following abdominal RT treatment regardless of technique (L-field or 
paraaortic field). 
 
ii. The crude cumulative incidence of metachronous contralateral TC in the TC cohort was 
lower after first TC treatment with PBCT and PBCT+RT than after surgery and RT. It 
was also significantly lower for those <30 years at first TC than those ≥30 years. The 
second TC risk was 13-fold higher than the risk of developing TC in the general 
population, and it was highest within the first 5 years of follow-up before gradually 
declining beyond 20 years. First TC histology was not associated with risk of second TC 
when adjusting for age and treatment at first TC. Compared with surgery, a dose-
dependent inverse relationship emerged for number of CBCT cycles, with a decreasing 
second TC risk for each additional CBCT cycle administered, significantly reduced after 






iii. Overall non-TC mortality was significantly increased after previous treatment with 
PBCT, RT or PBCT+RT compared with general population rates, but not after treatment 
with surgery. Mortality due to non-TC SCs was the most important cause of death, and 
the treatment groups were associated with mortality due different cancers. Importantly, 
increased risk of suicide was observed after PBCT. Seminoma vs. nonseminoma 
histology was not associated with different risks of non-TC mortality when adjusting for 
age at diagnosis and total treatment burden. Compared with surgery, ≥3 CBCT cycles 
were associated with an increased risk of non-TC mortality after >10 years follow-up. 
There was no indication of an increased mortality risk after 1-2 courses of adjuvant 












7 Implications for the future 
Given the unselected nationwide cohort, the unique quality of the National Registries in 
Norway,222,223 and the complete information on TC treatment burden, this thesis provides new 
insight on how a TC diagnosis and TC treatment influence the subsequent risk for SC, 
metachronous contralateral TC, mortality and causes of death. The knowledge generated in this 
thesis is valuable for health personnel involved in the follow up of TCS, and for present and future 
TCS of generalizable populations. It is also potentially valuable for survivors of other cancers 
treated by similar principles.  
Actions to prevent a delayed non-TC SC and second TC diagnosis, and hopefully prevent 
premature deaths, are imperative. Education of TCS themselves regarding the increased non-TC SC 
and second TC risk in a tailored manner to enhance health literacy and empowerment of TCS`s self-
management seem essential. This approach is underscored by the latency of non-TC SC 
development, non-TC mortality risk and the long-term second TC risk. In addition to information 
regarding CVD risk, second TC risk and lifestyle recommendations, information concerning the 
increased SC risk related to PBCT and RT has recently been included in an updated written patient 
care plan issued to TCS and the patient´s general practitioner in Norway and Sweden at the end of 
hospital follow-up.15 As the second TC risk may persist beyond 20 years, TCS, especially the 
youngest TCS treated with surgery only, must be well-informed about the importance of a lifelong 
self-examination of the remaining testicle.  
The results in this thesis support a constant evaluation of whether further reduction of 
cytotoxic treatment burden is possible without deterioration of TC survival. As a consequence of 
the increasing awareness of the non-TC SC risk associated with PBCT and RT, the recommended 
treatment of seminoma stage IIA has been modified to a primary unilateral RPLND, with PBCT or 
RT as possible treatment options, in the newly updated management program of SWENOTECA.15 
Clinical implementation of the promising biomarker miR-371a-3p may hopefully extend the 
possibility of a more personalized TC treatment in the near future.59,60  
Our results with increased incidence and mortality due to smoking and alcohol-related 
cancers, suggests that lifestyle improvements are important in TCS. TCS would presumably benefit 
from an implementation of counseling on lifestyle improvements in their survivorship care. It is 




strive to include information regarding modifiable risk factors. The possible cellular senescence 
brought on by cytotoxic treatment deserves attention, and an evaluation of possible underlying 
mechanisms and interventions in TCS is highly warranted. Further, future studies investigating 
biological pathways that influence the risk of non-TC SC and mortality in TCS are needed.  
The clinical role of transscrotal ultrasound for detection of GCNIS remains unclear.294,295 
The results of this thesis agrees with the present risk-adapted biopsy strategy of the contralateral 
testicle.9 and supports the need for future studies on the role of miR-371a-3p in detection of 
GCNIS.  
The increased risk of suicide after PBCT suggests that assessments regarding the mental 
health and suicide risk factors of TCS, especially the youngest TCS with additional treatment 
beyond orchiectomy, is important. Considerations as to whether psychosocial issues should be 






 1.  Cancer Registry of Norway. Cancer in Norway 2019 - Cancer incidence, mortality, survival 
and prevalence in Norway. Oslo: Cancer Registry of Norway, 2020 
 2. Cancer Registry of Norway. Cancer in Norway 2016 - Cancer incidence, mortality, survival 
and prevalence in Norway. Oslo: Cancer Registry of Norway, 2017 
 3. Gurney JK, Florio AA, Znaor A, et al: International Trends in the Incidence of Testicular 
Cancer: Lessons from 35 Years and 41 Countries. Eur Urol 76:615-623, 2019 
 4. Trama A, Foschi R, Larranaga N, et al: Survival of male genital cancers (prostate, testis and 
penis) in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer 51:2206-2216, 2015 
 5. Park JS, Kim J, Elghiaty A, et al: Recent global trends in testicular cancer incidence and 
mortality. Medicine (Baltimore) 97:e12390, 2018 
 6. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin 
combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-8, 1977 
 7. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer. 
JAMA 299:672-84, 2008 
 8. Haugnes HS, Bosl GJ, Boer H, et al: Long-term and late effects of germ cell testicular cancer 
treatment and implications for follow-up. J Clin Oncol 30:3752-63, 2012 
 9. Honecker F, Aparicio J, Berney D, et al: ESMO Consensus Conference on testicular germ 
cell cancer: diagnosis, treatment and follow-up. Ann Oncol 29:1658-1686, 2018 
 10. International Germ Cell Consensus Classification: a prognostic factor-based staging system 
for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-
603, 1997 
 11. Cancer Registry of Norway. Cancer in Norway 2009 - Cancer incidence, mortality, survival 
and prevalence in Norway. Oslo: Cancer Registry of Norway, 2011 
 12. Brydoy M, Fossa SD, Dahl O, et al: Gonadal dysfunction and fertility problems in cancer 
survivors. Acta Oncol 46:480-9, 2007 
 13. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, et al: Male Reproductive Disorders 
and Fertility Trends: Influences of Environment and Genetic Susceptibility. Physiol Rev 96:55-97, 2016 
 14. Rajpert-De Meyts E, McGlynn KA, Okamoto K, et al: Testicular germ cell tumours. Lancet 
387:1762-74, 2016 
 15. SWENOTECA: Swedish and Norwegian Testicular Cancer Group. Management Programs. 
Available from: www.swenoteca.org/procedures, 2021 
 16. Lafin JT, Bagrodia A, Woldu S, et al: New insights into germ cell tumor genomics. 
Andrology 7:507-515, 2019 
 17. Facchini G, Rossetti S, Cavaliere C, et al: Exploring the molecular aspects associated with 
testicular germ cell tumors: a review. Oncotarget 9:1365-1379, 2018 
 18. Wang Z, McGlynn KA, Rajpert-De Meyts E, et al: Meta-analysis of five genome-wide 
association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet 
49:1141-1147, 2017 
 19. Kratz CP, Han SS, Rosenberg PS, et al: Variants in or near KITLG, BAK1, DMRT1, and 
TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Med Genet 48:473-6, 2011 
 20. van der Zwan YG, Biermann K, Wolffenbuttel KP, et al: Gonadal maldevelopment as risk 
factor for germ cell cancer: towards a clinical decision model. Eur Urol 67:692-701, 2015 
 21. AlDubayan SH, Pyle LC, Gamulin M, et al: Association of Inherited Pathogenic Variants in 
Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol 5:514-
522, 2019 
 22. Hemminki K, Li X: Familial risk in testicular cancer as a clue to a heritable and 
environmental aetiology. Br J Cancer 90:1765-70, 2004 
 23. Fossa SD, Chen J, Schonfeld SJ, et al: Risk of contralateral testicular cancer: a population-




 24. Heimdal K, Olsson H, Tretli S, et al: Familial testicular cancer in Norway and southern 
Sweden. Br J Cancer 73:964-9, 1996 
 25. Frank C, Fallah M, Sundquist J, et al: Population Landscape of Familial Cancer. Sci Rep 
5:12891, 2015 
 26. Kharazmi E, Hemminki K, Pukkala E, et al: Cancer Risk in Relatives of Testicular Cancer 
Patients by Histology Type and Age at Diagnosis: A Joint Study from Five Nordic Countries. Eur Urol 
68:283-9, 2015 
 27. Del Risco Kollerud R, Ruud E, Haugnes HS, et al: Family history of cancer and risk of 
paediatric and young adult's testicular cancer: A Norwegian cohort study. Br J Cancer 120:1007-1014, 2019 
 28. Zhang L, Yu H, Hemminki O, et al: Familial Associations in Testicular Cancer with Other 
Cancers. Sci Rep 8:10880, 2018 
 29. Greene MH, Mai PL, Loud JT, et al: Familial testicular germ cell tumors (FTGCT) - 
overview of a multidisciplinary etiologic study. Andrology 3:47-58, 2015 
 30. Litchfield K, Shipley J, Turnbull C: Common variants identified in genome-wide association 
studies of testicular germ cell tumour: an update, biological insights and clinical application. Andrology 
3:34-46, 2015 
 31. Ruark E, Seal S, McDonald H, et al: Identification of nine new susceptibility loci for 
testicular cancer, including variants near DAZL and PRDM14. Nat Genet 45:686-9, 2013 
 32. Litchfield K, Levy M, Orlando G, et al: Identification of 19 new risk loci and potential 
regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat Genet 49:1133-1140, 
2017 
 33. Levy M, Hall D, Sud A, et al: Mendelian randomisation analysis provides no evidence for a 
relationship between adult height and testicular cancer risk. Andrology 5:914-922, 2017 
 34. Litchfield K, Thomsen H, Mitchell JS, et al: Quantifying the heritability of testicular germ 
cell tumour using both population-based and genomic approaches. Scientific Reports 5:13889, 2015 
 35. Bergstrom R, Adami HO, Mohner M, et al: Increase in testicular cancer incidence in six 
European countries: a birth cohort phenomenon. J Natl Cancer Inst 88:727-33, 1996 
 36. Hemminki K, Li X: Cancer risks in Nordic immigrants and their offspring in Sweden. Eur J 
Cancer 38:2428-34, 2002 
 37. Myrup C, Westergaard T, Schnack T, et al: Testicular cancer risk in first- and second-
generation immigrants to Denmark. J Natl Cancer Inst 100:41-7, 2008 
 38. Cook MB, Trabert B, McGlynn KA: Organochlorine compounds and testicular dysgenesis 
syndrome: human data. Int J Androl 34:e68-84; discussion e84-5, 2011 
 39. Pleskacova J, Hersmus R, Oosterhuis JW, et al: Tumor risk in disorders of sex development. 
Sex Dev 4:259-69, 2010 
 40. Moch H, Cubilla AL, Humphrey PA, et al: The 2016 WHO Classification of Tumours of the 
Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 70:93-
105, 2016 
 41. von der Maase H, Rorth M, Walbom-Jorgensen S, et al: Carcinoma in situ of contralateral 
testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 
293:1398-401, 1986 
 42. Taylor-Weiner A, Zack T, O'Donnell E, et al: Genomic evolution and chemoresistance in 
germ-cell tumours. Nature 540:114-118, 2016 
 43. Jostes S, Nettersheim D, Schorle H: Epigenetic drugs and their molecular targets in testicular 
germ cell tumours. Nat Rev Urol 16:245-259, 2019 
 44. Horwich A, Shipley J, Huddart R: Testicular germ-cell cancer. Lancet 367:754-65, 2006 
 45. Hanna NH, Einhorn LH: Testicular cancer--discoveries and updates. N Engl J Med 
371:2005-16, 2014 
 46. Motzer RJ, Jonasch E, Agarwal N, et al: Testicular Cancer, Version 2.2015. J Natl Compr 
Canc Netw 13:772-99, 2015 
 47. Cohn-Cedermark G, Stahl O, Tandstad T, et al: Surveillance vs. adjuvant therapy of clinical 




 48. Alexander EJ, White IM, Horwich A: Update on management of seminoma. Indian J Urol 
26:82-91, 2010 
 49. Classen J, Schmidberger H, Meisner C, et al: Radiotherapy for stages IIA/B testicular 
seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101-6, 2003 
 50. Kollmannsberger C, Tandstad T, Bedard PL, et al: Patterns of relapse in patients with 
clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:51-7, 2015 
 51. Pont J, Albrecht W, Postner G, et al: Adjuvant chemotherapy for high-risk clinical stage I 
nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14:441-8, 
1996 
 52. Klepp O, Olsson AM, Ous S, et al: Early clinical stages of nonseminomatous testis cancer. 
Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol 
Nephrol 25:179-90, 1991 
 53. Kollmannsberger C, Moore C, Chi KN, et al: Non-risk-adapted surveillance for patients with 
stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while 
maintaining efficacy. Ann Oncol 21:1296-1301, 2010 
 54. Sturgeon JF, Moore MJ, Kakiashvili DM, et al: Non-risk-adapted surveillance in clinical 
stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol 59:556-
62, 2011 
 55. Tandstad T, Stahl O, Hakansson U, et al: One course of adjuvant BEP in clinical stage I 
nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25:2167-2172, 2014 
 56. Kesler KA, Brooks JA, Rieger KM, et al: Mediastinal metastases from testicular 
nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with 
surgery. J Thorac Cardiovasc Surg 125:913-23, 2003 
 57. Schmoll HJ: Extragonadal germ cell tumors. Ann Oncol 13 Suppl 4:265-72, 2002 
 58. Ehrlich Y, Beck SD, Foster RS, et al: Serum tumor markers in testicular cancer. Urol Oncol 
31:17-23, 2013 
 59. Almstrup K, Lobo J, Morup N, et al: Application of miRNAs in the diagnosis and 
monitoring of testicular germ cell tumours. Nat Rev Urol 17:201-213, 2020 
 60. Dieckmann KP, Radtke A, Geczi L, et al: Serum Levels of MicroRNA-371a-3p (M371 Test) 
as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin 
Oncol 37:1412-1423, 2019 
 61. Radtke A, Cremers JF, Kliesch S, et al: Can germ cell neoplasia in situ be diagnosed by 
measuring serum levels of microRNA371a-3p? J Cancer Res Clin Oncol 143:2383-2392, 2017 
 62. Peckham MJ, McElwain TJ, Barrett A, et al: Combined management of malignant teratoma 
of the testis. Lancet 2:267-70, 1979 
 63. Gillessen S, Sauve N, Collette L, et al: Predicting Outcomes in Men With Metastatic 
Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin 
Oncol 39:1563-1574, 2021 
 64. Beyer J, Collette L, Sauve N, et al: Survival and New Prognosticators in Metastatic 
Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol 39:1553-1562, 2021 
 65. Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage I 
nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. 
Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 8:509-18, 1990 
 66. Aass N, Klepp O, Cavallin-Stahl E, et al: Prognostic factors in unselected patients with 
nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 9:818-26, 1991 
 67. Klepp O, Dahl O, Flodgren P, et al: Risk-adapted treatment of clinical stage 1 non-seminoma 
testis cancer. Eur J Cancer 33:1038-44, 1997 
 68. Lewis CR, Fossa SD, Mead G, et al: BOP/VIP--a new platinum-intensive chemotherapy 
regimen for poor prognosis germ cell tumours. Ann Oncol 2:203-11, 1991 
 69. Fossa SD, Droz JP, Stoter G, et al: Cisplatin, vincristine and ifosphamide combination 





 70. Dearnaley DP, Fossa SD, Kaye SB, et al: Adjuvant bleomycin, vincristine and cisplatin 
(BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J 
Cancer 92:2107-13, 2005 
 71. Horwich A, Sleijfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and 
cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic 
nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization 
for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844-52, 1997 
 72. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with 
BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ 
cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of 
Cancer study. J Clin Oncol 16:692-701, 1998 
 73. Horwich A, Oliver RT, Wilkinson PM, et al: A medical research council randomized trial of 
single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular 
Tumour Working Party. Br J Cancer 83:1623-9, 2000 
 74. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of 
bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell 
cancer: a randomized study of the European Organization for Research and Treatment of Cancer 
Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-40, 
2001 
 75. Cullen MH, Stenning SP, Parkinson MC, et al: Short-course adjuvant chemotherapy in high-
risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin 
Oncol 14:1106-13, 1996 
 76. Fossa SD, Horwich A, Russell JM, et al: Optimal planning target volume for stage I 
testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular 
Tumor Working Group. J Clin Oncol 17:1146, 1999 
 77. Donohue JP, Thornhill JA, Foster RS, et al: Clinical stage B non-seminomatous germ cell 
testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph 
node dissection. Eur J Cancer 31A:1599-604, 1995 
 78. SWENOTECA: Swedish and Norwegian Testicular Cancer Group. Management Programs. 
SWENOTECA V, Seminoma. Available from: https://www.swenoteca.org/old-management-programs, 2000 
 79. Jones WG, Fossa SD, Mead GM, et al: Randomized trial of 30 versus 20 Gy in the adjuvant 
treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European 
Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 
23:1200-8, 2005 
 80. Oliver RT, Mead GM, Rustin GJ, et al: Randomized trial of carboplatin versus radiotherapy 
for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 
30982 study (ISRCTN27163214). J Clin Oncol 29:957-62, 2011 
 81. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in 
adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293-300, 2005 
 82. Tandstad T, Smaaland R, Solberg A, et al: Management of seminomatous testicular cancer: a 
binational prospective population-based study from the Swedish norwegian testicular cancer study group. J 
Clin Oncol 29:719-25, 2011 
 83. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with 
cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-40, 1987 
 84. Friedman EL, Garnick MB, Stomper PC, et al: Therapeutic guidelines and results in 
advanced seminoma. J Clin Oncol 3:1325-32, 1985 
 85. SWENOTECA: Swedish and Norwegian Testicular Cancer Group. Management Programs. 
SWENOTECA IV, Nonseminoma metastatic. Available from: https://www.swenoteca.org/old-management-
programs, 1995 
 86. Haugnes HS, Solhaug O, Stenberg J, et al: Seminoma patients treated at a minor oncological 
department during 1986-2010: treatment and outcome. Anticancer Res 34:4253-60, 2014 
 87. Schultz SM, Einhorn LH, Conces DJ, Jr., et al: Management of postchemotherapy residual 




 88. Puc HS, Heelan R, Mazumdar M, et al: Management of residual mass in advanced 
seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 
14:454-60, 1996 
 89. Tandstad T, Dahl O, Cohn-Cedermark G, et al: Risk-adapted treatment in clinical stage I 
nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 
27:2122-8, 2009 
 90. Mencel PJ, Motzer RJ, Mazumdar M, et al: Advanced seminoma: treatment results, survival, 
and prognostic factors in 142 patients. J Clin Oncol 12:120-6, 1994 
 91. DeVita Jr VT, Lawrence TS, Rosenberg SA: DeVita, Hellman, and Rosenberg's Cancer: 
Principles & Practice of Oncology (ed 10th edition.). Philadelphia, Philadelphia: Wolters Kluwer Health, 
2014  
 92. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin 
and carboplatin. J Clin Oncol 17:409-22, 1999 
 93. de Vries G, Rosas-Plaza X, van Vugt M, et al: Testicular cancer: Determinants of cisplatin 
sensitivity and novel therapeutic opportunities. Cancer Treat Rev 88:102054, 2020 
 94. Jung Y, Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev 
107:1387-407, 2007 
 95. Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem 88:102925, 2019 
 96. Gerl A, Schierl R: Urinary excretion of platinum in chemotherapy-treated long-term 
survivors of testicular cancer. Acta Oncol 39:519-22, 2000 
 97. Gelevert T, Messerschmidt J, Meinardi MT, et al: Adsorptive voltametry to determine 
platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit 23:169-73, 
2001 
 98. Brouwers EE, Tibben MM, Pluim D, et al: Inductively coupled plasma mass spectrometric 
analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue 
from patients treated with cisplatin. Anal Bioanal Chem 391:577-85, 2008 
 99. Hongo A, Seki S, Akiyama K, et al: A comparison of in vitro platinum-DNA adduct 
formation between carboplatin and cisplatin. Int J Biochem 26:1009-16, 1994 
 100. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the 
literature. Ann Oncol 9:13-21, 1998 
 101. Ozols RF, Behrens BC, Ostchega Y, et al: High dose cisplatin and high dose carboplatin in 
refractory ovarian cancer. Cancer Treat Rev 12 Suppl A:59-65, 1985 
 102. Tothill P, Klys HS, Matheson LM, et al: The long-term retention of platinum in human 
tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 
28A:1358-61, 1992 
 103. Poirier MC, Reed E, Litterst CL, et al: Persistence of platinum-ammine-DNA adducts in 
gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-53, 1992 
 104. Gietema JA, Meinardi MT, Messerschmidt J, et al: Circulating plasma platinum more than 
10 years after cisplatin treatment for testicular cancer. Lancet 355:1075-1076, 2000 
 105. Brouwers EE, Huitema AD, Beijnen JH, et al: Long-term platinum retention after treatment 
with cisplatin and oxaliplatin. BMC Clin Pharmacol 8:7, 2008 
 106. Montecucco A, Zanetta F, Biamonti G: Molecular mechanisms of etoposide. EXCLI J 
14:95-108, 2015 
 107. Brenner DJ, Hall EJ: Computed tomography--an increasing source of radiation exposure. N 
Engl J Med 357:2277-84, 2007 
 108. Tarin TV, Sonn G, Shinghal R: Estimating the risk of cancer associated with imaging related 
radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181:627-
32; discussion 632-3, 2009 
 109. Joffe JK, Cafferty FH, Murphy L, et al: Imaging modality and frequency in surveillance of 
stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST). Journal of 
Clinical Oncology 39:374-374, 2021 
 110. Sagstuen H, Aass N, Fossa SD, et al: Blood pressure and body mass index in long-term 




 111. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term 
survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28:4649-57, 2010 
 112. SWENOTECA: Swedish and Norwegian Testicular Cancer Group. Management Programs. 
SWENOTECA VII, Seminoma all stages. Available from: https://www.swenoteca.org/old-management-
programs, 2007 
 113. SWENOTECA: Swedish and Norwegian Testicular Cancer Group. Management Programs. 
SWENOTECA VIII, Nonseminoma. Available from: https://www.swenoteca.org/old-management-
programs, 2012 
 114. Aziz NM: Cancer survivorship research: state of knowledge, challenges and opportunities. 
Acta Oncol 46:417-32, 2007 
 115. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: research strategies and 
recommendations. J Natl Cancer Inst 102:1114-30, 2010 
 116. Andreassen KE, Grotmol T, Cvancarova MS, et al: Risk of metachronous contralateral 
testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer 
129:2867-74, 2011 
 117. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, et al: Risk and prognostic 
significance of metachronous contralateral testicular germ cell tumours. Br J Cancer 107:1637-43, 2012 
 118. Wanderas EH, Fossa SD, Tretli S: Risk of a second germ cell cancer after treatment of a 
primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 33:244-52, 1997 
 119. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al: Second cancer risk 
following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 11:415-24, 1993 
 120. Colls BM, Harvey VJ, Skelton L, et al: Bilateral germ cell testicular tumors in New Zealand: 
experience in Auckland and Christchurch 1978-1994. J Clin Oncol 14:2061-5, 1996 
 121. Hemminki K, Liu H, Sundquist J: Second cancers after testicular cancer diagnosed after 
1980 in Sweden. Ann Oncol 21:1546-1551, 2010 
 122. Bandak M, Lauritsen J, Johansen C, et al: Sexual Function and Quality of Life in a National 
Cohort of Survivors of Bilateral Testicular Cancer. Eur Urol Focus 6:711-719, 2020 
 123. Fossa SD, Opjordsmoen S, Haug E: Androgen replacement and quality of life in patients 
treated for bilateral testicular cancer. Eur J Cancer 35:1220-5, 1999 
 124. Kier MGG, Lauritsen J, Almstrup K, et al: Screening for carcinoma in situ in the 
contralateral testicle in patients with testicular cancer: a population-based study. Ann Oncol 26:737-742, 
2015 
 125. Che M, Tamboli P, Ro JY, et al: Bilateral testicular germ cell tumors: twenty-year 
experience at M. D. Anderson Cancer Center. Cancer 95:1228-33, 2002 
 126. Osterlind A, Berthelsen JG, Abildgaard N, et al: Risk of bilateral testicular germ cell cancer 
in Denmark: 1960-1984. J Natl Cancer Inst 83:1391-5, 1991 
 127. Kier MG, Hansen MK, Lauritsen J, et al: Second Malignant Neoplasms and Cause of Death 
in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. JAMA Oncol 2:1624-1627, 2016 
 128. Brabrand S, Fossa SD, Cvancarova M, et al: Probability of metachronous testicular cancer in 
patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell 
cancer. J Clin Oncol 30:4004-10, 2012 
 129. Strumberg D, Brugge S, Korn MW, et al: Evaluation of long-term toxicity in patients after 
cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13:229-36, 2002 
 130. Brydoy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term 
Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 
101:1682-95, 2009 
 131. Bauer CA, Brozoski TJ: Cochlear structure and function after round window application of 
ototoxins. Hear Res 201:121-31, 2005 
 132. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced 
ototoxicity in patients with testicular cancer. Br J Cancer 77:1355-62, 1998 
 133. Wigley FM, Flavahan NA: Raynaud's Phenomenon. N Engl J Med 375:556-65, 2016 
 134. Rossen PB, Pedersen AF, Zachariae R, et al: Health-related quality of life in long-term 




 135. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other 
late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-38, 1995 
 136. Glendenning JL, Barbachano Y, Norman AR, et al: Long-term neurologic and peripheral 
vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116:2322-31, 2010 
 137. Gerl A, Muhlbayer D, Hansmann G, et al: The impact of chemotherapy on Leydig cell 
function in long term survivors of germ cell tumors. Cancer 91:1297-303, 2001 
 138. Sprauten M, Brydoy M, Haugnes HS, et al: Longitudinal serum testosterone, luteinizing 
hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular 
cancer survivors. J Clin Oncol 32:571-8, 2014 
 139. Huddart RA, Norman A, Moynihan C, et al: Fertility, gonadal and sexual function in 
survivors of testicular cancer. Br J Cancer 93:200-7, 2005 
 140. Wiechno P, Demkow T, Kubiak K, et al: The quality of life and hormonal disturbances in 
testicular cancer survivors in Cisplatin era. Eur Urol 52:1448-54, 2007 
 141. Nord C, Bjoro T, Ellingsen D, et al: Gonadal hormones in long-term survivors 10 years after 
treatment for unilateral testicular cancer. Eur Urol 44:322-8, 2003 
 142. Willemse PH, Sleijfer DT, Sluiter WJ, et al: Altered Leydig cell function in patients with 
testicular cancer: evidence for bilateral testicular defect. Acta Endocrinol (Copenh) 102:616-24, 1983 
 143. Bjerner J, Biernat D, Fossa SD, et al: Reference intervals for serum testosterone, SHBG, LH 
and FSH in males from the NORIP project. Scand J Clin Lab Invest 69:873-9 e1-11, 2009 
 144. Brydoy M, Fossa SD, Klepp O, et al: Paternity following treatment for testicular cancer. J 
Natl Cancer Inst 97:1580-8, 2005 
 145. Oldenburg J: Hypogonadism and fertility issues following primary treatment for testicular 
cancer. Urol Oncol 33:407-12, 2015 
 146. Ghezzi M, Berretta M, Bottacin A, et al: Impact of Bep or Carboplatin Chemotherapy on 
Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor. Front Pharmacol 
7:122, 2016 
 147. Lampe H, Horwich A, Norman A, et al: Fertility after chemotherapy for testicular germ cell 
cancers. J Clin Oncol 15:239-45, 1997 
 148. Weibring K, Nord C, Stahl O, et al: Sperm count in Swedish clinical stage I testicular cancer 
patients following adjuvant treatment. Ann Oncol 30:604-611, 2019 
 149. Bujan L, Walschaerts M, Moinard N, et al: Impact of chemotherapy and radiotherapy for 
testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the 
CECOS network. Fertil Steril 100:673-80, 2013 
 150. Brydoy M, Fossa SD, Klepp O, et al: Paternity and testicular function among testicular 
cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58:134-40, 2010 
 151. Pont J, Albrecht W: Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 
68:1-5, 1997 
 152. Dahl AA, Bremnes R, Dahl O, et al: Is the sexual function compromised in long-term 
testicular cancer survivors? Eur Urol 52:1438-47, 2007 
 153. Rossen P, Pedersen AF, Zachariae R, et al: Sexuality and body image in long-term survivors 
of testicular cancer. Eur J Cancer 48:571-8, 2012 
 154. Fukuda K, Straus SE, Hickie I, et al: The chronic fatigue syndrome: a comprehensive 
approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 
121:953-9, 1994 
 155. Orre IJ, Fossa SD, Murison R, et al: Chronic cancer-related fatigue in long-term survivors of 
testicular cancer. J Psychosom Res 64:363-71, 2008 
 156. Sprauten M, Haugnes HS, Brydoy M, et al: Chronic fatigue in 812 testicular cancer 
survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol 26:2133-40, 2015 
 157. Orre IJ, Murison R, Dahl AA, et al: Levels of circulating interleukin-1 receptor antagonist 
and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain 
Behav Immun 23:868-74, 2009 
 158. Bower JE: Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin 




 159. Stouten-Kemperman MM, de Ruiter MB, Caan MW, et al: Lower cognitive performance and 
white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp 36:4638-
47, 2015 
 160. Wefel JS, Vidrine DJ, Marani SK, et al: A prospective study of cognitive function in men 
with non-seminomatous germ cell tumors. Psychooncology 23:626-33, 2014 
 161. Dahl AA, Haaland CF, Mykletun A, et al: Study of anxiety disorder and depression in long-
term survivors of testicular cancer. J Clin Oncol 23:2389-95, 2005 
 162. Smith AB, Butow P, Olver I, et al: The prevalence, severity, and correlates of psychological 
distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship 
study. J Cancer Surviv 10:223-33, 2016 
 163. Eberhard J, Stahl O, Cohn-Cedermark G, et al: Emotional disorders in testicular cancer 
survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect 
Disord 122:260-6, 2010 
 164. Skaali T, Fossa SD, Bremnes R, et al: Fear of recurrence in long-term testicular cancer 
survivors. Psychooncology 18:580-8, 2009 
 165. Alanee S, Russo P: Suicide in men with testis cancer. Eur J Cancer Care (Engl) 21:817-21, 
2012 
 166. Shinn EH, Swartz RJ, Thornton BB, et al: Testis cancer survivors' health behaviors: 
comparison with age-matched relative and demographically matched population controls. J Clin Oncol 
28:2274-9, 2010 
 167. Fung C, Sesso HD, Williams AM, et al: Multi-Institutional Assessment of Adverse Health 
Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based 
Chemotherapy. J Clin Oncol 35:1211-1222, 2017 
 168. Bellizzi KM, Rowland JH, Jeffery DD, et al: Health behaviors of cancer survivors: 
examining opportunities for cancer control intervention. J Clin Oncol 23:8884-93, 2005 
 169. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second 
malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-8, 
2007 
 170. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term 
complication of treatment for testicular cancer. J Clin Oncol 21:1513-23, 2003 
 171. Feldman DR, Schaffer WL, Steingart RM: Late cardiovascular toxicity following 
chemotherapy for germ cell tumors. J Natl Compr Canc Netw 10:537-44, 2012 
 172. Lauritsen J, Hansen MK, Bandak M, et al: Cardiovascular Risk Factors and Disease After 
Male Germ Cell Cancer. J Clin Oncol 38:584-592, 2020 
 173. Haugnes HS, Aass N, Fossa SD, et al: Components of the metabolic syndrome in long-term 
survivors of testicular cancer. Ann Oncol 18:241-8, 2007 
 174. Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in 
hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-25, 2005 
 175. Wanderas EH, Fossa SD, Tretli S: Risk of subsequent non-germ cell cancer after treatment 
of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33:253-62, 1997 
 176. Richiardi L, Scelo G, Boffetta P, et al: Second malignancies among survivors of germ-cell 
testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120:623-31, 2007 
 177. Travis LB, Fossa SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer 
patients: focus on long-term survivors. J Natl Cancer Inst 97:1354-65, 2005 
 178. Howard R, Gilbert E, Lynch CF, et al: Risk of leukemia among survivors of testicular 
cancer: a population-based study of 42,722 patients. Ann Epidemiol 18:416-21, 2008 
 179. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following 
testicular cancer. J Natl Cancer Inst 92:1165-71, 2000 
 180. Travis LB, Rabkin CS, Brown LM, et al: Cancer survivorship--genetic susceptibility and 
second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98:15-25, 2006 
 181. Travis LB: Therapy-associated solid tumors. Acta Oncol 41:323-33, 2002 
 182. Travis LB, Demark Wahnefried W, Allan JM, et al: Aetiology, genetics and prevention of 




 183. Taghizadeh N, Vonk JM, Boezen HM: Lifetime Smoking History and Cause-Specific 
Mortality in a Cohort Study with 43 Years of Follow-Up. PLoS One 11:e0153310, 2016 
 184. Nelson DE, Jarman DW, Rehm J, et al: Alcohol-attributable cancer deaths and years of 
potential life lost in the United States. Am J Public Health 103:641-8, 2013 
 185. Li T, Wei S, Shi Y, et al: The dose-response effect of physical activity on cancer mortality: 
findings from 71 prospective cohort studies. Br J Sports Med 50:339-45, 2016 
 186. Curtis RE FD, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni Jf Jr. 
(eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, 
2006 
 187. Allan JM, Travis LB: Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5:943-
55, 2005 
 188. Horwich A, Fossa SD, Huddart R, et al: Second cancer risk and mortality in men treated 
with radiotherapy for stage I seminoma. Br J Cancer 110:256-63, 2014 
 189. Hauptmann M, Fossa SD, Stovall M, et al: Increased stomach cancer risk following 
radiotherapy for testicular cancer. Br J Cancer 112:44-51, 2015 
 190. Hauptmann M, Borge Johannesen T, Gilbert ES, et al: Increased pancreatic cancer risk 
following radiotherapy for testicular cancer. Br J Cancer 115:901-8, 2016 
 191. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al: Roles of radiation dose and 
chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 
75:1420-9, 2009 
 192. Greene MH: Is cisplatin a human carcinogen? J Natl Cancer Inst 84:306-12, 1992 
 193. World Health Organization. IARC monographs on the evaluation of the carcinogenic risks to 
humans. The United Kingdom, World Health Organization, 1987  
 194. Fink D, Nebel S, Norris PS, et al: Enrichment for DNA mismatch repair-deficient cells 
during treatment with cisplatin. Int J Cancer 77:741-6, 1998 
 195. Fung C, Fossa SD, Milano MT, et al: Solid tumors after chemotherapy or surgery for 
testicular nonseminoma: a population-based study. J Clin Oncol 31:3807-14, 2013 
 196. Curreri SA, Fung C, Beard CJ: Secondary malignant neoplasms in testicular cancer 
survivors. Urol Oncol 33:392-8, 2015 
 197. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: a 2000-02 
period analysis of EUROCARE-4 data. Lancet Oncol 8:784-96, 2007 
 198. Kvammen O, Myklebust TA, Solberg A, et al: Long-term Relative Survival after Diagnosis 
of Testicular Germ Cell Tumor. Cancer Epidemiol Biomarkers Prev 25:773-9, 2016 
 199. Gandaglia G, Becker A, Trinh QD, et al: Long-term survival in patients with germ cell 
testicular cancer: a population-based competing-risks regression analysis. Eur J Surg Oncol 40:103-12, 2014 
 200. Fossa SD, Aass N, Harvei S, et al: Increased mortality rates in young and middle-aged 
patients with malignant germ cell tumours. Br J Cancer 90:607-12, 2004 
 201. Fossa SD, Gilbert E, Dores GM, et al: Noncancer causes of death in survivors of testicular 
cancer. J Natl Cancer Inst 99:533-44, 2007 
 202. Fung C, Fossa SD, Milano MT, et al: Cardiovascular Disease Mortality After Chemotherapy 
or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol 33:3105-15, 2015 
 203. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin 
Oncol 22:640-7, 2004 
 204. Beard CJ, Travis LB, Chen MH, et al: Outcomes in stage I testicular seminoma: a 
population-based study of 9193 patients. Cancer 119:2771-7, 2013 
 205. Hjelle LV, Gundersen PO, Oldenburg J, et al: Long-term platinum retention after platinum-
based chemotherapy in testicular cancer survivors: a 20-year follow-up study. Anticancer Res 35:1619-25, 
2015 
 206. Hjelle LV, Bremnes RM, Gundersen POM, et al: Associations between long-term serum 
platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in 




 207. Sprauten M, Darrah TH, Peterson DR, et al: Impact of long-term serum platinum 
concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 
30:300-7, 2012 
 208. Olofsson SE, Tandstad T, Jerkeman M, et al: Population-based study of treatment guided by 
tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the 
Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 29:2032-9, 2011 
 209. Eurostat: European Shortlist for Causes of Death. Available from: 
https://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_NOM_DTL&StrNom=COD_
2012&StrLanguageCode=EN&IntPcKey=&StrLayoutCode=HIERARCHIC, 2012 
 210. Norwegian Institute of Public Health, Cause of Death Registry (database) Available from: 
http://statistikkbank.fhi.no/dar/ 2020 
 211. Giobbie-Hurder A, Gelber RD, Regan MM: Challenges of guarantee-time bias. J Clin Oncol 
31:2963-9, 2013 
 212. Aalen OO, Johansen S: An Empirical Transition Matrix for Non-Homogeneous Markov 
Chains Based on Censored Observations. Scand J Stat 5:141-150, 1978 
 213. Porta M, Porta MS, Hernâan M, et al: A Dictionary of Epidemiology (ed 6th ed.), Oxford 
University Press, 2014  
 214. Bhopal RS: Concepts of epidemiology : integrating the ideas, theories, principles and 
methods of epidemiology (ed Third ed.). Oxford, Oxford University Press, 2016  
 215. Szklo M, Nieto FJ: Epidemiology : beyond the basics (ed 3rd ed.). Burlington, Mass, Jones 
& Bartlett Learning, 2014  
 216. Klebanoff MA, Snowden JM: Historical (retrospective) cohort studies and other 
epidemiologic study designs in perinatal research. Am J Obstet Gynecol 219:447-450, 2018 
 217. Laake P: Epidemiologiske og kliniske forskningsmetoder. Oslo, Gyldendal akademisk, 2007  
 218. Vandenbroucke JP: Prospective or retrospective: what's in a name? BMJ 302:249-50, 1991 
 219. Lu CY: Observational studies: a review of study designs, challenges and strategies to reduce 
confounding. Int J Clin Pract 63:691-7, 2009 
 220. Cancer in Norway 2018. Special issue 2018: Sosial ulikhet, innvandring og kreft – En 
rapport om kreftforekomst etter landbakgrunn, utdanning, inntekt og bosted. Oslo: Cancer Registry of 
Norway, 2019 (Available in Norwegian only) 
 221. Fung C, Dinh PC, Fossa SD, et al: Testicular Cancer Survivorship. J Natl Compr Canc Netw 
17:1557-1568, 2019 
 222. Larsen IK, Småstuen M, Parkin DM, et al: Data Quality at the Cancer Registry of Norway. 
In: Cancer in Norway 2006 - Cancer incidence, mortality, survival and 
prevalence in Norway. Oslo: Cancer Registry of Norway, 2007 
 223. Pedersen AG, Ellingsen CL: Data quality in the Causes of Death Registry. Tidsskr Nor 
Laegeforen 135:768-70, 2015 
 224. Larsen IK, Smastuen M, Johannesen TB, et al: Data quality at the Cancer Registry of 
Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 45:1218-1231, 
2009 
 225. Warren TY, Barry V, Hooker SP, et al: Sedentary behaviors increase risk of cardiovascular 
disease mortality in men. Med Sci Sports Exerc 42:879-85, 2010 
 226. Khan SS, Ning H, Wilkins JT, et al: Association of Body Mass Index With Lifetime Risk of 
Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol 3:280-287, 2018 
 227. Bell S, Daskalopoulou M, Rapsomaniki E, et al: Association between clinically recorded 
alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study 
using linked health records. BMJ 356:j909, 2017 
 228. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable risk factors associated 





 229. Mannsverk J, Wilsgaard T, Mathiesen EB, et al: Trends in Modifiable Risk Factors Are 
Associated With Declining Incidence of Hospitalized and Nonhospitalized Acute Coronary Heart Disease in 
a Population. Circulation 133:74-81, 2016 
 230. Kreiberg M, Bandak M, Lauritsen J, et al: Adverse health behaviours in long-term testicular 
cancer survivors: a Danish nationwide study. Acta Oncol 60:361-369, 2021 
 231. Bucher-Johannessen C, Page CM, Haugen TB, et al: Cisplatin treatment of testicular cancer 
patients introduces long-term changes in the epigenome. Clin Epigenetics 11:179, 2019 
 232. Bland JM, Altman DG: Multiple significance tests: the Bonferroni method. BMJ 310:170, 
1995 
 233. Bender R, Lange S: Adjusting for multiple testing--when and how? J Clin Epidemiol 54:343-
9, 2001 
 234. Rothman KJ: No Adjustments Are Needed for Multiple Comparisons. 1:43-46, 1990 
 235. Theodore C, Terrier-Lacombe MJ, Laplanche A, et al: Bilateral germ-cell tumours: 22-year 
experience at the Institut Gustave Roussy. Br J Cancer 90:55-9, 2004 
 236. Blok JM, Groot HJ, Huele EH, et al: Dose-Dependent Effect of Platinum-Based 
Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. J Clin Oncol 39:319-327, 2021 
 237. D'Souza A, Van Veldhuizen P, Fung C: Surviving Testicular Cancer: The Role of the 
Contralateral Testicle. J Clin Oncol 39:265-268, 2021 
 238. Dieckmann KP, Wilken S, Loy V, et al: Treatment of testicular intraepithelial neoplasia 
(intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: 
a survey of the German Testicular Cancer Study Group. Ann Oncol 24:1332-7, 2013 
 239. Kleinschmidt K, Dieckmann KP, Georgiew A, et al: Chemotherapy is of limited efficacy in 
the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. 
Oncology 77:33-9, 2009 
 240. Christensen TB, Daugaard G, Geertsen PF, et al: Effect of chemotherapy on carcinoma in 
situ of the testis. Ann Oncol 9:657-60, 1998 
 241. Bottomley D, Fisher C, Hendry WF, et al: Persistent carcinoma in situ of the testis after 
chemotherapy for advanced testicular germ cell tumours. Br J Urol 66:420-4, 1990 
 242. Bart J, Groen HJ, van der Graaf WT, et al: An oncological view on the blood-testis barrier. 
Lancet Oncol 3:357-63, 2002 
 243. Dieckmann KP, Loy V: Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 
28:25-30, 1995 
 244. Tandstad T, Solberg A, Hakansson U, et al: Bilateral testicular germ cell tumors in patients 
treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncol 
54:493-9, 2015 
 245. Dieckmann KP, Anheuser P, Sattler F, et al: Sequential bilateral testicular tumours 
presenting with intervals of 20 years and more. BMC Urol 13:71, 2013 
 246. Dieckmann KP: Does Testicular Seminoma Involve a Higher Predisposition Than 
Nonseminoma to Develop Contralateral Testicular Tumors? J Clin Oncol 39:1689-1690, 2021 
 247. Ruf CG, Gnoss A, Hartmann M, et al: Contralateral biopsies in patients with testicular germ 
cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular 
intra-epithelial neoplasia. Andrology 3:92-8, 2015 
 248. Dieckmann KP, Loy V: Prevalence of contralateral testicular intraepithelial neoplasia in 
patients with testicular germ cell neoplasms. J Clin Oncol 14:3126-32, 1996 
 249. Jacobsen KD, Olsen DR, Fossa K, et al: External beam abdominal radiotherapy in patients 
with seminoma stage I: field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 38:95-
102, 1997 
 250. Zequi Sde C, da Costa WH, Santana TB, et al: Bilateral testicular germ cell tumours: a 
systematic review. BJU Int 110:1102-9, 2012 
 251. Tandstad T, Kollmannsberger CK, Roth BJ, et al: Practice Makes Perfect: The Rest of the 
Story in Testicular Cancer as a Model Curable Neoplasm. J Clin Oncol 35:3525-3528, 2017 
 252. Zhang L, Hemminki O, Chen T, et al: Second cancers and causes of death in patients with 




 253. Groot HJ, Lubberts S, de Wit R, et al: Risk of Solid Cancer After Treatment of Testicular 
Germ Cell Cancer in the Platinum Era. J Clin Oncol 36:2504-2513, 2018 
 254. Milano MT, Dinh PC, Yang H, et al: Solid and Hematologic Neoplasms After Testicular 
Cancer: A US Population-Based Study of 24 900 Survivors. JNCI Cancer Spectr 4:pkaa017, 2020 
 255. Groot HJ, van Leeuwen FE, Lubberts S, et al: Platinum exposure and cause-specific 
mortality among patients with testicular cancer. Cancer 126:628-639, 2020 
 256. Sung H, Hyun N, Leach CR, et al: Association of First Primary Cancer With Risk of 
Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States. JAMA 
324:2521-2535, 2020 
 257. Lee JS, DuBois SG, Coccia PF, et al: Increased risk of second malignant neoplasms in 
adolescents and young adults with cancer. Cancer 122:116-23, 2016 
 258. Lewinshtein D, Gulati R, Nelson PS, et al: Incidence of second malignancies after external 
beam radiotherapy for clinical stage I testicular seminoma. BJU Int 109:706-12, 2012 
 259. Benedetti M, Zona A, Beccaloni E, et al: Incidence of Breast, Prostate, Testicular, and 
Thyroid Cancer in Italian Contaminated Sites with Presence of Substances with Endocrine Disrupting 
Properties. Int J Environ Res Public Health 14, 2017 
 260. Fossa SD, Langmark F, Aass N, et al: Second non-germ cell malignancies after radiotherapy 
of testicular cancer with or without chemotherapy. Br J Cancer 61:639-43, 1990 
 261. Hemminki K, Chen B: Familial risks in testicular cancer as aetiological clues. Int J Androl 
29:205-10, 2006 
 262. Spiliopoulou P, Bowers SP, Gibson S, et al: Three cases of thyroid cancer following the 
diagnosis of testicular cancer: treatment-related complication or genetics? Scott Med J 61:111-116, 2016 
 263. Kim CY, Lee SH, Oh CW: Cutaneous malignant melanoma associated with papillary thyroid 
cancer. Ann Dermatol 22:370-2, 2010 
 264. Oakley GM, Curtin K, Layfield L, et al: Increased melanoma risk in individuals with 
papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 140:423-7, 2014 
 265. Li H, Zhu C, Wu J, et al: Urological second malignant neoplasms in testicular nonseminoma 
survivors: a population-based analysis. Int Urol Nephrol 53:471-477, 2021 
 266. Powles T, Robinson D, Shamash J, et al: The long-term risks of adjuvant carboplatin 
treatment for stage I seminoma of the testis. Ann Oncol 19:443-7, 2008 
 267. Patel HD, Srivastava A, Alam R, et al: Radiotherapy for stage I and II testicular seminomas: 
Secondary malignancies and survival. Urol Oncol 35:606 e1-606 e7, 2017 
 268. Gilbert ES, Curtis RE, Hauptmann M, et al: Stomach Cancer Following Hodgkin 
Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a 
Focus on Radiation Effects. Radiat Res 187:186-195, 2017 
 269. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-53, 1997 
 270. Motzer RJ, Amsterdam A, Prieto V, et al: Teratoma with malignant transformation: diverse 
malignant histologies arising in men with germ cell tumors. J Urol 159:133-8, 1998 
 271. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and 
radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94:182-92, 2002 
 272. Gilbert ES, Stovall M, Gospodarowicz M, et al: Lung cancer after treatment for Hodgkin's 
disease: focus on radiation effects. Radiat Res 159:161-73, 2003 
 273. Travis LB, Curtis RE, Glimelius B, et al: Bladder and kidney cancer following 
cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87:524-30, 1995 
 274. McNerney ME, Godley LA, Le Beau MM: Therapy-related myeloid neoplasms: when 
genetics and environment collide. Nat Rev Cancer 17:513-527, 2017 
 275. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based 
chemotherapy for ovarian cancer. N Engl J Med 340:351-7, 1999 
 276. Morton LM, Dores GM, Schonfeld SJ, et al: Association of Chemotherapy for Solid Tumors 
With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the 




 277. Kerns SL, Fung C, Monahan PO, et al: Cumulative Burden of Morbidity Among Testicular 
Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J Clin Oncol 
36:1505-1512, 2018 
 278. Ligibel J: Lifestyle factors in cancer survivorship. J Clin Oncol 30:3697-704, 2012 
 279. Ness KK, Kirkland JL, Gramatges MM, et al: Premature Physiologic Aging as a Paradigm 
for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. 
J Clin Oncol 36:2206-2215, 2018 
 280. Ness KK, Krull KR, Jones KE, et al: Physiologic frailty as a sign of accelerated aging among 
adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol 31:4496-
503, 2013 
 281. Maccormick RE: Possible acceleration of aging by adjuvant chemotherapy: a cause of early 
onset frailty? Med Hypotheses 67:212-5, 2006 
 282. Lubberts S, Meijer C, Demaria M, et al: Early ageing after cytotoxic treatment for testicular 
cancer and cellular senescence: Time to act. Crit Rev Oncol Hematol 151:102963, 2020 
 283. Norwegian Institute of Public Health, Suicide in Norway. Available from: 
https://www.fhi.no/en/op/hin/mental-health/suicide/, 2018 
 284. Gunnes MW, Lie RT, Bjorge T, et al: Suicide and violent deaths in survivors of cancer in 
childhood, adolescence and young adulthood-A national cohort study. Int J Cancer 140:575-580, 2017 
 285. Smith AB, Rutherford C, Butow P, et al: A systematic review of quantitative observational 
studies investigating psychological distress in testicular cancer survivors. Psychooncology 27:1129-1137, 
2018 
 286. Skoogh J, Steineck G, Cavallin-Ståhl E, et al: Feelings of loss and uneasiness or shame after 
removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. 
Int J Androl 34:183-92, 2011 
 287. Raphael MJ, Gupta S, Wei X, et al: Long-Term Mental Health Service Utilization Among 
Survivors of Testicular Cancer: A Population-Based Cohort Study. J Clin Oncol 39:779-786, 2021 
 288. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular 
disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-75, 2006 
 289. Steggink LC, Boer H, Meijer C, et al: Genome-wide association study of cardiovascular 
disease in testicular cancer patients treated with platinum-based chemotherapy. Pharmacogenomics J 21:152-
164, 2021 
 290. Kvammen O, Myklebust TA, Solberg A, et al: Causes of inferior relative survival after 
testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study. PLoS One 
14:e0225942, 2019 
 291. Townsend N, Nichols M, Scarborough P, et al: Cardiovascular disease in Europe--
epidemiological update 2015. Eur Heart J 36:2696-705, 2015 
 292. Nuver J, Smit AJ, van der Meer J, et al: Acute chemotherapy-induced cardiovascular 
changes in patients with testicular cancer. J Clin Oncol 23:9130-7, 2005 
 293. Fossa SD, Aass N, Kaalhus O: Radiotherapy for testicular seminoma stage I: treatment 
results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16:383-8, 1989 
 294. Lenz S, Giwercman A, Skakkebaek NE, et al: Ultrasound in detection of early neoplasia of 
the testis. Int J Androl 10:187-90, 1987 
 295. Holm M, Hoei-Hansen CE, Rajpert-De Meyts E, et al: Increased risk of carcinoma in situ in 






















Variables retrieved from medical journals 
Hospital 
Personal identification number 
Date of birth 
Registered  
Comments 
Date of orchiectomy 
Bilateral testicular cancer (no/yes synchronous/yes metachronous) 
Histology (seminoma/nonseminoma) 
Clinical stadium according to Royal Marsden 
Surveillance if clinical stage I (no/yes) 
Date of first chemotherapy 
Stop date chemotherapy 
Reason for first-line chemotherapy (adjuvant/metastatic/recurrence) 
First chemotherapy regimen 
Number of cycles first chemotherapy 
Second chemotherapy regimen 
Number of cycles second chemotherapy 
Third chemotherapy regimen 
Number of cycles third chemotherapy 
Fourth chemotherapy regimen 
Number of cycles fourth chemotherapy 
Fifth chemotherapy regimen 
Number of cycles fifth chemotherapy 
Radiotherapy field (no/field-type) 




Retroperitoneal lymph node dissection (no/yes) 
Date of first post-orchiectomy surgery  
Type of first post-orchiectomy surgery 
Histology first post-orchiectomy surgery 
Date of second post-orchiectomy surgery  
Type of second post-orchiectomy surgery 
Histology second post-orchiectomy surgery 
Date of third post-orchiectomy surgery  
Type of third post-orchiectomy surgery 
Histology third post-orchiectomy surgery 
Recurrence after primary treatment (yes/no) 
Clinical stage at first recurrence 
Date of first recurrence 
Treatment first recurrence 
Second recurrence (yes/no) 
Clinical stage at second recurrence 
Date of second recurrence 
Treatment second recurrence  
Dead (yes/no) 















ID Code Level Description ICD-10 ICD-9 ICD-8 
1 1. 1 Infectious and parasitic diseases A00-B99 001-139 000-136 





3 1.2 2 AIDS (HIV disease) B20-B24 042-044 
(279.1) 
- 
4 1.3 2 Viral hepatitis B15-B19,  
B94.2 
070 070 















6 2. 1 Neoplasms C00-D48 140-239 140-239 
7 2.1 2 Malignant neoplasms C00-C97 140-208 140-209 
8 2.1.1 3 Malignant neoplasm of lip,  
oral cavity, pharynx 
C00-C14 140-149 140-149 
9 2.1.2 3 Malignant neoplasm of 
oesophagus 
C15 150 150 





11 2.1.4 3 Malignant neoplasm of colon, 
rectum and anus 
C18-C21 153-154 153-154 
12 2.1.5 3 Malignant neoplasm of liver and 
intrahepatic bile ducts 
C22 155 155, 197.8 
13 2.1.6 3 Malignant neoplasm of pancreas C25 157 157 
14 2.1.7 3 Malignant neoplasm of larynx C32 161 161 
15 2.1.8 3 Malignant neoplasm of trachea, 
bronchus, lung 
C33-C34 162 162 
16 2.1.9 3 Malignant melanoma of skin C43 172 172 
17 2.1.10 3 Malignant neoplasm of breast C50 174-175 174 
18 2.1.11 3 Malignant neoplasm of cervix 
uteri 
C53 180 180 
 
19 2.1.12 3 Malignant neoplasm of other and 
unspecified parts of uterus 
C54-C55 179, 182 182 




21 2.1.14 3 Malignant neoplasm of prostate C61 185 185 
22 2.1.15 3 Malignant neoplasm of kidney C64 189.0 189.0 
23 2.1.16 3 Malignant neoplasm of bladder C67 188 188 
24 2.1.17 3 Malignant neoplasm of brain and 
central nervous system 
C70-C72 191-192 191-192 
25 2.1.18 3 Malignant neoplasm of thyroid C73 193 193 
 
26 2.1.19 3 Hodgkin disease and lymphomas  C81-C86 200-201 200-201 
27 2.1.20 3 Leukemia C91-C95 204-208 204-208 
28 2.1.21 3 Other malignant neoplasm of 
lymphoid and hematopoietic  
tissue  

















152, 156,  
158-160,  
163-171,  





152, 156,  
158-160,  
163-171,  






30 2.2 2 Non-malignant neoplasms 
(benign and uncertain)   
D00-D48 209-239 210-239 
 
31 3. 1 Diseases of the blood and blood 
forming organs and certain 
disorders involving the immune 
mechanism 
D50-D89 280-289 280-289 
32 4. 1 Endocrine, nutritional and 
metabolic diseases 
E00-E89 240-279 240-279 












35 5. 1 Mental and behavioral disorders F01-F99 290-319 290-315 
36 5.1 2 Dementia F01, F03 290 290 




291, 303 291, 303 














40 6. 1 Diseases of the nervous system 
and the sense organs 
G00-H95 320-389 320-389 
 
41 6.1 2 Parkinson’s disease G20 332.0 342 
42 6.2 2 Alzheimer’s disease G30 331.0 - 
43 6.3 2 Other diseases of the nervous 












44 7. 1 Diseases of the circulatory 
system 
I00-I99 390-459 390-444.1, 
444.3-458,  
782.4 
45 7.1 2 Ischaemic heart diseases I20-I25 410-414 410-414 
46 7.1.1 3 Acute myocardial infarction I21-I22 410-411 410-411 
47 7.1.2 3 Other ischaemic heart diseases I20, I23-I25 412-414 412-414 
48 7.2 2 Other heart diseases I30-I51  420-429 420-429 
49 7.3 2 Cerebrovascular diseases I60-I69 430-438 430-438 
 
50 7.4 2 Other diseases of  










51 8. 1 Diseases of the  
respiratory system 
J00-J99 460-519 460-519 
52 8.1 2 Influenza J09-J11 487 470-474 
53 8.2 2 Pneumonia J12-J18 480-486 480-486 










56 8.3.2 3 Other chronic lower respiratory 
diseases 




57 8.4 2 Other diseases of  









58 9. 1 Diseases of the digestive system K00-K92 520-579 520-577, 
444.2 
59 9.1 2 Ulcer of stomach, duodenum and 
jejunum 
K25-K28 531-534 531-534 
 





61 9.3 2 Other diseases of  












62 10. 1 Diseases of the skin and 
subcutaneous tissue 
L00-L99 680-709 680-709 
63 11. 1 Diseases of the musculoskeletal 
system/connective tissue 
M00-M99 710-739 710-738 


















66 12. 1 Diseases of the genitourinary 
system 
N00-N99 580-629 580-629, 792 
67 12.1 2 Diseases of kidney and ureter N00-N29 580-594 580-594 
 
68 12.2 2 Other diseases of  
the genitourinary system 
N30-N99 595-629 595-629, 792 
69 13. 1 Complications of pregnancy, 
childbirth and puerperium 
O00-O99 630-676 630-678 
70 14. 1 Certain conditions originating in 
the perinatal period 
P00-P96 760-779 760-779 
71 15. 1 Congenital malformations and 
chromosomal abnormalities 
Q00-Q99 740-759 740-759 
72 16. 1 Symptoms, signs, ill-defined 
causes 
R00-R99 780-799 780-782.3, 
782.5-791,  
793-796 









75 16.3 2 Other symptoms, signs, ill-
defined causes 






76 17. 1 External causes of morbidity 
and mortality 
V01-Y89 E800-E999 E800-E999 










79 17.1.2 3 Accidental falls W00-W19 E880-E888 E880-E887 
80 17.1.3 3 Drowning and accidental 
submersion 
W65-W74 E910 E910 
81 17.1.4 3 Accidental poisoning X40-X49 E850-E869 E850-E877 
82 17.1.5 3 Other accidents W20-W64,  




















85 17.4 2 Events of undetermined intent Y10-Y34,  
Y87.2 
E980-E989 E980-E989 
86 17.5 2 Other external causes of 






























Forskningsprosjekt: Ny kreftsykdom og dødelighet hos menn som 
er behandlet for testikkelkreft 
Jeg er prosjektleder for et nasjonalt forskningsprosjekt der vi ønsker å kartlegge alvorlige senfølger 
etter tidligere kreftbehandling ved testikkelkreft. Vi planlegger å inkludere informasjon om alle menn 
behandlet for testikkelkreft i Norge i perioden 1980 til og med 2009. Informasjon om 
sykdomsutbredelse og behandling vil bli hentet fra pasientjournalene. Vi vil hente data fra 
Kreftregisteret for å se på antallet som har fått en ny kreftdiagnose i perioden etter behandlingen for 
testikkelkreft, samt data fra Dødsårsaksregisteret for å kartlegge dødsårsaker for de som er døde. 
Dette er et prosjekt som vil kunne hjelpe oss med å bedre oppfølgingen etter avsluttet behandling 
for testikkelkreft. 
Prosjektet innebærer ikke noen ekstra kontroller eller legebesøk for ditt vedkommende. Vi vil ikke 
avdekke informasjon om deg som du ikke allerede er kjent med. Data om deg vil bli lagret 
avidentifisert på en forskningsserver på Universitetssykehuset i Nord-Norge. Forskningsresultatene 
vil etter hvert bli offentliggjort gjennom publisering i internasjonale, anerkjente tidsskrifter. 
Etisk Komité i Region Sør-øst har godkjent dette prosjektet. Det er ikke krav om aktivt samtykke for 
deltagelse i prosjektet. Det er imidlertid stilt som vilkår for prosjektet at alle gis muligheten til å 
reservere seg mot deltagelse i prosjektet. Det innebærer at alle aktuelle pasienter vil bli inkludert i 
studien med mindre en selv aktivt gir beskjed om at en ikke ønsker å delta. Det betyr at om du har 
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Continuing increased risk of second cancer in long-term
testicular cancer survivors after treatment in the cisplatin era
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Using complete information on total treatment burden, this population-based study aimed to investigate second cancer (SC) risk in
testicular cancer survivors (TCS) treated in the cisplatin era. The Cancer Registry of Norway identified 5,625 1-year TCS diagnosed
1980–2009. Standardized incidence ratios (SIRs) were calculated to evaluate the total and site-specific incidence of SC compared to the
general population. Cox regression analyses evaluated the effect of treatment on the risk of SC. After amedian observation time of
16.6 years, 572 TCS developed 651 nongerm cell SCs. The SC risk was increased after surgery only (SIR 1.28), with site-specific
increased risks of thyroid cancer (SIR 4.95) andmelanoma (SIR 1.94). After chemotherapy (CT), we observed 2.0- to 3.7-fold increased
risks for cancers of the small intestine, bladder, kidney and lung. There was a1.6- to 2.1-fold increased risk of SC after ≥2 cycles of
cisplatin-based CT. Radiotherapy (RT) was associatedwith 1.5- to 4.4-fold increased risks for cancers of the stomach, small
intestine, liver, pancreas, lung, kidney and bladder. After combined CT and RT, increased risks emerged for hematological malignancies
(SIR 3.23). TCS treated in the cisplatin era have an increased risk of developing SC, in particular after treatment with cisplatin-based
CT and/or RT.
Introduction
Patients with germ cell testicular cancer (TC) have a 15-year rela-
tive survival rate exceeding 98% in Norway.1 An important factor
for the excellent prognosis was the introduction of cisplatin in the
late 1970s.2,3 However, the relative overall survival beyond
20 years after successful TC treatment is continuously decreas-
ing.4 One explanation is second cancer (SC) development which
is a severe and possibly life-threatening late effect after cancer
treatment.5
Previous studies have demonstrated a 1.7 to 3.5-fold increased
risk for both hematological and solid nongerm cell SC in testicular
cancer survivors (TCS) compared to age-matched general
populations.6–9 The risk has been associated with both radiother-
apy (RT) and chemotherapy (CT), but not with surgery only. The
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majority of these studies have, however, been based on outdated
TC treatment principles. Consequently, there is a lack of studies on
SC risk after the introduction of cisplatin.9–12 Experimental data
and animal studies have suggested cisplatin as a carcinogen.13
Besides, high cumulative cisplatin doses have been linked to an
increased leukemia risk.14,15
Three recent publications have evaluated SC risk after
cisplatin-based chemotherapy (CBCT) in TCS, demonstrating
a 40–80% excess risk.7–9 However, two of these studies lack
complete treatment information.7,9 Rather than calculating
standardized incidence ratios (SIRs), Kier et al. calculated the
cumulative incidence of SC and hazard ratios (HR) by using a
control group from the general population matched 10:1 on
age at diagnosis.8 Importantly, this study presented favorable
results for the surveillance group, demonstrating no excess
risk of SC or reduced survival compared to the control group.
The aim of this population-based study was to investigate the
risk of nongerm cell SC among TCS in the cisplatin era, by (i)
comparing the incidence of SC to that of the general population,
and (ii) investigating the risks associated with different treatment
modalities (surgery, RT, CT and the surveillance strategy).
Methods
Study cohort and design
Men diagnosed with histologically verified germ cell TC from
January 1, 1980, to December 31, 2009, were identified through
the Cancer Registry of Norway (CRN).1 Major exclusion criteria
included extragonadal germ cell cancer, a prior malignancy, age
<16 years at TC diagnosis and death or SC before 12 months
follow-up (Supporting Information Fig. S1). Follow-up started
12 months after diagnosis to avoid inclusion of synchronous or
treatment-unrelated cancer.
The final study cohort consisted of 5,625 one year survivors of
first primary germ cell TC. Detailed information regarding disease
stage, histology and primary and subsequent TC treatment was
abstracted frommedical records and linkedwith CRNdata on sub-
sequent cancer diagnoses, updated throughDecember 31, 2016.
This historical prospective cohort study was approved by the
Regional Committee for Medical and Health Research Ethics
and the Data Protection Authorities at the University Hospital of
North Norway. All eligible TCS still alive have received a study
information letter with the possibility to withdraw from partici-
pation (passive consent). Twenty-three men (0.38%) declined
participation, for reasons undisclosed.
Staging and treatment groups
The clinical staging of TC was based on the Royal Marsden Hos-
pital staging system.16 Overall, treatment intensity has gradually
been reduced during the study period in line with increasing
knowledge about efficacy and toxicity (Supporting Information
Table S1).2,17 The number of CT cycles used to treat patients with
initially metastatic disease have been reduced over the years from
≥4 to 3 cycles for patients with good prognosis (the majority of
patients) and 4 cycles for patients with intermediate and poor
prognosis.2,18 During the study period, the usage of RT for stage I
seminoma and primary retroperitoneal lymph node dis-
section (RPLND) for early stages of nonseminoma was gradually
abandoned (Supporting Information Table S1).
The study cohort was categorized into three groups by decade
of TC diagnosis. It was further categorized into treatment groups
by overall treatment burden: Surgery only (including surveillance,
n = 1,394; 25%), CT (n = 2,471; 44%), RT (n = 1,542; 27%) and
CT and RT combined (CT + RT; n = 218; 3.9%; Table 1).
Statistical methods
Categorical variables are presented with numbers and percent,
while continuous variables are presented with median and
interquartile range (IQR), unless otherwise stated.
Participants were followed from the time of their first TC +
1 year, until the development of a nongerm cell SC of interest,
death, emigration or December 31, 2016, whichever occurred first.
To avoid immortal time bias (a period of follow-up during which,
by design, the outcome of interest cannot occur), treatment was
analyzed as a time-varying covariate. For instance, a patient
accrued person-years of observation time in the surgery only
group until the date they received CT or RT.
The crude probability of SC was estimated by the cumula-
tive incidence using the Aalen-Johansen estimator,19 treating
death from any cause as a competing risk.
SIRs were calculated to evaluate the total and site-specific inci-
dence of SC in the TC cohort compared to the general population.
A subgroup analysis was performed for those initially designated
to surveillance. SIRs were obtained by dividing the observed num-
ber of cancers in the cohort by the expected number in a TC-free,
male Norwegian population, matched by 5-year age groups
and calendar year of follow-up. SIRs were calculated for the total
cohort and for different treatment groups, taking the time-varying
treatment exposure into account. Results are presented with
What’s new?
Long-term survival to 15 years among germ cell testicular cancer survivors treated in the cisplatin era, marked by the
introduction of cisplatin in the late 1970s, generally has been excellent. Beyond 20 years, however, survival rates decline. In
this analysis of data on Norwegian men diagnosed with testicular cancer between 1980 and 2009, an increased overall risk for
nongerm cell second cancer was detected among survivors, despite treatment. Risk was elevated in particular beyond 10 years
of follow-up after cisplatin-based chemotherapy or radiotherapy. Despite reduced treatment intensity, two or more cycles of
cisplatin-based chemotherapy was associated with continuing increased second cancer risk.
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Table 1. Patient characteristics according to the decade of first primary TC diagnosis










Surgery only1 244 (19) 359 (19) 791 (32) 1,394 (25)
CT 413 (32) 735 (39) 1,323 (54) 2,471 (44)
RT2 518 (41) 729 (38) 295 (12) 1,542 (27)
CT + RT 99 (7.8) 73 (3.9) 46 (1.9) 218 (3.9)
Age at diagnosis, years 31.9 (26.2–39.8) 32.5 (26.7–40.0) 33.8 (27.9–41.4) 32.9 (27.1–40.7)
Seminoma 36.3 (30.1–44.9) 36.4 (30.7–44.4) 37.2 (31.6–44.6) 36.7 (30.8–44.5)
Nonseminoma 27.9 (23.3–33.9) 28.7 (23.9–34.9) 29.6 (24.8–36.4) 28.8 (24.2–35.3)
Age at diagnosis, n (%)
<20 years 77 (6.0) 82 (4.3) 59 (2.4) 218 (3.9)
20–30 years 468 (37) 671 (35) 764 (31) 1,903 (34)
30–40 years 417 (33) 663 (35) 926 (38) 2,006 (36)
40–50 years 187 (14) 298 (16) 474 (19) 959 (17)
>50 years 125 (10) 182 (10) 232 (10) 539 (9.6)
Histology, n (%)
Seminoma 619 (49) 967 (51) 1,356 (55) 2,942 (52)
Nonseminoma 655 (51) 929 (49) 1,099 (45) 2,683 (48)
Observation time, years 29.3 (24.2–32.2) 20.5 (18.0–23.5) 11.3 (8.8–14.0) 16.6 (10.9–23.8)
Observation time, n (%)
<10 years 99 (7.8) 132 (7.0) 959 (39) 1,191 (21)
10–19 years 128 (10) 712 (38) 1,496 (61) 2,336 (42)
20–29 years 480 (38) 1,052 (55) 0 1,532 (27)
30–37 years 567 (44) 0 0 567 (10)
Initial disease stage, n (%)3
I 798 (63) 1,348 (71) 1829 (74) 3,975 (71)
Mk+/II 325 (25) 359 (19) 440 (18) 1,124 (20)
III 31 (2.4) 43 (2.3) 40 (1.6) 114 (2.0)
IV 120 (9.4) 146 (7.7) 146 (6.0) 412 (7.3)
Cause of first-line CT, n (%)
Adjuvant, CSI 39 (7.6) 199 (25) 639 (47) 877 (32)
Primary metastatic disease 410 (80) 513 (63) 601 (44) 1,524 (57)
Recurrence 63 (12) 96 (12) 129 (9.4) 288 (11)
First CT regimen, n (%)
BEP-20 129 (25) 552 (68) 839 (61) 1,520 (57)
CVB 324 (63) 36 (4.5) 0 360 (13)
EP 6 (1.2) 36 (4.5) 208 (15) 250 (9.3)
Other CBCT4 44 (8.6) 118 (15) 21 (1.5) 183 (6.8)
Adjuvant carboplatin 15 (0.2) 26 (3.2) 287 (21) 314 (12)
CEB 3 (0.6) 31 (3.8) 8 (0.6) 42 (1.6)
Other6 5 (1.0) 9 (1.1) 6 (0.4) 20 (0.7)
CBCT cycles, n (%)7
1 8 (1.6) 30 (4.0) 188 (17) 226 (10)
2 27 (5.3) 116 (15) 177 (16) 320 (14)
3 93 (18) 106 (14) 252 (24) 451 (19)
4 289 (57) 351 (47) 381 (35) 1,021 (43)
>4 90 (18) 149 (20) 84 (7.8) 323 (14)
(Continues)
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observed numbers of SC in our database, SIRs and 95% confidence
intervals (95%CIs).
The effect of treatment was analyzed in age-adjusted Cox
regressionmodels with follow-up time as time scale and the surgery
only group as a reference. The proportional hazard assumption for
the analysis of treatment groups was judged to be violated using
both visual inspection of−log−log survival curves and a significant
Schoenfeld test (p = 0.005). All analyses were thus performed using
a time-dependent Cox model with two-way interaction terms
between each treatment and a dummy variable of follow-up time
(before/after 10 years). Similar subgroup analyses were performed
to evaluate the SC risk in relation to histology and treatment
intensity. When we investigated the association between the num-
ber of CBCT cycles and risk of SC, men who had subsequently
received RT were censored at the start date for their first RT treat-
ment. Likewise, when analyzing effects of the first RT field and
abdominal RT dose, individuals who had received CT were cen-
sored at the date of administration of CT. Estimates are presented
for those with >10 years observation time, starting 1 year from TC
diagnosis, unless otherwise specified. Results are presented as HRs
with corresponding 95%CIs.
Data were analyzed using Stata statistical software (version
MP 14.2; STATA, College Station, TX). A p-value <0.05 was
considered significant.
Table 1. Patient characteristics according to the decade of first primary TC diagnosis (Continued)









CBCT containing vinca alkaloids or etoposide, n (%)
Vinca alkaloids 257 (50) 61 (7.6) 0 318 (12)
Etoposide 153 (30) 649 (80) 1,080 (79) 1882 (70)
Both 98 (19) 66 (8.2) 10 (0.7) 174 (6.5)
Other CT 4 (0.8) 32 (4.0) 279 (20) 315 (12)
RT first field, n (%)
L-field8 549 (89) 626 (78) 224 (66) 1,399 (80)
Paraaortic 24 (3.9) 147 (18) 99 (29) 270 (15)
Supradiaphragmatic 7 (1.3) 5 (0.6) 1 (0.3) 13 (0.7)
Supra- and infradiaphragmatic9 21 (3.4) 0 0 21 (1.2)
RT metastatic10 16 (2.6) 24 (3.0) 17 (5.0) 57 (3.2)
RT dose for first field, Gy 36.0 (36.0–40.0) 30.0 (25.2–30.0) 25.2 (25.2–30.0) 30.0 (27.0–36.0)
RT dose for first field11
20–29 Gy 7 (1.1) 309 (38) 208 (60) 524 (30)
30–39 Gy 409 (66) 462 (58) 125 (36) 996 (56)
≥40 Gy 199 (32) 24 (3.0) 10 (2.9) 233 (13)
Total recurrences, n (%) 99 (7.8) 166 (8.8) 206 (8.4) 471 (8.4)
Initial surveillance, n (%)12 75 (5.9) 387 (20) 911 (37) 1,373 (24)
Recurrences in initial surveillance group, n (%)13 19 (25) 72 (19) 122 (13) 213 (16)
Note: Data are presented as median (IQR), unless otherwise stated.
Abbreviations: BEP-20, bleomycin, etoposide and cisplatin; CBCT, cisplatin-based CT; CEB, carboplatin, etoposide and bleomycin; CSI, clinical stage I;
CT + RT, combination of CT and RT; CT, chemotherapy; CVB, cisplatin, vinblastine and bleomycin; EP, etoposide and cisplatin; Gy, grey; IQR, interquartile
range; Mk+, marker positive; n, number; RT, radiotherapy; TC, testicular cancer.
1The surgery only group included men followed with surveillance after orchiectomy (n = 1,146; 20%) and men submitted to additional retroperitoneal
lymph node dissection without CT or RT (n = 248; 4.4%).
2There were a total of 10 individuals that received scrotal RT of 16–20 Gy because of carcinoma in situ or a new tumor of the remaining testicle who
underwent partial orchiectomy. These 10 individuals are not included in the RT group in our analyses.
3As described by Peckham et al. Combined management of malignant teratoma of the testis.16
4Of which a total of 139 were dose-escalated CBCT.
5Adjuvant carboplatin administered in 2005 because of metachronous TC.
6Constitutes the following regimes: carboplatin monotherapy in metastatic setting (n = 16), sendoxan/adriamycin (n = 1), CAOS (actinomycin D,
adriamycin, vincristine, sendoxan; n = 2), actinomycin D (n = 1).
7Number of total CBCT cycles administered. May have received additional CT regimens, but these are not accounted for in this number.
8L-field or dogleg-field. Included in this category are also 52 individuals who received RT of groin in addition to L-field and 9 individuals who received a
reversed Y-field.
9Sixteen of 21 individuals received infradiaphragmatic RT as first RT field and a short while later received supradiaphragmatic RT.
10RT toward bone (n = 19), CNS (n = 16), abdominal residual masses (n = 16), intraoperative RT (n = 1), skin lesions (n = 1) and nonspecified sites (n = 4).
11Overall, 17 TCS for various reasons received only 1–20 Gy (2, 9 and 6 TCS from first to last decade, respectively). One patient received versions of
overlapping infradiaphragmatic fields two times within 3 years. For this, one case the dose presented is an addition of Field 1 and Field 2.
12This group consists of all cases with CSI initially intended for surveillance as treatment strategy.
13The percentage stated is the amount of recurrences among those initially treated with surveillance.
24 Second cancer risk after testicular cancer
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The data that support the outcomes of our study are available
from the CRN (SC) and a local database (treatment informa-
tion). Restrictions apply to the availability of these data, which
were used under license for our study. Data can be requested
by application to the CRN.
Results
Study cohort
Over the decades, the use of surgery only or CT increased, while
there was decreasing use of RT or CT + RT (Table 1). Median age
at diagnosis was 32.9 years (IQR 27.1–40.7), 36.7 years for semi-
nomas and 28.8 years for nonseminomas. Median observation
time for the total cohort was 16.6 years (IQR 10.9–23.8), and 37%
had an observation time >20 years.
From 1980–1989 to 2000–2009, the proportion of
chemotherapy-treated men receiving adjuvant CT for stage I dis-
ease increased from 7.6% to 47%, and the use of the surveillance
strategy increased from 5.9% to 37% (Table 1). Of the 1,373
(24%) men subjected to surveillance, 213 (16%) experienced a
recurrence.
Overall and site-specific risk of SC in TCS compared to the
general population
Overall, 572 TCS (10.2%) developed 651 SCs, with prostate,
lung, bladder, melanoma and colon cancer being the most
common malignancies (Supporting Information Table S2).
Figure 1. Crude cumulative probability of second cancer by follow up-time. (a) All patients (with 95% confidence interval) and (b) by
histology. In a, the red line indicates the probability of second cancer, and the blue area indicates the 95% confidence interval. *years since
diagnosis +1 year. [Correction added on 1 May 2020, after first online publication: Figure 1b was incorrect due to a mathematical error and
has been replaced in this version.]
Figure 2. Proportion diagnosed with second cancer by follow-up time, adjusted for age at testicular cancer diagnosis. (a) By treatment, (b) by
number of cisplatin-based chemotherapy cycles and carboplatin monotherapy. *years since diagnosis +1 year. Abbreviations: Carbomono,
adjuvant carboplatin monotherapy; CT + RT, combination of CT and RT; CT, chemotherapy; RT, radiotherapy; SC, second cancer.
Hellesnes et al. 27












The crude probability of SC accelerated beyond 15–20 years
(2.6% at 10 years and 15.2% at 25 years for the total cohort;
Fig. 1a).
The TCS had a 58% overall excess risk of developing non-
germ cell SC (SIR 1.58, 95% CI 1.45–1.71) compared to the gen-
eral population. All treatment groups had significantly increased
risks, ranging from 28% excess risk after surgery only to twofold
increased risk after CT + RT (Table 2).
The overall excess risk of developing a solid cancer was 44%,
with significantly elevated risks for cancers of the stomach, small
intestine, colon/rectum, liver/bile ducts, pancreas, lung, mela-
noma, soft tissue, kidney, bladder and thyroid. In addition, the
TCS had an overall increased risk of hematological malignancies
(SIR 1.31, 95% CI 1.00–1.71).
After surgery only, there were increased risks for melanoma
(SIR 1.94, 95% CI 1.10–3.42) and cancer of the thyroid (SIR 4.95,
95% CI 1.86–13.18; Table 2). CT was associated with a signifi-
cantly 1.9 to 3.7-fold increased risk of cancers of the small intes-
tine, lung, melanoma, kidney and bladder. After RT, the risks
were 1.5–4.4 times significantly increased for cancers of the stom-
ach, small intestine, liver and bile ducts, pancreas, lung, kidney
and bladder. CT + RT increased the risks for cancers of the stom-
ach, small intestine, pancreas, soft tissue, thyroid, lymphoma and
leukemia (Table 2).
Table 4. HRs for total and solid nongerm cell SC according to treatment intensity
Total SC Solid SC
HR 95% CI HR 95% CI
CBCT cycles1
Surgery only 1 ref 1 ref
1 0.41 0.07–2.54 0.47 0.07–2.92
2 1.91 1.01–3.59 2.19 1.16–4.15
3 1.41 0.83–2.37 1.24 0.70–2.21
4 1.60 1.12–2.30 1.73 1.19–2.50
>4 2.09 1.23–3.53 2.19 1.27–3.78
Carboplatin2 1.17 0.18–7.68 2.54 0.62–10.43
Other3 2.21 0.80–6.11 1.77 0.55–5.71
Vinca alkaloids vs. etoposide
Surgery only 1 ref 1 ref
Vinca alkaloids 1.64 1.09–2.48 1.82 1.19–2.77
Etoposide 1.56 1.07–2.26 1.57 1.06–2.32
Both vinca alkaloids and etoposide 1.79 1.02–3.13 1.84 1.03–3.29
Other CT 0.55 0.08–4.02 1.22 0.30–5.03
RT field
Surgery only 1 ref 1 ref
L-field4 1.66 1.23–2.25 1.76 1.29–2.42
Paraaortic 1.65 0.95–2.87 1.73 0.97–3.06
Other5 4.40 1.07–18.07 5.06 1.23–20.85
RT dose for first abdominal RT field
Surgery only 1 ref 1 ref
20–29 Gy 1.88 1.21–2.90 2.01 1.28–3.16
30–39 Gy 1.71 1.25–2.33 1.80 1.30–2.51
≥40 Gy 1.42 0.93–2.18 1.50 0.96–2.33
Notes: Significant results marked with bold. Results presented for patients with >10 years observation time. Results for hematological SCs not shown as
none were significant.
Abbreviations: 95% CI, 95% confidence interval; CBCT, cisplatin-based chemotherapy; CT, chemotherapy; Gy, grey; HR, hazard ratio; RT, radiotherapy;
SC, second cancer.
1Number of total CBCT cycles administered. May have received additional CT regimens, but these are not accounted for in this number. A total of
140 TCS received dose-escalated CBCT, of which 1, 27, 12, 35 and 65 men received 1, 2, 3, 4 or >4 cycles, respectively. Then, 13% of those that
received dose-escalated CBCT developed SC, compared to 7% in the CT-group overall and 9% in the CT-group when excluding those that received adju-
vant CT.
2Carboplatin monotherapy, carboplatin in adjuvant setting for stage I seminoma.
3Thirty-three CEB (carboplatin, etoposide, bleomycin; of which 32 received 4 cycles and 1 received 2 cycles of CEB), 4 other carboplatin-based CT (3 of
which received 4 cycles and 1 received 1 cycle) and 1 actinomycin D.
4L-field and variations: The majority received L-field or dogleg-field. Included in this category are also 52 cases who received RT of groin in addition to L-
field and 9 cases who received a reverse Y-field.
5Eleven supra- and infradiaphragmatic fields, two RT in metastatic setting (bone and abdominal residual tumor).
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In TCS initially intended for surveillance, the SIR was 1.34,
95% CI 1.07–1.68, with a significantly increased risk for thy-
roid cancer (SIR 7.35, 95% CI 3.06–17.66).
Both seminoma and nonseminoma histology were associated
with increased risks of SC with SIRs 1.59 (95% CI 1.44–1.76)
and 1.55 (95% CI 1.35–1.77), respectively.
Risk of SC by age and follow-up time in TCS compared to
the general population
The risk of SC generally declined with increasing age at initial
treatment for TC, regardless of which treatment was given.
Overall, SIRs ranged from 2.29 (95% CI 1.09–4.80) among
patients who initiated treatment before 20 years of age to 1.39
(95% CI 1.19–1.63) among those 50 years or older (Table 3).
The risk of SC generally increased with increasing follow-up
time. Overall, SIRs ranged from 1.28 (95% CI 1.09–1.51) among
TCS followed less than 10 years to 2.12 (95% CI 1.55–2.90)
among patients followed for 30–37 years. Significantly increased
risks of SC after CT or RT alone did only emerge with follow-up
beyond 10 years, while significantly increased SC risk after sur-
gery was only present with less than 10 years of follow-up.
Overall, SIRs were relatively similar at 1.6 regardless of attained
age at first SC diagnosis. Unlike the other treatment groups, the
increased SC risk among patients who received surgery only was
restricted to SC diagnosed before 40 years of age.
Overall and site-specific risk of SC by histology and
treatment group compared to surgery only
The crude cumulative probability of SC at 25 years was 20% (95%
CI 18–22%) for seminoma and 10% (95% CI 8.7–12%) for non-
seminoma survivors (Fig. 1b). SC risk among individuals with
seminoma was significantly increased compared to nonseminoma
in age-adjusted analysis (HR 1.20, 95% CI 1.01–1.44). [Correction
added on 1 May 2020, after first online publication: The values in
the preceding paragraph have been corrected.]
With surgery only as the reference group, SC risks increased
with observation time in all treatment groups (Fig. 2a, Supporting
Information Table S3), except among the 11 nonseminoma
patients treated with RT only when stratifying according to histol-
ogy (Supporting Information Fig. S2). Risks of solid SCs were sig-
nificantly increased >10 years of follow-up regardless of treatment
group, with HRs ranging from 1.65 to 1.79. The only significantly
increased SC risk <10 years of follow-up was for all hematological
malignancies after CT + RT (HR 8.73, 95% CI 1.76–43.29).
Compared to the surgery group, we observed a significant
5.1 to 5.3-fold excess risk of bladder cancer after CT or RT, a
7.6-fold excess risk of kidney cancer after RT, and a 24-fold
excess risk of cancer of the stomach after combined CT + RT.
SC risk in relation to treatment intensity
The time to development of SC by number of CBCT cycles is
illustrated in Figure 2b. After >10 years of follow-up, we observed
a 1.6 to 2.1-fold excess risk of SC after two or more CBCT cycles
compared to surgery only (Table 4). Similar excess risk was found
for solid cancer, but not for hematological cancer. No increased
SC risk was observed after one CBCT cycle or adjuvant car-
boplatin, however median observation time was only 9.5 years.
Both the L-field technique and paraaortic RT were associ-
ated with 1.6-fold increased risks for SC in comparison to sur-
gery only (Table 4). After paraaortic RT, 9.3% developed SC,
of which 0.4% (n = 1) was bladder cancer, compared to 19%
developing SC after L-field, of which 1.7% (n = 22) were blad-
der cancers. SC risks were also increased after RT doses of
≥20 Gy to the first abdominal field.
Discussion
In this national TCS cohort treated since 1980, we found, to the
best of our knowledge for the first time, a significantly increased
overall risk for nongerm cell SC among TCS treated with surgery
only when compared to the general population, with site-specific
excess risks of thyroid cancer and melanoma. We also demon-
strated that contemporary treatment with CBCT leads to a
continuing increased risk of SC, with significantly increased
site-specific risk of cancers of the small intestine, lung, mela-
noma, kidney and bladder. Two or more cycles of CBCT were
associated with an excess risk of SC, and CT in combination
with RT led to particularly high risks.
The considerable latency from cancer therapy to SC occur-
rence, as well as the excess risk with increasing follow-up time in
our study cohort, is comparable to previous findings,7–9,20 and
underscores the importance of designing studies with sufficient
observation time when investigating SC risk in cancer survivors.
Previous publications have reported an excess risk of thyroid
cancer after CBCT7,9 or RT.20 The elevated risk of thyroid cancer
in the surgery only group reported herein, although based on rel-
atively few cases, is a novel finding that needs to be further eluci-
dated in future research. The median time to development of
thyroid cancer in our study population was 5.8 years, and our
findings may partly be explained by surveillance bias. A few rare
inherited syndromes that can cause both thyroid and testicular
tumors have been described however,21 and thyroid cancer can
on rare occasions develop from teratomas.22 It is unknown
whether this was the case in our study population.
Excess risk of melanoma in TCS after RT has been reported
in previous studies,20,23,24 but in line with results reported by van
den Belt-Dusebout et al.,25 we demonstrated a significant excess
risk of melanoma in the surgery only group. However, the num-
ber of cases diagnosed with melanoma was low, even though our
study includes hitherto the highest number of patients with com-
plete treatment details. Some authors have attributed these find-
ings to increased medical attention during the first years of
follow-up.23 Surveillance bias is a less likely explanation in our
cohort due to the long median latency of 14.6 years between
diagnosis of TC and melanoma.
Patients with cutaneous melanoma have been found to be at
increased risk of developing SC, including testicular and thyroid
cancer.26 There is a genetic link between thyroid cancer and mel-
anoma through a susceptibility to BRAF mutations. A 2014 US
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study found a reciprocal twofold increased risk of developing
papillary thyroid cancer after cutaneous melanoma or vice versa,
and a high incidence of BRAF v600e-mutations.27 In our study
population, no patients presented with both thyroid cancer and
melanoma.
An association between childhood tumor risk and first-
degree family history of solid tumors was recently observed
for several solid cancers, including melanomas, even after con-
trolling for probable hereditary cancer syndromes.28 The
increased risk of SC after surgery only, together with the
young age at TC diagnosis and the familial risk of developing
TC, similarly implies a genetic susceptibility and/or that envi-
ronmental factors during fetal life or early childhood predis-
pose for both TC and other malignancies.29–31 The genetic
susceptibility for TC is thought to be driven by multiple low-
penetrance alleles.32–34 Additionally, a recent study demon-
strated evidence for CHEK2 as a moderate-penetrance suscep-
tibility gene.35 To this date, however, TC has not been linked
to a cancer syndrome that predisposes to other cancers,32 but
our findings suggest that further research within this field
should be prioritized. CT-scans during follow-up after treat-
ment for TC have been associated with increased SC risk,36,37
and might contribute to the excess risk in the surgery only
group. Future studies evaluating the impact of follow-up with
CT-scans vs. MRI should be prioritized.
The increased overall SC risk after surgery alone only
before 10 years of follow-up could indicate surveillance bias
(Table 3), even though follow-up started 1 year after TC diag-
nosis. However, in that case, we would also expect increased
SC risks after RT or CT before 10 years of follow-up, which
was not seen. In summary, we believe that our findings in
general are not explained by surveillance bias.
In line with previous publications, we demonstrated a 62%
increased risk of SC after treatment with CT in the cisplatin
era.7–9 Bladder cancer was among the most frequent SCs in
our study cohort, corroborating previous reports,7–9,20,25 and
we observed a threefold increased risk for bladder cancer after
CT when compared to the general population. The risks for
cancers of the kidney and upper urinary tract and lung were
twofold increased following CT, which is comparable to previ-
ous reports.7–9 There is a possibility that at least some of the
cancers diagnosed as soft tissue sarcoma are in fact trans-
formed teratomas,38,39 but we did not find any increased risk
of sarcomas after CBCT as previously reported.7,9
Cisplatin is a platinum compound which has been detected
in plasma decades after treatment,40 and in most organs sev-
eral months after treatment,41,42 where it remains partly reac-
tive. Despite the lack of long-term data, the accumulation of
platinum might be a pathophysiological explanation for the
increased risk of SC.10 In a recent publication by Hjelle et al.,
a reduced risk of SC was found in individuals with larger
long-term declines in serum-platinum levels.43 Importantly,
platinum is eliminated through renal clearance, and it has
been detected in urine up to 16 years after treatment.44 An
association between CBCT and cancers of the urinary tract is
therefore likely.
The 64% excess SC risk following RT confirms the established
association between RT and subsequent SC development.8,9,20,25
The increased risks of cancers of the gastrointestinal tract, pan-
creas, liver, lung, kidney and bladder after RT compared to the
general population reported herein, are in line with previous pub-
lications demonstrating that SCs often are localized in relation to
previous RT fields.20,45–48 The excess risk was almost similar after
both paraaortic lymph node portal and the more extensive L-field
portal, which also includes ipsilateral iliac lymph nodes. The asso-
ciation was, however, not statistically significant after paraaortic
RT, probably due to the low number and the shorter follow-up.
The absolute numbers suggested that the risk of developing blad-
der cancer was reduced after paraaortic RT compared to L-field,
but statistical analysis was not possible because of low numbers.
We could not confirm a linear trend for increasing risk of solid
SC with increasing abdominal RT dose, as reported by Groot
et al.,9 despite our larger study population.
In our study, combined CT and RT was associated with the
highest risks for SC compared to the general population, which is
in agreement with previous reports.49–51 The increased risk of
stomach cancer after combination therapy has been previously
reported.25 The risks for all hematological malignancies, lym-
phoma and leukemia were also increased after CT + RT. Subse-
quent hematological malignancies generally develop within
10 years following cancer treatment,14,52 and our results were
consistent with this.
To the best of our knowledge, analyses of TCS intended for
surveillance after surgery has not been performed previously,
and also in this group, we found a significantly increased risk of
SC. Kier et al. presented favorable results for the surveillance
group,8 however these authors’ findings were based on a group
that excluded all individuals that relapsed from analyses. There is
an ongoing debate as to whether surveillance is superior to adju-
vant chemotherapy in the treatment of stage I TC. Of note, we
did not observe any increased risk of SC after one cycle of CBCT
or carboplatin, but the observation time is still short, and longer
follow-up is needed before any conclusions can be drawn.
We found an almost 60% significantly increased risk of SC
after both seminomas and nonseminomas compared to the gen-
eral population, which is in line with the recent Dutch publica-
tion.9 Our remarkably higher 25-year crude probability of all SCs
following seminomas of 20%, compared to 12.6% in the Dutch
report is interesting. [Correction added on 1 May 2002, after first
online publication: 28% has been changed to 20% in the preced-
ing sentence.] Some of the difference might be explained by the
longer median follow-up after seminoma in our study of
16.0 years compared to 13.5 years in the Dutch study.
Strengths of our study are the inclusion of detailed informa-
tion regarding total treatment burden for the entire study cohort,
and the unique quality of the CRN. Based on a distinct personal
identification number used in Norway, the CRN receives infor-
mation from several sources to ensure accuracy, and reporting to
30 Second cancer risk after testicular cancer












this registry is instructed by law.1 SIRs are easy to understand
and interpret, and we considered that calculation of absolute
excess risks (AERs) would not provide more information to the
reader. The use of time-dependent Cox-regression implements
the important element of observation time in our analyses.
Limitations include the lack of details regarding known risk
factors for cancer, for example, smoking, hereditary factors and
comorbidities. There is, however, no reason to believe that
smoking prevalence among TCS differs from the general
population.53,54
In conclusion, despite reduced treatment intensity during the
last decades, we find a continuing increased risk of SC in TCS
treated in the cisplatin era. While treatment-related late effects
remain the main culprit, increased SC risks among patients
treated with surgery only suggest that genetic and environmental
factors are also important. Regardless of cause, improvement of
lifestyle behavior, in particular, smoking cessation, reduction
of alcohol intake, increased physical activity and a healthy
diet may reduce the risk of SC.55 Promotion and guidance
for a healthy lifestyle should thus be implemented to a larger
degree during long-term follow-up of all TCS than it is
today. Health care professionals must be aware of the SC risk
so that proper examination is initiated by the slightest suspi-
cion of a SC to ensure diagnosis at an early stage.
Disclaimer
The study has used data from the Cancer Registry of Norway.
The interpretation and reporting of these data are the sole
responsibility of the authors, and no endorsement by the Can-
cer Registry of Norway is intended nor should be inferred.
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Excluded (n=274, 4.3%) 
 Extragonadal localization (ICD-7 178.4) (n=180) 
 Localization ductus deferens or funicle (ICD-
7 178.3) (n=24) 
 Localization epididymis (ICD-7 178.2) (n=4) 
 Age < 16 years (n=66) 
   
  
Males diagnosed with GC TC in the CRN (coded with 
localization ICD-7 178.x) between 01/01/1980-
12/31/2009 (n=6354) 
Excluded (n=333 5.5%) 
 Previous diagnosis of non-TC cancer (n=58) 
 TC before 1980 (n=27) 
 Extragonadal localization (n=51) 
 Clinical data missing (n=55) 
 Other histology than GC cancer (n=99) 
 Treated abroad (n=11) 
 Clinical diagnosis only/histology not performed 
(n=11) 
 Other causes (n=2) 
 Synchronous non-TC diagnosis (n=19) 
 
 
Cohort for the analysis of non-GC SC in TCS = study 
population (n=5625, 88.5%) 
Dataset used as basis for information letter                
(n=6080, 95.7%) 
 Declined to participate (n=23, 0.38%) 
 
Dataset used as basis for collection of clinical data 
(n=6057, 95.3%) 
 
Excluded from the present study (n=99, 1.7%) due to the 
following events less than 12 months after TC diagnosis: 
 Non-GC SC (n=14)  
 Death (n=77)  
 Emigration (n=8) 
Cohort of TCS with complete clinical data              
(n=5724, 90.1%) 
Supplemental appendix Figure 1. Flow chart presenting the study cohort 
Abbreviations: GC: germ cell; TC: testicular cancer; CRN: Cancer Registry of Norway; ICD-7: International Classification of Diseases 








Supplemental Appendix Figure 2. Proportion diagnosed with second cancer after seminoma or 
nonseminoma by follow up-time, adjusted for age at testicular cancer diagnosis. A) Seminoma, 
B) Nonseminoma. 
*years since diagnosis + 1 year 
Abbreviations: SC: second cancer; CT: chemotherapy; RT: radiotherapy; CT + RT: combination of 
CT and RT. 
 
  
Supplemental appendix Table 1. General treatment principles for TC patients in Norway by decade of 
diagnosis 
 
Decade Localized disease Metastatic disease 
1980 to 1989 Seminomas: adjuvant RT towards 
paraaortal and ipsilateral iliacal lymph 
nodes by the L-field technique.1 The target 
dose was gradually reduced from 36-40 Gy 
to 25.2-27 Gy.1, 2  
One institution offered RT restricted to the 
para-aortic area only from 1989.3 
Nonseminomas: staging RPLND followed 
by adjuvant chemotherapy if metastases 
were histologically verified.4  
Majority of cases treated with CT. CVB 
standard CT-regimen up until 1987 when BEP 
became standard treatment.5 Some treated 
according to experimental regimens within 
research protocols.6-11 Generally ≥4 cycles 
administered. 
Seminoma patients received post-chemo RT to 
residual masses until 1986. Residual masses 
after CT in nonseminoma patients were 
resected, primarily as a RPLND. RT was a 
treatment option if residual masses persisted 
after CT and/or surgery. Nerve-sparing 
RPLND from 1989.4 
1990 to 1999 Seminomas: adjuvant RT continued as 
above, target dose usually <30 Gy. 
Nonseminomas: After 1990, primary 
RPLND was abandoned, and stage 1 
patients were instead offered surveillance 
or 1-2 cycles of adjuvant CBCT.12-14 
The BEP-regimen remains standard first-line 
therapy in metastatic disease. High-dose 
chemotherapy with autologous stem cell 
support available from 1995.  
Some treated according to experimental 
regimens within research protocols.6-11 
Residual masses after CT in nonseminoma 
patients were resected, primarily as a RPLND 
2000 to 2009 Seminomas: From 2000, RT was gradually 
abandoned in stage I, and patients were 
increasingly offered surveillance or 
adjuvant carboplatin.15, 16 
Nonseminomas: patients are offered 
surveillance or one adjuvant cycle of 
BEP.17 
 
Follow-up: By the end of the study-period 
recommendation to use MRI-scan because 
of the concern about increased second 
cancer risk after multiple CT-scans.18, 19 
 
The number of CT cycles have been reduced to 
3 cycles for patients with good prognosis (the 
majority of patients) and 4 cycles for patients 
with intermediate and poor prognosis.11, 20 
Seminoma patients offered EP instead of BEP. 
Decrease in usage of RT for seminomas, but 
still an option in stage IIA disease. 
 
 
TC: testicular cancer; RT: radiotherapy; RPLND: retroperitoneal lymph node dissection; CT: chemotherapy; 
CVB: cisplatin, vinblastine, bleomycin; BEP: cisplatin, etoposide, bleomycin; Gy: Grey; CBCT: cisplatin-
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Supplemental appendix Table 2. Presentation of numbers of first and subsequent non-germ cell SC in the study 
cohort according to diagnostic code 
Diagnostic code ICD-10 First Second Third Fourth SUM 
C00-C14 Ear, nose, throat 14 1 0 0 15 
C15 Esophagus 8 0 0 0 8 
C16 Stomach 20 1 0 0 21 
C17 Small intestine 8 3 0 0 11 
C18 Colon 35 6 0 0 41 
C19 Rectosigmoid junction 4 0 0 0 4 
C20 Rectum 24 2 0 0 26 
C22 Liver and intrahepatic bile ducts  6 0 0 0 6 
C24 Extrahepatic bile ducts 6 0 0 0 6 
C25 Pancreas 25 3 0 0 28 
C26 Ill-defined digestive organs 1 1 0 0 2 
C31 Accessory sinuses 1 0 0 0 1 
C32 Larynx 3 1 0 0 4 
C34 Bronchus and lung 65 3 1 0 69 
C41 Bone and articular cartilage 2 0 1 0 3 
C43 Malignant melanoma of skin 38 6 1 0 45 
C44 Other malignant neoplasms of skin 22 2 1 0 25 
C45 Mesothelioma 4 0 0 0 4 
C47 Peripheral nerves and autnomic nervous system 1 0 0 1 2 
C48 Retroperitoneum and peritoneum 2 0 0 0 2 
C49 Other connective and soft tissue 2 0 0 0 2 
C50 Breast 2 0 0 0 2 
C60 Penis 2 0 0 0 2 
C61 Prostate 107 11 2 2 122 
C64 Kidney 23 4 0 0 27 
C65 Renal pelvis 2 1 0 0 3 
C66 Ureter 4 3 2 0 9 
C67 Bladder 49 7 1 0 57 
C68 Other and unspecified urinary organs 0 1 0 0 1 
C69 Eye 1 0 0 0 1 
C70 Meninges 4 0 0 0 4 
C71 Brain 12 0 0 0 12 
C72 Spinal cord, cranial nerves and other parts of CNS 3 0 0 0 3 
C75.1 Pituitary gland 9 0 0 0 9 
C73 Thyroid 10 0 0 0 10 
C76 Other and ill-defined sites 8 2 0 0 10 
C81 Hodgkin lymphoma 7 0 0 0 7 
C82 Follicular lymphoma 8 0 1 1 10 
C83 Non-follicular lymphoma 6 1 1 0 8 
C85 Non-Hodgkin lymphoma, unspecified 2 1 0 0 3 
C88 Malignant immunoproliferative diseases 1 0 0 0 1 
C90 Multiple myeloma 3 1 0 0 4 
C91 Lymphoid leukaemia 5 0 0 0 5 
C92 Myeloid leukaemia 6 1 1 0 8 
C93 Monocytic leukaemia 1 0 0 0 1 
C95 Leukaemia, unspecified 1 0 0 0 1 
D45 Polycytemia vera 1 0 0 0 1 
D46 Myelodysplastic syndrome 4 1 0 0 5 
SUM 572 64 12 4 651 
Note: Data are presented as numbers. Thirteen cases are registered with identical ICD-10 diagnoses twice, and as a result, the 
sum in this table does not add up to the numbers presented in table 2 for certain diagnoses. Median time between first and 
second diagnosis: 2.04 years (IQR 4.75); median time between second and third diagnosis: 1.54 years (IQR 4.05); median 
time between third and fourth diagnosis: 0.33 years (IQR 0.34).  
SC: non-germ cell second cancer; CNS: central nervous system; ICD-10: international classification of diseases; IQR: 
interquartile range. 
Supplemental Table 3. HRs for non-germ cell SC according to treatment group: age-adjusted time-dependent 
Cox 
 Surgery only1 CT RT CT + RT 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Total SC2         
>10 y obs 1 ref 1.57 1.13-2.16 1.71 1.27-2.31 1.71 1.06-2.78 
>15 y obs3 1 ref 1.78 1.23-2.60 1.83 1.29-2.62 1.85 1.07-3.19 
>20 y obs 1 ref 1.96 1.22-3.14 1.78 1.13-2.80 2.08 1.13-4.00 
All solid cancers 
C00-C80 
1 ref 1.65 1.18-2.31 1.77 1.29-2.42 1.79 1.09-2.95 
Ear, nose and throat 
C00-14, C31-32 
1 ref 1.16 0.28-4.91 0.84 0.21-3.36 NA NA 
Esophagus C15 1 ref 0.98 0.16-5.94 0.35 0.05-2.47 NA NA 
Stomach C16 1 ref 0.78 0.05-12.57 4.19 0.54-32.50 24.25 2.89-203.41 
Small intestine C17 1 ref 0.92 0.15-5.51 0.70 0.13-3.88 1.72 0.15-19.22 
Colorectal C18-20 1 ref 2.31 0.85-6.28 2.10 0.81-5.41 0.66 0.08-5.63 
Liver and bile ducts 
C22, C24 
1 ref 0.29 0.03-3.25 1.42 0.29-6.95 NA NA 
Pancreas C25 1 ref 0.64 0.09-4.52 2.75 0.63-11.99 3.47 0.49-24.77 
Lung C344 1 ref 2.16 0.87-5.39 1.59 0.65-3.89 1.80 0.45-7.25 
Skin, malignant 
melanoma C43 
1 ref 1.06 0.41-2.75 0.56 0.21-1.48 0.63 0.08-5.10 
Skin, other C44 1 ref 0.80 0.11-5.70 1.25 0.26-6.05 3.76 0.52-27.14 
Soft tissue C47-49 1 ref 0.55 0.03-8.89 1.43 0.14-14.32 NA NA 
Prostate C61 1 ref 1.27 0.65-2.50 1.56 0.85-2.85 0.81 0.23-2.86 
Kidney and upper 
urinary tract  
C64-C665 
1 ref 6.03 0.77-47.15 7.58 1.01-56.94 7.88 0.71-87.27 
Bladder C67 1 ref 5.07 1.16-22.09 5.33 1.27-22.43 5.10 0.85-30.68 
Brain C70-72, C75.1 1 ref 4.01 0.49-32.63 2.77 0.33-23.14 NA NA 
Thyroid C73 1 ref 0.59 0.04-9.43 0.92 0.08-10.39 NA NA 
Malignant neoplasm 
of other and ill-
defined sites C76 
1 ref 2.50 0.28-22.44 1.69 0.20-14.62 NA NA 
All haematological 
malignancies6 C81-
85, C88, C90-93, 
C95, D45, D46 
1 ref 0.92 0.33-2.59 1.13 0.44-2.87 1.30 0.26-6.49 
Lymphoma C81-85 1 ref 0.60 0.12-2.98 1.27 0.34-4.75 2.76 0.46-16.64 
Leukaemia C91-93, 
C95 
1 ref 1.83 0.19-17.63 1.64 0.18-14.87 NA NA 
Note: HRs reported for cancers or groups of cancers (of defined sites) with occurrence of ≥5. Please refer to the supplemental 
appendix Table 2 for details. Results presented only for >10 year observation time. Significant results marked with bold. C 
refers to diagnostic code according to the ICD-10 classification.  
Abbreviations: HR, hazard ratio; SC, second cancer; CT, chemotherapy; RT, radiotherapy; CT + RT, combination of 
chemotherapy and radiotherapy; 95% CI, 95% confidence interval; y, years; obs, observation, NA, not available because of 
too few events. 
                                                          
1 Includes men treated with surveillance and men treated with retroperitoneal lymph node dissection in addition to 
orchiectomy. 
2 Of the total n of 4199 with > 10 y obs time, 431 cases developed SC. Of the total n of 2974 with > 15 y obs, 340 cases 
developed SC. Of the total n of 1876 with > 20 y obs time, 213 cases developed SC.  
3 Analyses with >15 and >20 years done with time-dependent Cox model and a dummy variable of follow-up time 
(before/after 15 or 20 years). 
4 All of which were localized in the bronchi  
5 The morphology of C64 was diverse. We chose to analyze kidney and upper urinary tract together. 
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Helene F. S. Negaard, MD, PhD7; Torgrim Tandstad, MD, PhD8,9; Tom Wilsgaard, PhD10; Sophie D. Fosså, MD, PhD4,7,11; and
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abstract
PURPOSE It is hypothesized that cisplatin-based chemotherapy (CBCT) reduces the occurrence of meta-
chronous contralateral (second) germ cell testicular cancer (TC). However, studies including treatment details
are lacking. The aim of this study was to assess the second TC risk, emphasizing the impact of previous TC
treatment.
PATIENTS AND METHODS Based on the Cancer Registry of Norway, 5,620 men were diagnosed with first TC
between 1980 and 2009. Treatment data regarding TC were retrieved from medical records. Cumulative in-
cidences of second TC were estimated, and standardized incidence ratios were calculated. The effect of
treatment intensity was investigated using Cox proportional hazard regression.
RESULTS Median follow-up was 18.0 years, during which 218 men were diagnosed with a second TC after
median 6.2 years. Overall, the 20-year crude cumulative incidence was 4.0% (95% CI, 3.5 to 4.6), with lower
incidence after chemotherapy (CT) (3.2%; 95%CI, 2.5 to 4.0) than after surgery only (5.4%; 95%CI, 4.2 to 6.8).
The second TC incidence was also lower for those age$ 30 years (2.8%; 95% CI, 2.3 to 3.4) at first TC diagnosis
than those age, 30 years (6.0%; 95% CI, 5.0 to 7.1). Overall, the second TC risk was 13-fold higher compared
with the risk of developing TC in the general male population (standardized incidence ratio, 13.1; 95% CI, 11.5
to 15.0). With surgery only as reference, treatment with CT significantly reduced the second TC risk (hazard ratio
[HR], 0.55). For each additional CBCT cycle administered, the second TC risk decreased significantly after
three, four, and more than four cycles (HRs, 0.53, 0.41, and 0.21, respectively).
CONCLUSION Age at first TC diagnosis and treatment intensity influenced the second TC risk, with significantly
reduced risks after more than two CBCT cycles.
J Clin Oncol 39:308-318. © 2020 by American Society of Clinical Oncology
INTRODUCTION
After being diagnosed with a primary germ cell tes-
ticular cancer (TC), the estimated 15-20–year cu-
mulative incidence of a metachronous contralateral
(second) TC is 1.9%-3.9%.1-4 Standardized incidence
ratios (SIRs), comparing the incidence of second TC
with the incidence of TC in the general population,
range from 12.4 to 35.7.1-7 Treatment of the second TC
will usually involve a surgical castration, leading to
infertility and lifelong dependency of testosterone
substitution.8,9 From personal experience, many tes-
ticular cancer survivors (TCS) with unilateral disease
fear losing their remaining testicle.
Shared etiological factors for the first and second TC,
hypothesized to cause the testicular dysgenesis syn-
drome, represent a likely explanation for the increased
incidence of a second TC.10,11 Young age at diagnosis
of the first TC is associated with the increased risk of
developing a second TC.1-4,12 The results are, however,
inconclusive regarding the effect of first TC histology
and subsequent second TC risk.1,4,7,13,14
The introduction of cisplatin in the late 1970s led to
dramatically improved survival of patients with meta-
static TC.15,16 Cisplatin-based chemotherapy (CBCT) is
hypothesized to reduce or delay the incidence of a
metachronous contralateral TC. However, the existing
literature lacks TC treatment details, if based on public
registries,1,2 involves populations screened for germ
cell neoplasia in situ (GCNIS),12,17 or includes patients
treated in the precisplatin era.3-5
Andreassen et al2 investigated the risk for metachro-
nous contralateral TC in 7,102 TCS in Norway treated
during 1953-2007. They found a 50% risk reduction
for a second TC in men treated for metastatic com-
pared with localized disease only for those treated after
1980, implying that this risk reduction was related to
the introduction of CBCT. They emphasized that the
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treatment details. Furthermore, Fosså et al1 conducted a
large register-based study involving 29,515 TCS from the
United States. They concluded that a potential dose-
response relationship between cisplatin and eradication
of germ cell carcinoma in situ should be investigated in
future clinical studies.
The aim of this population-based study was to assess the
risk of developing a metachronous contralateral TC, with
emphasis on the impact of previous TC treatment including
CBCT, in a national cohort with complete data on TC
treatment.
PATIENTS AND METHODS
Study Cohort and Design
The Cancer Registry of Norway (CRN) identified men di-
agnosed with histologically verified primary germ cell TC
from January 1, 1980, to December 31, 2009.18 Major
exclusion criteria included age, 16 years at TC diagnosis,
a prior malignancy, extragonadal germ cell cancer, and
synchronous contralateral TC or death within 2 months of
follow-up (Appendix Fig A1, online only). Metachronous
TC was defined as a second germ cell TC diagnosed
. 2 months after the primary TC.
After exclusions, this historical prospective cohort
study consisted of 5,620 patients with TC. Details re-
garding disease stage, histology, and TC treatment for
first and second TCs, including relapse treatment, were
retrieved from medical records. Linkage with the CRN
updated through December 31, 2018, was done to
ensure complete information on the incidence of
second TC.
The study was approved by the Regional Committee for
Medical and Health Research Ethics and the Data Pro-
tection Authorities at the University Hospital of North
Norway. Passive consent from all eligible men still alive was
obtained through a study information letter with the pos-
sibility to withdraw from participation, after which 23
(0.38%) men declined participation.
Staging, Treatment, and Treatment Groups
TC was staged according to the Royal Marsden Hospital
staging system.19 During the study period, the treatment
principles for TC changed as previously described.20 Ad-
juvant radiotherapy (RT) for stage I seminoma has gradually
been abandoned, and the number of CBCT cycles applied
for metastatic disease has been reduced. The use of a risk-
adapted surveillance strategy or one cycle of adjuvant
CBCT (nonseminoma) or carboplatin (seminoma) for stage
I disease has been implemented as recommended by the
Swedish and Norwegian Testicular Cancer Group
(SWENOTECA).21
Based on total treatment burden for the first TC, the cohort
was divided into four treatment groups: surgery only (in-
cluding surveillance n 5 1,417; 25%), chemotherapy (CT,
n 5 2,450; 44%), RT (n 5 1,543, 27%), and both CT and
RT (CT 1 RT, n 5 210; 3.7%) (Table 1).
Statistical Methods
Continuous variables were presented with median and
interquartile range (IQR), and categorical variables were
presented with numbers and percent.
Follow-up was calculated from 2 months after diagnosis of
the first TC until a diagnosis of a second TC, death, emi-
gration, or December 31, 2018, whichever occurred first.
Treatment was analyzed as a time-varying covariate,
achieved by splitting follow-up time at exact treatment dates
for each treatment modality, to avoid immortal time bias.
The K-sample median test was used to test differences in
median time to second TC among those developing a
second TC, presented with two-sided P-values.
The crude cumulative incidence of metachronous con-
tralateral TC was estimated using the Aalen-Johansen
estimator,22 with death of any cause as a competing risk.
To compare the incidence of metachronous contralateral
TC to the incidence of TC in the general population, SIRs
were calculated. The estimates were obtained by dividing
the number of metachronous contralateral TCs in the co-
hort to the expected number of metachronous contralateral
CONTEXT
Key Objective
Does cisplatin-based chemotherapy (CBCT) reduce the risk of a metachronous contralateral (second) testicular cancer
(TC)?
Knowledge Generated
The overall 20-year cumulative incidence of second TC in a population-based cohort was 4%. Treatment with CBCT
significantly reduced the second TC risk, with a stronger risk reduction for each additional CBCT cycle administered.
Older age at diagnosis of first TC also reduced the risk.
Relevance
Our findings add important knowledge concerning the risk of second TC. Our results are important and appreciated
information for patients with TC and healthcare personnel involved in TC treatment.
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TABLE 1. Patient Characteristics at First Primary TC Diagnosis
Characteristic Total at Risk (N 5 5,620)
Individuals Without Second TC
(n 5 5,402)
Individuals Developing Second TC
(n 5 218)
Decade of first TC diagnosis
1980-1989 1,287 (23) 1,228 (23) 59 (27)
1990-1999 1,897 (34) 1,824 (34) 73 (34)
2000-2009 2,436 (43) 2,350 (43) 86 (39)
Follow-up, years, median (IQR)a 18.0 (12.0-25.5) 18.5 (12.5-25.8) 6.2 (3.3-10.6)b
Age at diagnosis, years, median (IQR) 33.0 (27.2-40.9) 33.3 (27.3-41.2) 28.7 (24.6-33.5)
Age at diagnosis, dichotomized, years
, 30 2,124 (38) 1,999 (37) 125 (57)
$ 30 3,496 (62) 3,403 (63) 93 (43)
Histology
Seminoma 2,938 (52) 2,831 (52) 107 (49)
Nonseminoma 2,682 (48) 2,571 (48) 111 (51)
Initial disease stagec
I 3,942 (70) 3,766 (70) 176 (80)
Mk1/II 1,127 (20) 1,097 (20) 30 (14)
III 116 (2.1) 114 (2.1) 2 (1.0)
IV 435 (7.7) 425 (7.9) 10 (4.6)
Treatmentd
Surgery onlye 1,417 (25) 1,345f (25) 72 (33)
CT 2,450 (44) 2,379 (44) 71 (32)
RT 1,543 (27) 1,471 (27) 72 (33)
CT 1 RT 210 (3.7) 207 (3.8) 3 (1.4)
Cause of first-line CT
Adjuvant, CS I 843 (32) 811 (31) 32 (43)
Primary metastatic disease 1,538 (58) 1,502 (58) 36 (49)
Recurrence 279 (10) 273 (11) 6 (8.1)
First CT regimen
BEP-20 1,507 (57) 1,464 (57) 43 (58)
CVB 367 (14) 357 (14) 10 (13.5)
EP 241 (9.1) 237 (9.2) 4 (5.4)
Other CBCTg 184 (6.9) 180 (6.9) 4 (5.4)
Adjuvant carboplatinh 295 (11) 285 (11) 10 (13.5)
CEB 44 (1.6) 42 (1.6) 2 (2.7)
Otheri 22 (0.8) 21 (0.8) 1 (1.4)
No. of CBCT cyclesj
1 220 (9.5) 210 (9.3) 10 (16)
2 319 (14) 307 (14) 12 (20)
3 439 (19) 427 (19) 12 (20)
4 1,028 (44) 1,004 (44) 24 (39)
. 4 320 (14) 317 (14) 3 (4.9)
RT first field
L-Fieldk 1,388 (79) 1,321 (79) 67 (89)
Para-aortal 267 (15) 260 (15) 7 (9.3)
(continued on following page)
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TC, given the incidence of TC in a comparable Norwegian
male population, matched by 5-year age groups and cal-
endar year of follow-up. Cumulative incidences and SIRs
with respective 95% CIs were calculated for the whole
cohort and stratified according to treatment groups, age at
diagnosis, follow-up time, and histology.
The effect of treatment and histology on the second TC
risk were evaluated using Cox proportional hazard re-
gression models with time since diagnosis as time scale,
the surgery-only group as reference, and adjusting for
age at diagnosis.20 Additionally, histology as a risk factor
was investigated in a multivariable Cox regression model
which included treatment. Cumulative CT doses were
estimated based on the CT regimen and number of CT
cycles. The Cox regression model was also used to
evaluate the effect of age at diagnosis (dichotomized). A
nonsignificant Schoenfeld test showed that the propor-
tional hazard assumption was met for all analyses, except
for cumulative doses (Appendix Table A1, online only)
and the dichotomized age variable (P 5 .049). For the
latter, the proportional hazard assumption was judged to
be met by visual inspection of a log-log survival plot. The
results are presented as hazard ratios (HRs) with cor-
responding 95% CIs and P-values.
Data were analyzed using Stata statistical software (version
MP 16.1; STATA, College Station, TX). A P-value, .05 was
considered significant.
RESULTS
Characteristics of the Total Study Cohort and the
Metachronous TC Subcohort
The total study cohort consisted of 5,620 men with a
median follow-up time of 18 years (IQR, 12.0-25.5)
(Table 1). Median age at diagnosis was 33 years, 38%
were , 30 years, and 70% were diagnosed with stage I
disease at first TC. Overall, 25% were treated with surgery
only, and 44% were treated with CT at first TC.
TABLE 1. Patient Characteristics at First Primary TC Diagnosis (continued)
Characteristic Total at Risk (N 5 5,620)
Individuals Without Second TC
(n 5 5,402)
Individuals Developing Second TC
(n 5 218)
Supradiaphragmatic 13 (0.7) 12 (0.7) 1 (1.3)
Supra- and infradiaphragmaticl 21 (1.2) 21 (1.3) 0
Otherm 64 (3.6) 64 (3.8) 0
RT dose for first RT field, Gy
1-20 13 (0.7) 12 (0.7) 1 (1.3)
20-29 514 (29) 490 (29) 24 (32)
30-39 986 (56) 943 (56) 43 (57)
$ 40 240 (14) 233 (14) 7 (9.3)
NOTE. Data are presented as n (%), unless otherwise stated.
Abbreviations: BEP-20, bleomycin, etoposide, and cisplatin; CBCT, cisplatin-based chemotherapy; CEB, carboplatin, etoposide, and bleomycin; CS I,
clinical stage I; CT, chemotherapy; CT1RT, combination of CT and RT; CVB, cisplatin, vinblastine, and bleomycin; EP, etoposide and cisplatin; Gy, gray; IQR,
interquartile range; Mk1, marker positive; RT, radiotherapy; TC, testicular cancer.
aFollow-up until diagnosis of metachronous contralateral TC, death, emigration, or December 31, 2018, whichever occurred first.
bThe longest time interval between first TC and second TC was 27.1 years.
cAs described by Peckham et al.19
dBased on total treatment burden.
eThe surgery-only group included men followed with surveillance after orchiectomy (n5 1,167; 21%) and men who underwent additional retroperitoneal
lymph node dissection without CT or RT (n 5 250; 4.4%).
fTwo men included in the surgery-only group were diagnosed with clinical stage IV. One refused treatment, and the other was no candidate for treatment.
They both died shortly (but . 2 months) after diagnosis.
gOf which a total of 141 were dose-escalated CBCT.
hFifteen of the 295 men initially treated with adjuvant carboplatin were subsequently treated with CBCT and, as a consequence, analyzed according to the
total number of CBCT cycles. Also, one person had RT in addition to carboplatin. Of the 279 men treated with adjuvant carboplatin monotherapy included in
the Cox regression analysis, 273 received one cycle and 6 received two cycles.
iCarboplatin monotherapy in metastatic setting (n 5 17), cyclophosphamide/adriamycin (n 5 1), CAOS (actinomycin D, adriamycin, vincristine,
cyclophosphamide) (n 5 3), actinomycin D (n 5 1).
jMay have received additional CT regimes, but these are not accounted for in this number. A total of 334 men received non-CBCT, which are not included
here.
kL-Field or dogleg-field. Also included in this category are 53 individuals who received RT of groin in addition to L-field and two individuals who received a
reversed Y-field.
lSixteen of 21 individuals received infradiaphragmatic RT as first RT-field and a short while later received supradiaphragmatic RT.
mRT toward bone (n5 21), CNS (n5 21), abdominal residual masses (n5 16), intraoperative RT (n5 1), skin lesions (n5 1), nonspecified sites (n5 4).
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Overall, 218 (3.9%) men developed a metachronous
contralateral TC after median 6.2 years (IQR, 3.3-10.6)
(Table 1). Among these 218 men, median age at first TC
diagnosis was 28.7 years, 57% were , 30 years at diag-
nosis of first TC, and seminoma (49%) and nonseminoma
(51%) histology of the first TC was equally distributed.
Furthermore, 80% were diagnosed with clinical stage I at
first TC, and as treatment for first TC, 33% had surgery only
and 32% received CT. Median time to second TC did not
differ according to treatment (P5 .55) or age at diagnosis of
first TC (P 5 .10) (Appendix Table A2, online only).
The majority of the second TCs were seminomas (72%)
(Appendix Table A3, online only). At diagnosis of the
second TC, 84% had stage I disease and 53% were treated
with surgery only.
Cumulative Incidences of Second TC
The overall crude cumulative second TC incidence was
4.0% (95% CI, 3.5 to 4.6) at 20 years (Fig 1A, Table 2). The
second TC incidence was lower in those age $ 30 years at
first TC diagnosis (2.8%; 95% CI, 2.3 to 3.4) than in those
age , 30 years (6.0%; 95% CI, 5.0 to 7.1) (Fig 1B). The
second TC incidence was also lower after treatment with CT
(3.2%; 95% CI, 2.5 to 4.0) and CT 1 RT at first TC (1.4%;
95% CI, 0.4 to 3.9) than after surgery only (5.4%; 95% CI,
4.2 to 6.8) or RT (4.5%; 95% CI, 3.6 to 5.6) (Fig 1C).
For those age , 30 years at first TC diagnosis, 20-year
cumulative incidence after surgery only was 8.0% (95% CI,
5.8 to 10.6), and after CT, it was 4.8% (95% CI, 3.6 to 6.3)
(Table 2). In comparison, for those age $ 30 years at first
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FIG 1. Crude cumulative incidences of metachronous contralateral TC by follow-up time. (A) All patients (with 95% CI), (B) by age at first TC,
dichotomized (C) by treatment groups at first TC, and (D) by histology at first TC. In (A), the red line indicates the incidence of metachronous
contralateral TC, and the blue area indicates the 95% CI. CT, chemotherapy; CT1 RT, combination of CT and RT; RT, radiotherapy; TC, testicular
cancer.
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2.1 to 4.6) after surgery only and 1.7% (95% CI, 1.1 to 2.7)
after CT.
The second TC incidence did not differ according to first TC
histology, with estimates of 3.8% (95% CI, 3.1 to 4.6) after
seminoma and 4.3% (95% CI, 3.5 to 5.1) after non-
seminoma (Fig 1D).
Risk of Second TC in Relation to the General Population
Overall, the second TC risk was 13-fold higher compared
with the risk of developing TC in the general population
(SIR, 13.1; 95% CI, 11.5 to 15.0) (Table 3). The risk was
lower after treatment with CT (SIR, 9.1; 95%CI, 7.2 to 11.5)
and CT1 RT (SIR, 8.6; 95% CI, 2.8 to 26.7) at first TC than
after surgery only (SIR, 16.3; 95% CI, 12.9 to 20.5) and RT
(SIR, 17.7; 95% CI, 14.1 to 22.3). SIRs decreased with
increasing age at diagnosis and was highest for those age
20-30 years (SIR, 14.0; 95% CI, 11.7 to 16.8.). The risk for
a second TC was the highest within the first 5 years of
follow-up after diagnosis of the first TC (SIR, 17.0; 95% CI,
13.7 to 21.2) and decreased with increasing follow-up time.
HRs for Second TC
With surgery only as the reference group, the second TC
risk was significantly lower after treatment with CT at first TC
(HR, 0.55; 95% CI, 0.40 to 0.76) (Table 4). A sensitivity
analysis excluding those treated with CT other than CBCT
TABLE 2. Cumulative Incidences of Metachronous Contralateral TC According to Treatment, Age, and Histology at First TC and Specified Follow-up Time
< 5 years < 10 years < 15 years < 20 years
Variable n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Total 82 1.5 1.2 to 1.8 157 2.8 2.4 to 3.3 192 3.5 3.1 to 4.1 209 4.0 3.5 to 4.6
Age at diagnosis, years
, 30 38 1.8 1.3 to 2.4 86 4.1 3.3 to 5.0 106 5.2 4.3 to 6.2 118 6.0 5.0 to 7.1
$ 30 44 1.3 0.9 to 1.7 71 2.0 1.6 to 2.6 86 2.6 2.1 to 3.1 91 2.8 2.3 to 3.4
Treatment, all patients
Surgery onlya 24 1.6 1.1 to 2.4 52 3.6 2.8 to 4.7 62 4.5 3.5 to 5.7 68 5.4 4.2 to 6.8
CT 25 1.0 0.7 to 1.5 52 2.1 1.6 to 2.7 63 2.7 2.1 to 3.4 69 3.2 2.5 to 4.0
RT 32 2.0 1.4 to 2.8 50 3.2 2.4 to 4.2 64 4.1 3.2 to 5.2 69 4.5 3.6 to 5.6
CT 1 RT 1 0.5 0.1 to 2.5 3 1.4 0.4 to 3.9 3 1.4 0.4 to 3.9 3 1.4 0.4 to 3.9
Treatment, age , 30 years
Surgery onlya 11 1.8 1.0 to 3.1 28 4.7 3.2 to 6.6 36 6.3 4.5 to 8.5 42 8.0 5.8 to 10.6
CT 18 1.6 1.0 to 2.5 40 3.6 2.6 to 4.8 46 4.2 3.1 to 5.6 50 4.8 3.6 to 6.3
RT 9 2.5 1.2 to 4.6 16 4.5 2.7 to 7.0 22 6.3 4.0 to 9.1 24 6.9 4.6 to 10.0
CT 1 RT 0 0 0 2 2.9 0.6 to 9.1 2 2.9 0.6 to 9.1 2 2.9 0.6 to 9.1
Treatment, age $ 30 years
Surgery onlya 13 1.5 0.9 to 2.5 24 2.9 1.9 to 4.2 26 3.2 2.1 to 4.6 26 3.2 2.1 to 4.6
CT 7 0.5 0.2 to 1.0 12 0.9 0.5 to 1.5 17 1.4 0.9 to 2.2 19 1.7 1.1 to 2.7
RT 23 1.9 1.2 to 2.8 34 2.8 2.0 to 3.9 42 3.5 2.6 to 4.7 45 3.8 2.8 to 5.0
CT 1 RT 1 0.7 0.1 to 3.6 1 0.7 0.1 to 3.6 1 0.7 0.1 to 3.6 1 0.7 0.1 to 3.6
Histology, all patients
Seminoma 44 1.5 1.1 to 2.0 78 2.7 2.1 to 3.3 97 3.4 2.8 to 4.2 104 3.8 3.1 to 4.6
Nonseminoma 38 1.4 1.0 to 1.9 79 3.0 2.4 to 3.7 95 3.7 3.0 to 4.4 105 4.3 3.5 to 5.1
Histology, age , 30 years
Seminoma 13 2.1 1.2 to 3.4 26 4.2 2.8 to 5.9 35 5.8 4.1 to 7.9 38 6.6 4.7 to 8.8
Nonseminoma 25 1.7 1.1 to 2.4 60 4.0 3.1 to 5.1 71 4.9 3.8 to 6.1 80 5.8 4.6 to 7.1
Histology, age $ 30 years
Seminoma 31 1.3 0.9 to 1.9 52 2.3 1.7 to 2.9 62 2.8 2.2 to 3.5 66 3.1 2.4 to 3.9
Nonseminoma 13 1.1 0.6 to 1.8 19 1.6 1.0 to 2.5 24 2.1 1.4 to 3.1 25 2.3 1.5 to 3.3
NOTE. n refers to the cumulative number of men developingmetachronous contralateral TC up until specified follow-up time. Age refers to age at diagnosis
of first TC, dichotomized on , 30 or $ 30 years.
Abbreviations: CT, chemotherapy; CT 1 RT, combination of CT and RT; RT, radiotherapy; TC, testicular cancer.
aIncludes men treated with surveillance and men treated with retroperitoneal lymph node dissection in addition to orchiectomy.
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(carboplatin-based, n 5 332; other CT, n 5 2) was per-
formed with no significant change of results (data not
shown). Treatment with RT did not affect the second TC risk
(HR, 1.10; 95% CI, 0.79 to 1.54).
For each additional CBCT cycle administered, the point
estimates for second TC risk decreased, with significantly
reduced risks after three (HR, 0.53; 95% CI, 0.29 to 0.97),
four (HR, 0.41; 95% CI, 0.25 to 0.66), and more than four
cycles (HR, 0.21; 95% CI, 0.07 to 0.66) (Table 4, Fig 2). The
hazard of second TC was not significantly different after
treatment with adjuvant carboplatin monotherapy (HR, 1.22;
95% CI, 0.62 to 2.39). For each increase of 100 mg/m2
cisplatin, the second TC risk decreased equivalent to the
results according to the number of CBCT cycles. The effect
on second TC risk was weakened for the dose level of
101-200 mg/m2 when carboplatin was included in the
analysis of cumulative platinum doses (Appendix Table A1).
The second TC risk was significantly reduced for those
age $ 30 years at first TC diagnosis (HR, 0.47; 95% CI,
0.36 to 0.62). In age-adjusted Cox regression, non-
seminoma histology at first TC was associated with a de-
creased risk of second TC (HR, 0.73; 95%CI, 0.55 to 0.98).
However, compared with seminoma, this association dis-
appeared when treatment at first TC was included in the
model (HR, 0.97; 95% CI, 0.65 to 1.45) (Table 4).
DISCUSSION
In this population-based study, the overall 20-year cu-
mulative incidence of a metachronous TC was 4.0% in a
well-described cohort with complete information on total
treatment burden and a long follow-up time. We demon-
strated, to the best of our knowledge for the first time, that
the risk of a metachronous contralateral TC decreased with
each additional CBCT cycle administered, with significantly
reduced risks after more than two CBCT cycles.
The overall second TC cumulative incidence of 4% and
total SIR of 13.1 found in this study are in accordance with
the existing literature.1-7 We found a reduced second TC
risk after treatment with CT at first TC, and our results lend
strong support to the hypothesis that cisplatin reduces the
second TC risk.1-3,5 Treatment with RT has not been
considered to affect the TC incidence,3,4,12 and our results
are in agreement with this. Adjuvant infradiaphragmatic RT
after seminoma results in a total dose of 0.09-0.32 Gy of
scattered radiation to the remaining testicle, which is
probably insufficient for eradication of GCNIS if present.23
GCNIS is the precursor of germ cell TC.24 If left untreated for
5 years, 50% of patients with GCNIS will develop an in-
vasive cancer.25 There has not been a tradition to screen for
GCNIS in Norway during the study period as it has only
been performed in selected high-risk patients.17,26,27
Metastatic TC is highly sensitive to cisplatin. However,
cisplatin seems to have a modest but possibly dose-
dependent effect on eradication of GCNIS.17,25,28-31 In
the present study, we found a strong association between
the number of CBCT cycles, cumulative cisplatin dose, and
the second TC risk. Our results are in line with the study by
Brabrand et al,17 who found significantly reduced second
TC risk after more than four compared with one to three
CBCT cycles or no CT in a study of 61 TCS with biopsy-
proven GCNIS in the contralateral testicle. We found no risk
reduction after one to two CBCT cycles, which corroborates
results from a prospective study on second TC risk after one
to two adjuvant CBCT cycles in patients with stage I
nonseminoma.26 In contrast to the results from the ran-
domized trial by Oliver et al32 comparing adjuvant carbo-
platin with RT, we found no decrease of second TC risk after
treatment with adjuvant carboplatin.
TABLE 3. SIRs for Metachronous Contralateral TC According to
Treatment, Age, and Histology at First TC and Follow-up Time
Variable No. of Events SIR 95% CI
Total 218 13.1 11.5 to 15.0
Treatment, first TC
Surgery onlya 72 16.3 12.9 to 20.5
CT 71 9.1 7.2 to 11.5
RT 72 17.7 14.1 to 22.3
CT 1 RT 3 8.6 2.8 to 26.7
Age, dichotomized, years
, 30 125 13.4 11.2 to 15.9
$ 30 93 12.8 10.4 to 15.7
Age at diagnosis, years
16-20 9 8.5 4.4 to 16.4
20-30 116 14.0 11.7 to 16.8
30-40 76 13.6 10.9 to 17.0
40-50 14 10.3 6.1 to 17.4
. 50 3 9.6 3.1 to 29.6
Histology
Seminoma 107 14.7 12.2 to 17.8
Nonseminoma 111 11.9 9.9 to 14.3
Follow-up time, years
, 5 82 17.0 13.7 to 21.2
5-10 75 15.5 12.3 to 19.4
10-15 35 10.4 7.4 to 14.4
15-20 17 8.7 5.4 to 13.9
. 20b 9 5.6 2.9 to 10.7
Abbreviations: CT, chemotherapy; CT1 RT, combination of CT and
RT; RT, radiotherapy; SIR, standardized incidence ratio; TC, testicular
cancer.
aIncludes men treated with surveillance and men treated with
retroperitoneal lymph node dissection in addition to orchiectomy.
bThe longest time interval between first TC and second TC was 27.1
years.
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The modulating effect of the blood-testis barrier on the
intratubular concentration of cytotoxic drugs,33,34 possibly
in part, explains the need for higher cumulative doses of
cisplatin before effect on GCNIS and the subsequent
second TC risk. However, cisplatin undoubtedly has an
effect on the testis, demonstrated by the decrease of
sperm concentration and quality and the changes of
sperm DNA following CBCT.35-37 Furthermore, there
seems to be a relationship between the number of CBCT
cycles and the recovery of spermatogenesis.36-39 A re-
cent publication by Weibring et al40 did not find a long-
term reduction of sperm count after one cycle of CBCT.
On the other hand, three or more cycles of CBCT may
lead to long-term or permanent impairment of sperm
function.36-38
It has been suggested that cisplatin delays rather than
reduces the development of a second TC.29,31 In accor-
dance with Schaapveld et al,3 our results do not lend
support to this hypothesis. On the contrary, we found that
there was a longer median time interval between first TC
and second TC after surgery only (7.0 years) than after CT
(5.8 years), although not statistically significant. The overall
latency of 6.2 years between first TC and second TC agrees
with previous studies.1-3 In the present study, with a very
long follow-up time of median 18 years, 72% of second TCs
developed within 10 years of follow-up. This is in line with
the report of a plateau in incidence after 15-20 years.3,4
However, second TCs may occur late,41 and the longest
time interval between first TC and second TC in our cohort
was 27 years.
A polygenic susceptibility, coupled with fetal and early-life
environmental factors, is involved in TC development.10,11,42-45
The shared prenatal predisposition of the first and
second TC probably accounts for the increased risk of
metachronous contralateral TC, and the increased risk in
younger versus older men is in turn presumably
explained by this.1,46 Young age at TC diagnosis has been
established as an important risk factor for developing
metachronous contralateral TC,1-4,12,13,47 and our results
are in complete agreement with this. In our study, me-
dian age at diagnosis of first TC was 4.6 years younger in
men who later developed a second TC than men with
unilateral TC. Furthermore, men age , 30 years at first
TC had more than twice as high 20-year cumulative
second TC incidence than those 30 years or older at first
TC diagnosis.
The current knowledge regarding histology and the risk of
metachronous contralateral TC is inconsistent.1,4,7,13,14
Studies conducted in the precisplatin era found a
higher risk for metachronous contralateral TC after
nonseminoma than after seminoma.4,14 In the cisplatin
era, some studies concluded with the opposite,7,13
supporting an effect of CBCT.1 We found no associa-
tion between first TC histology and the risk of a second
TC when adjusting for age and treatment, which is in line
with Andreassen et al.2 Our results suggest that the
differences found in histology1,4,7,13,14 are in fact caused
by the effect of CBCT, as patients with nonseminoma
TABLE 4. Age-Adjusted HRs for Metachronous Contralateral TC
According to Treatment Groups, Treatment Intensity, Age, and
Histology at First TC
Variable HR 95% CI P
Treatment
Surgery only 1 Ref Ref
CT 0.55 0.40 to 0.76 < .001
RT 1.10 0.79 to 1.54 .580
CT 1 RT 0.50 0.16 to 1.57 .233
No. of CBCT cycles
Surgery only 1 Ref Ref
1 1.01 0.52 to 1.96 .983
2 0.74 0.40 to 1.36 .332
3 0.53 0.29 to 0.97 .040
4 0.41 0.25 to 0.66 < .001
. 4 0.21 0.07 to 0.66 .008
Carboplatin, adjuvanta 1.22 0.62 to 2.39 .565
RT field
Surgery only 1 Ref Ref
L-Field 1.17 0.78 to 1.62 .521
Para-aortal 0.75 0.34 to 1.64 .468
RT dose for first abdominal
RT-field, Gy
Surgery only 1 Ref Ref
20-29 1.24 0.77 to 1.98 .383
30-39 1.04 0.70 to 1.55 .832
$ 40 1.17 0.50 to 2.70 .721
Age at diagnosis,b years
, 30 1 Ref Ref
$ 30 0.47 0.36 to 0.62 < .001
Histology
Age-adjusted
Seminoma 1 Ref Ref
Nonseminoma 0.73 0.55 to 0.98 .034
Multivariablec
Seminoma 1 Ref Ref
Nonseminoma 0.97 0.65 to 1.45 .883
NOTE. Significant results marked with bold. Age refers to age at
diagnosis of first TC, dichotomized on , 30 or $ 30 years.
Abbreviations: CBCT, cisplatin-based chemotherapy; CT,
chemotherapy; CT 1 RT, combination of CT and RT; Gy, gray; HR,
hazard ratio; Ref, reference; RT, radiotherapy; TC, testicular cancer.
aCarboplatin monotherapy, carboplatin in adjuvant setting for stage I
seminoma.
bNot age adjusted.
cAdjusted for treatment in addition to age.
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are more often treated with CBCT than patients with
seminoma.
In a recent review by Zequi et al,48 60.4% of metachronous
contralateral TCs had a seminoma histology. This is in line
with the present study in which 72% of the second TCs
were seminomas. The abundancy of seminoma histology of
second TCs is probably caused by age.18
In our study, the majority (84%) of second TCs were di-
agnosed as clinical stage I, and this correlates with the
results published in the review by Zequi et al48 (73.3% in
stage I). Our even higher proportion diagnosed in stage I
might be a result of robust follow-up procedures, central-
ized treatment of TC in Norway, and the risk-adapted bi-
opsy strategy of the contralateral testicle.27,49
Important strengths of our study include the consideration
of a nationwide cohort, the completeness of cancer inci-
dence rates of the CRN,18 and the complete information on
treatment burden in a large and unselected study cohort
with a long follow-up time. The risk-adapted treatment
strategy in clinical stage I disease recommended by
SWENOTECA has made it possible to compare adjuvant CT
with the surveillance strategy.21
The lack of information regarding GCNIS and risk factors for
TC, such as family history of TC, history of cryptorchidism,
or infertility, are potential limitations. Tissue samples
available for genetic analyses could have been of particular
interest.
In conclusion, we found a strong association between the
number of CBCT cycles and the subsequent risk of a
metachronous contralateral TC. Patients with metastatic
unilateral TC might appreciate information on the signifi-
cant risk reduction of second TC after treatment with CT.
Although most second TCs develop within 10 years after
diagnosis of the first TC, they may develop after more than
20 years. It is important that TCS are aware of this risk and
that the importance of regular lifelong self-examination is
emphasized.
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FIG 2. Proportion diagnosed with metachronous contralateral TC by follow-up time and the number of cisplatin-
based chemotherapy cycles, adjusted for age at TC diagnosis. The risk table presents the crude number of
individuals by follow-up time. TC, testicular cancer.
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Negaard, Torgrim Tandstad, Sophie D. Fosså, Hege S. Haugnes
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APPENDIX
 ♦ Declined to participate (n = 23, 0.38%)
Dataset used as basis for collection of clinical data
(n = 6 057, 95.3%)  
Males diagnosed with germ cell TC in the NCR (coded
with localization ICD-7 178.x) between 01/01/1980-12/31/2009
(N = 6 354)
Dataset used as basis for information letter
(n = 6 080, 95.7%)
Cohort for the analysis of metachronous contralateral
TC = study population
(n = 5 620, 88.4%)
Cohort of TCS with complete clinical data





  ♦ Extragonadal localization (ICD-7 178.4)
  ♦ Localization ductus deferens or funicle (ICD-7 178.3)
  ♦ Localization epididymis (ICD-7 178.2)
  ♦ Age < 16 years
Excluded (n = 274, 4.3%)
  ♦ Previous diagnosis of non-TC cancer
   ♦ TC before 1980
   ♦ Extragonadal localization
   ♦ Clinical data missing
   ♦ Other histology than GC cancer
   ♦ Treated abroad
   ♦ Clincial diagnosis only/histology not performed
   ♦ Other causes
   ♦ Synchronous non-TC diagnosis
(n = 58)







   (n = 19)
(n = 333 5.5%)Excluded
Excluded from the present study (n = 104, 1.8%) due to the
following events < 2 months after first primary TC-diagnosis:        
  ♦ Synchronous bilateral TC (n = 61)
  ♦ Death (n = 35 [of which 7 were also diagnosed
      with synchronous bilateral TC])
  ♦ Emigration (n = 8 [of which 3 were also
     diagnosed with bilateral TC])        
FIG A1. Flowchart presenting the study cohort. GC, germ cell; ICD-7, International Classification of Diseases Version 7; NCR, the
Norwegian Cancer Registry; TC, testicular cancer; TCS, testicular cancer survivors.
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TABLE A1. Age-Adjusted HRs for Metachronous Contralateral TC According to Cumulative Cisplatin, Platinum, and Bleomycin Doses at First TCa
Chemotherapy Dose HR 95% CI P
Cumulative cisplatin dose, mg/m2
Surgery only 1 Reference Reference
1-100 1.01 0.52 to 1.96 .984
101-200 0.74 0.40 to 1.36 .331
201-300 0.53 0.29 to 0.98 .043
301-400 0.43 0.27 to 0.70 .001
. 400 0.14 0.03 to 0.52 .004
Carboplatin 1.15 0.62 to 2.12 .667
Cumulative total platinum dose, mg/m2b
Surgery only 1 Reference Reference
1-100 1.01 0.52 to 1.96 .984
101-200 0.91 0.56 to 1.47 .697
201-300 0.53 0.29 to 0.99 .045
301-400 0.46 0.29 to 0.72 .001
. 400 0.12 0.03 to 0.50 .003
Cumulative bleomycin dose, IU
Surgery only 1 Reference Reference
1-100,000 0.92 0.50 to 1.70 .789
100,001-200,000 0.55 0.26 to 1.14 .107
200,001-300,000 0.46 0.30 to 0.69 <.001
. 300,000 0.29 0.07 to 1.19 .086
Chemotherapy without bleomycin 0.84 0.47 to 1.50 .550
NOTE. Significant results marked with bold.
Abbreviations: HR, hazard ratio; TC, testicular cancer.
aWhen analyzing the effect of cumulative doses, the proportional hazard assumption was violated for some treatment groups. We fitted newmodels with an
interaction effect between follow-up time and the selected treatment groups and compared model fit using BIC. In all cases, the best fit was provided by the
simple model without interaction effects, and hence, the results from these are presented.
bCumulative total platinum doses contain cumulative doses of cisplatin and/or carboplatin. For carboplatin, the corresponding cisplatin-equivalent doses
were estimated by dividing the carboplatin doses by four (Ozols Cancer Treat Rev. 1985).
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TABLE A3. Patient Characteristics at Diagnosis of Metachronous Contralateral TC





Disease stage, second TCa
I 184 (84)





Surgery only 115 (53)
CTb 71 (33)
RT 16 (7.3)
CT 1 RT 0
Missing 16 (7.3)
NOTE. Data are presented as n (%).
Abbreviations: CT, chemotherapy; CT 1 RT, combination of CT and RT; Mk1, marker positive; RT, radiotherapy; TC, testicular cancer.
aAs described by Peckham et al.19
bOf which one had disseminated synchronous nongerm cell SC (C34) treated with CT. A few of these cases were originally treated with surveillance but
received CT at relapse.
TABLE A2. Time to Metachronous Contralateral TC According to Characteristics at First TC
Characteristic Individuals Developing Metachronous Contralateral TC (n 5 218)
By time since treatment at first TC, years
Surgery onlya 7.0 (4.3-10.0)
CT 5.8 (3.2-10.9)
RT 6.5 (2.7-10.7)
CT 1 RT 5.9 (4.9-6.2)
By age at first TC, dichotomized, years
, 30 years 7.2 (4.4-10.9)
$ 30 years 5.3 (2.6-9.3)
By histology at first TC, years
Seminoma 6.7 (3.2-10.5)
Nonseminoma 5.9 (4.1-10.9)
NOTE. Data are presented as median (IQR).
Abbreviations: CT, chemotherapy; CT 1 RT, combination of CT and RT; IQR, interquartile range; RT, radiotherapy; TC, testicular cancer.
aIncludes men treated with surveillance and men treated with retroperitoneal lymph node dissection in addition to orchiectomy.
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Using complete information regarding testicular cancer (TC) treatment burden, this study 
aimed to investigate cause-specific non-TC mortality with impact on previous treatment with 
platinum-based chemotherapy (PBCT) or radiotherapy (RT). 
 
Patients and methods 
Overall, 5707 men, identified by the Cancer Registry of Norway diagnosed with TC 1980-
2009, were included in this population-based cohort study. By linking data with the 
Norwegian Cause of Death Registry, standardized mortality ratios (SMRs), absolute excess 
risks (AERs) and adjusted hazard ratios (HRs) were calculated. 
 
Results 
Median follow-up was 18.7 years, during which non-TC death was registered for 665 (12%) 
men. The overall excess non-TC mortality was 23% (SMR 1.23, 95% CI 1.14-1.33, AER 
11.14) compared with the general population, with increased risks after PBCT (SMR 1.23, 
95% CI 1.07-1.43, AER 7.68) and RT (SMR 1.28, 1.15-1.43, AER 19.55), but not after 
surgery. The highest non-TC mortality was observed in those <20 years at TC diagnosis 
(SMR 2.27, 95% CI 1.32-3.90, AER 14.42). The most important cause of death was non-TC 
second cancer with an overall SMR of 1.53 (95% CI 1.35-1.73, AER 7.94), with significantly 
increased risks after PBCT and RT. Overall non-cancer mortality was increased by 15% 
(SMR 1.15, 95% CI 1.04-1.27, AER 4.71). Importantly, excess suicides appeared after PBCT 
(SMR 1.65, 95% CI 1.01-2.69, AER 1.39). Compared with surgery, increased non-TC 
mortality appeared after 3 (HR 1.47, 95% CI 0.91-2.39) 4 (HR 1.41, 95% CI 1.01-1.99) and 




TC treatment with PBCT or RT is associated with a significant excess risk of non-TC 
mortality, and increased risks emerged after >2 cisplatin-based chemotherapy cycles after >10 






The excellent cure rates of germ cell testicular cancer (TC), predominantly affecting men 
aged 20-40 years, has led to a growing number of long-term TC survivors (TCS).1 However, 
their future is threatened by increased mortality rates compared with the general population 
20-30 years after the TC diagnosis.2 The inferior survival is presumed to be related to 
previous cytotoxic treatment.3  
Platinum-based chemotherapy (PBCT) was introduced in the late 1970s and has been 
crucial for the exceptional improvement in survival.4 On the downside, this life-saving 
treatment has been linked with life-threatening late effects such as cardiovascular disease 
(CVD)5-7 and second cancers (SC).8-11 Radiotherapy (RT) was until the early 2000s the 
standard treatment of localized and small-volume metastatic seminoma.12 RT has been 
abandoned as standard treatment of seminomas in many countries, in part because of the 
strong association between treatment with RT and SC risk.8,9,11,13,14  
Previous PBCT6,9,15,16 and RT9,16-19 is related to increased non-TC mortality compared 
with the general population, and in particular deaths due to non-TC SCs.9,16 Excess non-
cancer mortality has also been described,15 with an association between PBCT and increased 
cardiovascular mortality.5,6,16 However, analyses regarding detailed treatment data and its 
impact on overall and cause-specific mortality are sparsely described. 
The aim of the present study was to assess non-TC mortality and causes of death in 
relation to TC treatment, including the impact of number of cisplatin-based chemotherapy 





Study cohort and design 
Through the Cancer Registry of Norway (CRN), men diagnosed with histologically verified 
germ cell TC from January 1, 1980 to December 31, 2009 were identified.20 Principal 
exclusion criteria included a prior malignancy, age <16 years at TC diagnosis, extragonadal 
germ cell cancer or missing clinical data (Supplemental Figure S1).  
The final study population in this historical prospective cohort study comprised 5707 
TC patients. Detailed information regarding disease stage, histology and complete TC 
treatment, including relapse treatment, was collected from medical records. The clinical 
database was linked with data from the Norwegian Cause of Death Registry (NCoDR) 
updated through December 31, 2018. Mortality due to TC was not the scope of this study. 
Accordingly, SC refers to non-TC SC. 
The Regional Committee for Medical and Health Research Ethics has approved the 
study (2014/1745). Passive consent was obtained through a study information letter 
distributed to all eligible men still alive, upon which 24 (0.39%) declined participation.   
 
Staging, Treatment and Treatment Groups 
The staging of TC was performed according to the Royal Marsden Hospital staging system.21 
The TC treatment principles were modified during the study period.8 The number of PBCT 
cycles used to treat metastatic TC has been reduced, adjuvant RT for stage I seminoma was 
gradually discontinued, and a risk-adapted strategy with surveillance or 1 cycle of adjuvant 
PBCT has been implemented.12,22 
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 By total TC treatment, the study population was categorized into four groups: Surgery 
only (n=1405; 25%), PBCT (n=2521; 44%), RT (n=1550; 27%), and both PBCT and RT 
(PBCT+RT, n=231; 4.0%) (Table 1).  
  
Statistical Methods 
Median, interquartile range (IQR) and range were used to present continuous variables, and 
absolute and relative frequencies were used to present categorical variables.  
 Follow-up was defined as time from TC diagnosis date, until non-TC death date or 
censoring (date of TC-death, emigration or December 31, 2018, whichever occurred first). By 
splitting follow-up time at exact treatment dates for each treatment modality, treatment was 
analyzed as a time-varying covariate for all analyses to avoid immortal time bias. Total TC 
treatment burden, including relapse treatment, was included in the models. 
Standardized mortality ratios (SMRs) were calculated by dividing the observed 
number of deaths in the study cohort by the expected number of deaths, calculated using 
mortality rates in the general Norwegian male population, matched by 5-year age groups and 
calendar year of follow-up. Absolute excess risks (AERs) were calculated using the following 
formula: [(observed number of deaths – expected number of deaths)/person-years of 
observation]*10000. Causes of deaths were classified according to the European Shortlist 
(Supplemental Table 1).23 SMRs were calculated for total non-TC mortality, and according to 
specified non-TC SCs and groups of non-cancer causes of death if >4 deaths were observed, 
and stratified by follow-up time, age at diagnosis and attained age. For cause-specific 
analyses, all individuals with other causes of death not explicitly analyzed were censored at 
the date of death. The estimates with 95% confidence intervals (CIs) are presented for the 
total cohort and stratified on treatment modality.  
6 
 
The cumulative incidence of non-TC mortality was estimated using the Aalen-
Johansen estimator treating TC death as a competing risk and presented with 95% CIs.24  
 The impact of treatment and histology on non-TC and SC mortality were investigated 
using Cox regression adjusting for age in addition to histology and treatment. As the 
proportional hazards assumption, assessed by Schoenfeld residuals, was violated for several 
of the analyses, both histology and treatment were analyzed as time-varying coefficients, i.e., 
by including an interaction between the covariates and follow-up time. In this respect we 
dichotomized follow-up time as up-to and after 10 years. The 10-year cut-off was chosen 
based on previous research which shows that non-TC mortality increases after 10 years.2,15,16 
Accordingly, we present hazard ratios (HRs) with corresponding 95% CIs for >10 years 
follow-up time unless otherwise specified. Non-TC mortality stratified by treatment groups 
and number of cisplatin-based chemotherapy cycles were illustrated using Kaplan-Meier 
failure plots adjusted for age centered on mean, and unadjusted Kaplan-Meier curves 
including population expected risks calculated from population lifetables containing mortality 
rates stratified by 1-year age groups and calendar year. 
Data were analyzed using Stata statistical software (version MP 16.1; STATA, 
College Station, TX). A p-value <0.05 was considered statistically significant. 
 
Results 
Patient characteristics  
The median follow-up time was 18.7 years (IQR 12.7-35.0), with follow-up time >20 years 
for 46% of the 5707 study participants (Table 1). Median age at diagnosis was 33.1 years 




 Overall, 846 (15%) participants died during follow-up (Supplemental Table 1). TC 
was the cause of death for 181 (3.2%) men, of which 82% died within the first 5 years after 
diagnosis. Non-TC deaths were registered for 665 (12%) men, for which median follow-up 
time was 17.7 years (IQR 10.3-24.7), median age at diagnosis was 44.6 years (IQR 34.9-
54.7), and 67% had seminoma histology (Table 1). 
 
Total non-TC mortality  
The overall 25-year crude cumulative non-TC mortality was 13.7% (95% CI 12.5-14.9), 
whereas the population expected (PE) risk was 11.3%. The 25-year cumulative non-TC 
mortality was 10.1 % after surgery (95% CI 8.0-12.4) (PE risk 10.6%), 9.5% after PBCT 
(95% CI 7.9-11.3) (PE risk 8.1%), 19.0% after RT (95% CI 16.8-21.2) (PE risk 14.9%), and 
18.4% after PBCT+RT (95% CI 13.3-24.2) (PE risk 14.1%) (Supplemental Figure S2). 
Compared with the general population, the overall non-TC mortality in the study 
cohort was significantly increased (SMR 1.23, 95% CI 1.14-1.33) (Table 2). No excess 
mortality appeared after treatment with surgery, while mortality after treatment with PBCT, 
RT or PBCT+RT was 1.23 to 2.04-fold higher than expected.  
 SMRs due to non-TC mortality increased significantly with increasing follow-up time 
≥10 years after TC diagnosis (Table 2). After RT, increased SMRs were observed after the 
first post-diagnosis decade, while two decades passed before non-TC mortality increased 
following PBCT.  
The highest non-TC mortality risk was observed in those <20 years at TC diagnosis 
(SMR 2.27, 95% CI 1.32-3.90), particularly in those treated with PBCT (SMR 2.49, 95% CI 




SC mortality  
Non-TC SC was the cause of death in 257 (4.5%) of the study participants (Table 3), which 
constituted a 53% excess compared with the general population (SMR 1.53, 95% CI 1.35-
173). Significantly 1.43 to 3.24-fold increased SC mortality emerged after treatment with 
PBCT, RT and PBCT+RT, while no increase followed treatment with surgery alone. 
 Analyses of death due to specified SCs unveiled overall 2.09 to 4.17-fold excesses 
caused by multiple cancers (Table 3). PBCT was associated with 1.69 to 6.82-fold excess 
mortality due to cancers of the lip/oral cavity/pharynx, esophagus, lung, bladder, and 
leukemia. After RT, 3.02 to 4.91-fold excess mortality emerged for cancers of the lip/oral 
cavity/pharynx, stomach, liver, pancreas and bladder.  
 With increasing age at TC diagnosis, a decrease in SMRs for SC mortality appeared; 
from SMR 3.68 (95% CI 1.19-11.40) in those <20 years, and SMR 2.00 (95% CI 1.28-2.99) 
in those 20-30 years, to SMR 1.28 (95% CI 1.04-1.57) in those >50 years. 
  
Non-cancer mortality 
Overall, 408 (7.1%) of the participants died as a result of non-cancer causes, which was 15% 
higher than among the general population (SMR 1.15, 95% CI 1.04-1.27) (Table 4). After 
treatment with PBCT, RT and PBCT+RT, the overall non-cancer mortality was 1.17 to 1.55-
fold higher than expected. 
Deaths due to infectious diseases were 3.73-fold increased after surgery (Table 4). 
PBCT was associated with 3.29-fold increased mortality due to diseases of the genitourinary 
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system and a 1.65-fold excess of suicide compared with the general population. RT was 
associated with a 2.46-fold increased risk of death due to diseases of the digestive system.  
 Apart from the increased mortality due to other heart diseases observed after 
PBCT+RT (Table 4), the overall CVD death was not increased in the total study cohort nor 
according to treatment modality. However, CVD death within the first year of follow-up was 
significantly increased after PBCT (SMR 3.90, 95% CI 1.26-12.08, AER 10.42, n=3; two 
acute myocardial infarctions, one stroke).   
 
HRs for total non-TC mortality and SC mortality 
Compared with surgery, total non-TC mortality was 1.42 to 2.79-fold increased after 
treatment with PBCT, RT and PBCT+RT (Table 5, Figure 1A). The risk was more 
pronounced for SC mortality, with 1.69 to 3.95-fold excess risks. In the multivariable models 
including histology, the hazards for PBCT remained unchanged, while minimal changes of 
hazards were observed for RT and PBCT+RT. 
Non-TC mortality significantly increased after 4 (HR 1.41, 95% CI 1.01-1.99) and >4 
(HR 2.04, 95% CI 1.25-3.35) cisplatin-based chemotherapy cycles, compared with surgery 
(Table 5, Figure 1B). Hazards for SC mortality were significantly 1.79 to 2.85-fold increased 
after 4 and >4 cycles, respectively.  
RT with the L-field technique or paraaortic RT was associated with 1.48- to 1.60-fold 
increased non-TC mortality, and with 1.75 to 2.81-fold increased SC mortality, respectively, 
compared with surgery (Table 5). Significantly increased risks emerged after RT doses of ≥30 





We observed an excess total non-TC mortality, and in particular SC mortality, following 
treatment with PBCT or RT, but not after surgery alone when compared with the general 
population. The highest mortality risk was observed in the youngest TCS. This is, to the best 
of our knowledge, the first time the impact of number of cisplatin-based chemotherapy cycles 
on non-TC mortality was investigated in a population-based cohort with detailed TC 
treatment information. Significantly increased suicide risk emerged in the PBCT-group 
compared with the general population.  
The overall 23% excess of non-TC mortality demonstrated in this study agrees with a 
previous Norwegian study,3 and a recent publication by Sung et al.,25 but lower than the 40% 
excess non-TC mortality reported in a previous Dutch study.16 Corroborating previous studies, 
the non-TC mortality increased with follow-up time, especially beyond 20 years after TC 
diagnosis.2,16 This demonstrates that adequate follow-up time is essential when studying 
mortality in TCS. In our study, the median follow-up time was longer for RT, and this may in 
part explain some of the differences in the observed risk estimates of PBCT and RT. 
In line with previous publications,3,16,25 we observed increased mortality caused by 
SCs for the total study cohort. In agreement with the Dutch study,16 a distinct age-gradient 
emerged with decreasing risk of SC mortality with increasing age at TC diagnosis. Young age 
at TC diagnosis has been associated with an elevated SC incidence in previous studies. 8,13  
The 43% excess SC mortality emerging after PBCT is in line with a Danish study,9 
and lower than the SMR of 2.5 presented by the Dutch study.16 Active compounds of cisplatin 
have been detected in plasma for up to 20 years after treatment,26 and numerous long-term 
toxicities, including cisplatin-induced carcinogenesis, may follow this treatment.27,28  After 
PBCT, we found a 6-fold increased SMR of bladder cancer, in contrast to the Dutch study.16 
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However, increased bladder cancer incidence after PBCT has been reported in multiple 
studies.8-11 The renal clearance of cisplatin and the detection of cisplatin in urine up to 16 
years after treatment, substantiates this result.29  
In line with the Dutch study,16 increased lung cancer death emerged after PBCT, while 
no increased risk followed surgery. The same pattern has been reported in other studies of 
lung cancer incidence after TC treatment.8-11 Consistent with available literature, we found 
that mortality due to leukemia was 3-fold increased after PBCT compared with the general 
population, however based on few events.16 Increased leukemia mortality in TCS has also 
been reported in register-based studies, though without treatment details.3,25  
We report increased non-TC mortality after >2 cisplatin-based chemotherapy cycles, 
with significant hazards observed after >3 cycles. The even stronger association that emerged 
for SC mortality is in line with the Dutch study,16 although that study lacked complete 
treatment data. Statistical significance was not reached for 3 cycles, probably because of few 
numbers and a shorter follow-up time. Compared with surgery, we did not find an indication 
of increased mortality after one or two courses of adjuvant chemotherapy, however follow-up 
time was shorter than for >3 cycles.   
Consistent with previous studies,9,16-19 we found an overall 60% excess SC mortality 
after RT compared with the general population. As previously described,16,18,19 significantly 
elevated SMRs emerged for cancers within the boundaries of the prior RT field (cancers of 
the stomach, liver, pancreas and bladder), confirming the previously reported dose-
dependency.16 Because the use of adjuvant RT was discarded during the early 2000s,12 we 
expect the malignancies and mortality associated with RT to persist for the next decade, 
before gradually diminishing. 
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The overall 15% excess risk of non-cancer death is in line with previous 
publications.15,16 The 23% and 55% excess non-cancer mortality after PBCT and PBCT+RT, 
respectively, are comparable with one previous report,15 whereas two previous studies 
reported higher estimates for non-cancer mortality after PBCT.6,16 The increased mortality 
due to infections after surgery is in line with a previous study.15  
Based on available literature, there is a concern that TCS are more liable to 
committing suicide,3,18,30,31 and in the present study increased suicide risk emerged after 
PBCT compared with the general population. A population-based study from Canada recently 
reported that the use of mental health services were more common in TCS, especially in TCS 
with treatment beyond surveillance.32 Cisplatin-based chemotherapy is associated with 
numerous side-effects like fatigue, neuropathy and hypogonadism, long-term cognitive 
impairment and memory problems.33,34 Increased risk of anxiety, but not depression, has been 
observed among long-term TCS, especially in the youngest.35 A review identified passive 
coping strategies and treatment-related side effects in TCS as associated with an inferior 
psychological outcome.36 Together, these conditions may endanger TCS, and in particular the 
youngest TC patients treated with cisplatin in a vulnerable life period, for an increased suicide 
risk.37 This calls for health professionals´ increased awareness towards suicide risk factors in 
TCS in order to prevent future deaths from suicide. 
PBCT is associated with an increased long-term risk of CVD.5,7 While some studies 
have found an association between PBCT and long-term CVD mortality,5,16 other studies, 
including the present one, failed to support this association.3,6 The most likely explanation for 
the lack of an association between PBCT and CVD mortality in the present study is the 
general reduction of coronary heart disease (CHD) mortality during the last two decades, 
achieved by a reduction in modifiable CVD risk factors combined with improvement in 
treatment options for CHD.38,39 Additionally, based on increasing knowledge regarding excess 
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CVD morbidity after PBCT,40 screening for CVD risk factors was gradually implemented in 
the TC follow-up guidelines in Norway from 2007.41  
It is hypothesized that cytotoxic therapy induces an ageing phenotype that imperils 
TCS of early onset CVD or SCs,42-45 or leads to epigenetic changes in genes associated with 
metabolic syndrome.46 Unfavorable lifestyle factors (smoking, physical inactivity, unhealthy 
nutrition, alcohol abuse), may contribute to premature cellular senescence and increased SC 
risk.45 Continued tobacco use after a first cancer has in numerous studies been linked to 
increased SC risk.47 In a recent report,25 smoking-related cancers (lung, bladder, oral 
cavity/pharynx and esophagus) accounted for up to 45% of the total SC mortality. Our results, 
with increased SC mortality due to smoking- and alcohol-related cancers, support such 
observations.  
Strengths of the present study include complete information on treatment burden in an 
unselected, nationwide cohort with extended follow-up time. Incident TC cases were provided 
by the CRN, a cancer registry with very high completeness.20 Another strength is the near-
complete coverage of the NCoDR.48  
A limitation is the lack of information on possible lifestyle risk factors for cancer and 
CVD. Further, when calculating SMRs of total SC, TC deaths were not excluded from the 
background data provided by the NCoDR, leading to a potential underestimation of the 
SMRs. However, since TC deaths constitutes a small fraction of the total, this bias is 
considered negligible. When conducting multiple hypothesis testing, the risk of type 1 errors 
increases. As advised by Rothman,49 correcting for multiple testing was not done due to the 
risk of increasing type II errors. Caution must therefore be taken when interpreting results 
involving only a few cases. 
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In conclusion, TCS treated with PBCT or RT suffer increased mortality rates 
compared with the general population. The most notable excess mortality was caused by non-
TC SCs, and measures to avoid delayed SC diagnosis is essential. We hypothesize that 
cytotoxic treatment is the main risk factor for increased mortality. The increased mortality 
risk might be reduced by lifestyle improvements, which should be recommended following 
TC treatment. It is of outmost importance that TCS and health personnel involved in the 




Non-TC mortality by follow-up time adjusted for age centered on mean. A) Stratified by 
treatment group, B) Stratified by number of cisplatin-based chemotherapy cycles. The risk 
tables present the crude number of individuals by follow-up time. 
Abbreviations: TC, testicular cancer; PBCT, platinum-based chemotherapy; RT, radiotherapy 
 
Supplemental Figure S2 
Crude non-TC mortality by follow-up time, stratified by treatment group. The dashed lines 
represent population expected risks. The risk table present number of individuals by follow-up 
time. 
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Table 1. Patient Characteristics  
Characteristic Total Study Cohort 
(n = 5707) 
Non-TC Death 
(n = 665, 12%) 
Decade of first TC diagnosis   
  1980-1989 1303   (23) 342   (51) 
  1990-1999 1919   (34) 225   (34) 
  2000-2009 2485   (43)   98   (15) 
Follow-up, y, median (IQR)a  (range) 18.7 (12.7-35.0) (0.0-39.0) 17.7  (10.3-24.7) (0.0-38.2) 
Follow-up groups    
  <1     76   (1.3)   12   (1.8) 
  1-10   582   (10) 153   (23) 
  10-20 2476   (43) 214   (32) 
  20-30 1742   (31) 211   (32) 
  >30   831   (15)   75   (11) 
Age at diagnosis, y, median (IQR) (range) 33.1 (27.2-40.8) (16.0-83.8) 44.6 (34.9-54.7) (16.5-83.8) 
Age groups, y   
  <20   219   (3.8)   13   (2.0) 
  20-30 1931   (34)   81   (12) 
  30-40 2012   (35)  160   (24) 
  40-50   979   (17)  176   (27) 
  >50    566   (10)  235   (35) 
Histology   
  Seminoma 2976   (52) 447   (67) 
  Nonseminoma 2731   (48) 218   (43) 
Age at diagnosis according to histology, y, median (IQR) (range)   
  Seminoma 36.8 (31.0-44.6) (17.3-83.8) 46.6 (38.2-56.3) (18.8-83.8) 
                                    Nonseminoma 28.9 (24.2-35.5) (16.0-78.5) 36.8 (28.6-49.8) (16.5-78.5) 
Initial disease stageb   
  I 3996   (70) 456   (69) 
  Mk+/II 1144   (20) 140   (21) 
  III   119   (2.1)   27   (4.1) 
  IV   448   (7.9)   42   (6.3) 
Treatmentc   
  Surgery onlyd 1405   (25) 109   (16) 
  PBCT 2521   (44) 184   (28) 
  RT 1550   (27) 323   (49) 
  PBCT + RT   231   (4.0)   49   (7.4) 
Cause of first-line chemotherapy   
  Adjuvant, CS I   883   (32)   28   (12) 
  Primary metastatic disease 1580   (57) 175   (75) 
  Recurrence   290   (11)   30   (13) 
First chemotherapy regimen   
  BEP-20 1553   (56)   88   (38) 
  CVB   377   (14)   77   (33) 
  EP   254   (9.3)   24   (11) 
  Other cisplatin-based CTe   187   (6.8)   21   (9.0) 
  Adjuvant Carboplatin    315   (11)     8   (3.4) 
  CEB      44   (1.6)   11   (4.7) 
  Otherf       22   (0.8)     4   (1.7) 
Cumulative no. of cisplatin-based CT cyclesg   
  1   242   (10)     6   (2.8) 
  2   325   (14)   15   (7.1) 
  3   457   (19)   34   (16) 
  4 1038   (43) 124   (59) 
  > 4   337   (14)   32   (15) 
RT first field   
  L-fieldh 1408   (79) 315   (85) 
  Paraaortal   275   (15)   39   (11) 
  Supradiafragmatic     13   (0.7)     1   (0.3) 
  Supra- and infradiafragmatici     21   (1.2)   11   (3.0) 
  Otherj     64   (3.6)     6   (1.6) 
RT dose for first RT field   
  1-20 Gy     13   (0.7)     1   (0.3) 
  20-29Gy   522   (29)   54   (15) 
  30-39 Gy 1005   (56) 232   (62) 
  ≥40 Gy   241   (14)   85   (23) 
Note: Data are presented as n (%), unless otherwise stated.  
Abbreviations: TC, testicular cancer; n, number; y, years; IQR, interquartile range; Mk+, marker positive; PBCT, platinum-based 
chemotherapy; RT, radiotherapy; PBCT + RT, combination of PBCT and RT; CS I, clinical stage I; BEP-20, bleomycin, etoposide and 
cisplatin; CVB, cisplatin, vinblastine and bleomycin; EP, etoposide and cisplatin; CEB, carboplatin, etoposide and bleomycin; CT, 
chemotherapy; no, number; Gy, grey.  
  
a Follow-up until death of all causes, emigration or December 31st 2018, whichever occurred first.  
b As described by Peckham et al.21  
c Based on total treatment burden. 
d The surgery only group included men followed with surveillance after orchiectomy (n = 1167; 21%) and men who underwent additional 
retroperitoneal lymph node dissection without PBCT or RT (n = 250; 4.4%). Also included in this group are 4 men who were diagnosed with 
clinical stage IV but for various reasons did not receive further treatment. 
e Of which a total of 143 were dose-escalated cisplatin-based chemotherapy.  
f Carboplatin monotherapy in metastatic setting (n=17), sendoxan/adriamycin (n=1), CAOS (actinomycin D, adriamycin, vincristine, 
sendoxan) (n=3), actinomycin D (n=1). 
g Only cisplatinbased chemotherapy cycles are accounted for in cumulative number. A total of 350 men received carboplatin-based 
chemotherapy (adjuvant carboplatin monotherapy n=299, other carboplatin-based chemotherapy (n=52)). In total two men received non-
PBCT (actinomycin D (n=1), CAOS (actinomycin D, adriamycin, vincristine, sendoxan) (n=1)). 
h L-field or dogleg-field. Included in this category are also 55 individuals who received RT of groin in addition to L-field and 2 individuals 
who received a reversed Y-field. 
i 16 of 21 individuals received infradiafragmatic RT as first RT-field and a short while later received supradiafragmatic RT. 




                                                          
Table 2. Total Non-TC Mortality by Follow-up Time, Age at Diagnosis and Attained Age According to Treatment Group 
 
Variable Total cohort Surgery PBCT RT PBCT + RT 
 n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER 
Total non-TC death 665 1.23 (1.14-1.33) 11.14 109 0.95 (0.79-1.14) -2.21 184 1.23 (1.07-1.43) 7.68 323 1.28 (1.15-1.43) 19.55 49 2.04 (1.54-2.70) 75.45 
Follow-up time                
 <1 year 12 0.84 (0.48-1.48) -3.94 3 0.64 (0.21-1.98) -9.07 5 1.29 (0.54-3.10) 5.23 3 0.55 (0.18-1.71) -15.26 1 4.48 (0.63-31.80) 129.68 
 >1-10 years 153 1.01 (0.86-1.18) 0.20 42 1.08 (0.80-1.46) 2.48 48 1.02 (0.77-1.35) 0.41 57 0.94 (0.77-1.35) -2.66 6 1.12 (0.50-2.49) 5.15 
 10-20 years 214 1.15 (1.01-1.32) 7.48 35 0.86 (0.62-1.20) -6.70 53 1.04 (0.80-1.37) 1.48 109 1.25 (1.04-1.51) 16.87 17 2.29 (1.42-3.69) 79.65 
 20-30 years 211 1.48 (1.29-1.69) 42.00 26 1.11 (0.76-1.63 8.04 60 1.68 (1.30-2.16) 41.43 107 1.41 (1.17-1.70) 47.73 18 2.37 (1.49-3.76) 154.89 
 30-40 years 75 1.64 (1.31-2.06) 89.51 3 0.41 (0.13-1.27) -61.53 18 1.55 (0.98-2.46) 50.89 47 2.01 (1.51-2.67) 203.24 7 2.05 (0.98-4.31) 234.21 
Age at diagnosis                
 <20 years 13 2.27 (1.32-3.90) 14.42 3 2.06 (0.66-6.34) 11.78 9 2.49 (1.29-4.78) 16.55 0 0  -13.71 1 4.52 (0.64-32.06) 50.97 
 20-30 years 81 1.26 (1.01-1.56) 4.06 14 0.84 (0.50-1.42) -2.34 42 1.42 (1.05-1.92) 6.28 21 1.29 (0.84-1.99) 5.47 4 1.94 (0.73-5.17) 18.88 
 30-40 years 160 1.36 (1.16-1.58) 10.58 22 0.93 (0.62-1.42) -1.75 45 1.22 (0.91-1.64) 5.67 81 1.53 (1.23-1.90) 18.44 12 2.57 (1.46-4.53) 61.40 
 40-50 years 176 1.42 (1.23-1.65) 29.47 20 1.05 (0.67-1.63) 2.59 41 1.28 (0.94-1.74) 15.99 95 1.43 (1.17-1.75) 36.80 20 3.04 (1.96-4.71) 208.58 
 >50 years 235 1.03 (0.91-1.17) 7.58 50 0.92 (0.70-1.22) -20.79 47 1.00 (0.75-1.33) -0.56 126 1.08 (0.91-1.29) 23.40 12 1.14 (0.65-2.01) 51.44 
Attained age                
 <40 years 51 1.21 (0.92-1.59) 2.25 12 1.04 (0.59-1.84) 0.44 26 1.29 (0.88-1.90) 3.00 12 1.26 (0.72-2.22) 3.13 1 1.04 (0.15-7.41) 0.48 
 40-60 years 227 1.31 (1.15-1.49) 9.26 45 1.25 (0.94-1.68) 7.06 82 1.37 (1.10-1.70) 10.03 84 1.17 (0.95-1.45) 6.02 16 2.46 (1.51-4.01) 51.53 
 60-75 years 235 1.25 (1.10-1-42) 36.68 20 0.57 (0.37-0.88) -63.11 47 1.06 (0.79-1.40) 7.47 143 1.44 (1.22-1.69) 67.42 25 2.76 (1.87-4.09) 295.23 
 >75 years 152 1.12 (0.95-1.31) 77.77 32 0.99 (0.70-1.40) -6.73 29 1.18 (0.82-1.70) 112.62 84 1.17 (0.94-1.45) 112.56 7 0.93 (0.44-1.95) -51.54 
Note: Significant associations for SMRs are marked with bold.  
Abbreviations: TC, testicular cancer; PBCT, platinum-based chemotherapy; RT, radiotherapy; n, number; SMR, standardized mortality ratio; 95% CI, 95% confidence interval, AER, absolute excess risk. 
 
Table 3. Risk of Deaths Due to Non-TC Second Cancers (if >4 Deaths Observed) According to Treatment Groups 
Cause of Death Total Surgery PBCT RT PBCT + RT EU 
codei 
 n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER  
Total non-TC SC 257 1.53 (1.35-1.73) 7.94 39 1.13 (0.83-1.55) 1.71 64 1.43 (1.12-1.83) 4.25 130 1.59 (1.34-1.89) 13.38 24 3.24 (2.17-4.83) 50.13 2.1- 
TC 
Specified cancers                 
 Oral cavity, pharynxii 9 3.89 (2.03-7.48) 0.60 0 0 -0.17 4 6.82 (2.56-18.16) 0.75 5 4.28 (1.78-10.27) 1.06 0 0 -0.30 2.1.1 
 Esophagus 7 2.29 (1.09-4.80) 0.35 3 4.83 (1.56-14.97) 0.88 3 3.74 (1.21-11.59) 0.48 1 0.66 (0.09-4.69) -0.14 0 0 -0.36 2.1.2 
 Stomach 18 2.92 (1.84-4.63) 1.06 3 2.45 (0.79-7.59) 0.66 1 0.69 (0.10-4.90) -0.10 10 3.15 (1.69-5.85) 1.89 4 12.85 (4.82-34.23) 11.15 2.1.3 
 Colorectaliii  29 1.31 (0.91-1.88) 0.61 3 0.66 (0.21-2.06) -0.56 10 1.73 (0.93-3.22) 0.93 15 1.38 (0.83-2.28) 1.13 1 1.01 (0.14-7.14) 0.03 2.1.4 
 Liveriv  5 1.75 (0.73-4.20) 0.19 1 1.67 (0.24-11.85) 0.15 0 0 -0.18 4 3.02 (1.13-8.04) 0.74 0 0 -0.33 2.1.5 
 Pancreas 33 3.20 (2.28-4.51) 2.03 5 2.40 (1.00v-5.78) 1.08 3 1.10 (0.35-3.40) 0.06 22 4.36 (2.87-6.62) 4.70 3 6.86 (2.21-21.27) 7.74 2.1.6 
 Lungvi  49 1.26 (0.95-1.66) 0.89 3 0.39 (0.13-1.21) -1.73 17 1.69 (1.05-2.72) 1.53 25 1.28 (0.86-1.89) 1.23 4 2.30 (0.86-6.13) 6.83 2.1.8 
 Melanoma of skin 8 1.38 (0.69-2.77) 0.20 3 2.52 (0.81-7.82) 0.67 1 0.59 (0.08-4.21) -0.15 3 1.12 (0.36-3.47) 0.09 1 4.43 (0.62-31.43) 2.33 2.1.9 
 Prostate 14 0.78 (0.46-1.32) -0.35 1 0.26 (0.04-1.88) -1.03 3 0.79 (0.25-2.45) -0.18 7 0.74 (0.35-1.55) -0.68 3 3.27 (1.06-10.15) 6.29 2.1.14 
 Kidney 5 1.26 (0.53-3.03) 0.09 2 2.53 (0.63-10.14) 0.45 1 1.03 (0.15-7.34) 0.01 2 0.99 (0.25-3.95) -0.01 0 0 -0.54 2.1.15 
 Bladder 16 4.17 (2.56-6.81) 1.09 1 1.23 (0.17-8.75) 0.07 5 6.33 (2.63-15.21) 0.93 10 4.91 (2.64-9.13) 2.20 0 0 -0.60 2.1.16 
 Brain and CNS 10 1.32 (0.71-2.45) 0.22 3 1.89 (0.61-5.86) 0.52 5 2.07 (0.86-4.96) 0.57 2 0.61 (0.15-2.42) -0.36 0 0 -0.85 2.1.17 
 Lymphomavii 5 1.12 (0.46-2.68) 0.05 3 3.45 (1.11-10.70) 0.79 0 0 -0.24 1 0.43 (0.06-3.05) -0.37 1 4.83 (0.68-34.30) 2.39 2.1.19 
 Leukemia 8 2.09 (1.05-4.19) 0.37 0 0 -0.29 3viii 3.26 (1.05-10.12) 0.46 4 2.04 (0.77-5.44) 0.57 1 5.74 (0.81-40.76) 2.51 2.1.20 
Note: Significant associations for SMRs are marked with bold.  
Abbreviations: TC, testicular cancer; PBCT, platinum-based chemotherapy; RT, radiotherapy; SMR, standardized mortality ratio; n, number; 95% CI, 95% confidence interval; AER, absolute excess risk. 
i Eurostat. European Shortlist of Causes of Death, May 2012. Available from: 
http://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_NOM_DTL&StrNom=COD_2012&StrLanguageCode=EN&IntPcKey=&StrLayoutCode=HIERARCHIC. 
 
ii Lip, oral cavity and pharynx 
iii Colon, rectum and anus 
iv Liver and intrahepatic bile ducts 
v 0.997 
vi Trachea, bronchus and lung 
vii Hodgkin disease and lymphomas 
viii Time to leukemia death from PBCT: 2.6 years (4 cycles PBCT), 17.8 years (3 cycles PBCT) and 27.1 years (>4 cycles PBCT).  
                                                          
Table 4. Risk of Death Due to Selected Non-Cancer Causes According to Treatment Groups 
 
Cause of Death Total Surgery PBCT RT PBCT + RT  EU 
code
a 
 n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER n SMR (95% CI) AER  
Non-cancer death, total 408 1.15 (1.04-1.27) 4.71 70 0.92 (0.72-1.16) -2.40 120 1.23 (1.03-1.47) 4.95 193 1.17 (1.01-1.34) 7.68 25 1.55 (1.05-2.30) 26.86  
Infectious and parasitic diseases 15b 2.35 (1.42-3.90) 0.77 5 3.73 (1.55-8.95) 1.36 4 2.49 (0.94-6.64) 0.53 6 1.91 (0.86-4.25) 0.79 0 0 -0.88 1. 
Endocrine and metabolic diseasesc 12 1.13 (0.64-1.99) 0.12 2 0.91 (0.23-3.64) -0.07 0 0 -0.63 9 1.76 (0.91-3.37) 1.07 1 2.16 (0.30-15.37) 1.63 4. 
Mental and behavioural disorders  18 1.00 (0.63-1.59) 0.00 3 0.79 (0.26-2.45) -0.29 2 0.38 (0.09-1.51) -0.72 12 1.47 (0.84-2.59) 1.07 1 1.34 (0.19-9.49) 0.76 5. 
Diseases of the nervous systemd 20 1.16 (0.75-1.80) 0.25 5 1.38 (0.57-3.31) 0.51 6 1.27 (0.57-2.83) 0.28 8 0.98 (0.49-1.96) -0.04 1 1.40 (0.20-9.91) 0.85 6. 
Cardiovascular disease 151 1.01 (0.86-1.18) 0.08 28 0.89 (0.62-1.29) -1.25 42 1.18 (0.87-1.60) 1.41 71 0.94 (0.75-1.19) -1.23 10 1.29 (0.69-2.40) 6.83 7. 
 Ischemic heart diseases 90 1.12 (0.91-1.37) 0.84 20 1.22 (0.79-1.89) 1.34 22 1.16 (0.77-1.77) 0.68 45 1.10 (0.82-1.47) 1.10 3 0.70 (0.22-2.16) -3.96 7.1 
 Other heart diseases  31 1.37 (0.97-1.95) 0.75 5 1.03 (0.43-2.47) 0.05 9 1.76 (0.91-3.34) 0.85 11 0.96 (0.53-1.73) -0.13 6e 5.30 (2.38-11.81) 14.72 7.2 
 Cerebrovascular diseases 17 0.65 (0.40-1.05) -0.82 1 0.18 (0.03-1.27) -1.71 6 1.04 (0.47-2.31) 0.05 9 0.67 (0.35-1.29) -1.22 1 0.73 (0.10-5.20) -1.09 7.3 
 Other circulatory diseases 13 0.85 (0.49-1.46) -0.21 2 0.63 (0.16-2.52) -0.44 5 1.45 (0.60-3.48) 0.34 6 0.76 (0.34-1.69) -0.53 0 0 -2.36 7.4  
Diseases of the respiratory system 33 0.96 (0.68-1.35) -0.13 2 0.27 (0.07-1.09) -1.99 10 1.29 (0.70-2.40) 0.50 18 1.02 (0.64-1.62) 0.10 3 1.78 (0.57-5.53) 3.99 8. 
Diseases of the digestive system  32 1.89 (1.34-2.67) 1.35 4 1.15 (0.43-3.089 0.20 6 1.31 (0.59-2.91) 0.31 20 2.46 (1.59-3.82) 3.29 2 2.68 (0.67-10.71) 3.78 9. 
Diseases of the genitourinary system 7 1.55 (0.74-3.24) 0.22 2 1.96 (0.49-7.85) 0.36 3f 3.29 (1.06-10.21) 0.46 1 0.42 (0.06-3.02) -0.37 1 4.07 (0.57-38.89) 2.27 12. 
External causes 85 1.25 (1.01-1.55) 1.52 14 0.87 (0.51-1.46) -0.79 35 1.34 (0.96-1.86) 1.95 32 1.36 (0.96-1.92) 2.34 4 1.79 (0.67-4.78) 5.35 17. 
 Accidents 51 1.22 (0.93-1.61) 0.83 9 0.91 (0.48-1.76) -0.32 19 1.22 (0.78-1.92) 0.76 21 1.41 (0.92-2.16) 1.68 2 1.41 (0.35-5.64) 1.75 17.1 
 Suicide  33 1.38 (0.98-1.94) 0.81 4 0.70 (0.26-1.86) -0.65 16 1.65 (1.01-2.69) 1.39 11 1.41 (0.78-2.55) 0.89 2 2.73 (0.68-10.93) 3.84 17.2 
Note:  The table present results for those main groups of causes of death (as defined by EU-codes) if >4 deaths observed. Significant associations for SMRs are marked with bold.  
Abbreviations: PBCT, platinum-based chemotherapy; RT, radiotherapy; n, number; SMR, standardized mortality ratio; 95% CI, 95% confidence interval; AER, absolute excess risk. 
 
a Eurostat. European Shortlist of Causes of Death, May 2012. Available from: 
http://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_NOM_DTL&StrNom=COD_2012&StrLanguageCode=EN&IntPcKey=&StrLayoutCode=HIERARCHIC. 
 
b Of which AIDS = 3 
c Endocrine, nutritional and metabolic diseases 
d Diseases of the nervous system and the sense organs 
e Two participants received supradiaphragmatic RT. The following diseases were listed as cause of death: Endocarditis=1, mitral valve disease=1, aortic valve disease = 2, unspecified heart disease = 1, cardiomyopathy=1.  
f Kidney failure (n=1), urinary tract infection (n=1), prostatitis (n=1). 
                                                          
Table 5. HRs for Total Non-TC Mortality and Non-TC SC Mortality According to Treatment 
Groups, Treatment Intensity and Histology After >10 Years of Follow-up 
 All non-TC mortality Non-TC SC mortality Follow-up, y, 
median (IQR) 
Variable Age-adjusted 
HR (95% CI) 
Multivariable 
HR (95% CI) 
Age-adjusted 
HR (95% CI) 
Multivariable 
HR (95% CI) 
 
Treatment Groups      
 Surgery 1 (ref) 1 (ref) 1 (ref) 1 (ref) 16.8 (12.1-24.0) 
 PBCT 1.42 (1.05-1.91) 1.42 (1.05-1.91) 1.69 (1.05-2.73) 1.69 (1.05-2.73) 16.8 (11.6-23.9) 
 RT 1.61 (1.23-2.12) 1.94 (1.39-2.73) 1.87 (1.20-2.90) 1.83 (1.07-3.14) 23.3 (17.7-28.8) 
 PBCT + RT 2.79 (1.89-4.13) 3.27 (2.14-5.00) 3.95 (2.22-7.02) 3.89 (2.06-7.33) 17.0 (3.7-26.3) 
Cisplatin-based chemotherapy cyclesi      
 Surgery 1 (ref) 1 (ref) 1 (ref) 1 (ref)  
 1 0.79 (0.25-2.53) 0.78 (0.25-2.49) NA NA 13.0 (9.9-17.0) 
 2 0.43 (0.16-1.19) 0.43 (0.15-1.17) 0.30 (0.04-2.20) 0.30 (0.04-2.21) 17.1 (13.5-22.3) 
 3 1.47 (0.91-2.39) 1.43 (0.88-2.33) 1.64 (0.76-3.54) 1.65 (0.76-3.56) 16.7 (11.7-24.2) 
 4 1.41 (1.01-1.99) 1.43 (1.02-2.01) 1.79 (1.06-3.04) 1.79 (1.05-3.03) 20.7 (14.0-28.1) 
 >4 2.04 (1.25-3.35) 1.98 (1.21-3.25) 2.85 (1.40-5.84) 2.87 (1.40-5.88) 18.4 (4.0-25.6) 
 Carboplatin, adjuvant 1.21 (0.38-3.86) 1.39 (0.43-4.52) 2.33 (0.55-9.97) 2.29 (0.52-10.05) 11.2 (10.0-12.8) 
RT field      
 Surgery 1 (ref) 1 (ref) 1 (ref) 1 (ref)  
 L-field 1.60 (1.21-2.12) 1.94 (1.38-2.73) 1.75 (1.12-2.74) 1.71 (0.99-2.96) 24.4 (18.1-29.7) 
 Paraaortic 1.48 (0.89-2.44) 1.77 (1.03-3.03) 2.81 (1.45-5.45) 2.75 (1.33-5.67) 19.6 (16.3-23.0) 
 Supra & infradiafragmatic 5.07 (2.04-12.63) 6.17 (2.42-15.70) 5.11 (1.20-21.68) 4.98 (1.13-21.91) 12.5 (3.5-27.3) 
RT dose for first abdominal RT-field      
 Surgery 1 (ref) 1 (ref) 1 (ref) 1 (ref)  
 1-20 Gy 1.75 (0.24-12.69) 2.05 (0.28-14.97) NA NA 18.5 (13.1-21.4) 
 20-29 Gy 1.31 (0.87-1.98) 1.55 (0.98-2.44) 1.93 (1.06-3.52) 1.84 (0.94-3.59) 19.5 (15.5-22.2) 
 30-39 Gy 1.68 (1.26-2.23) 2.00 (1.41-2.85) 1.69 (1.06-2.70) 1.60 (0.91-2.82) 25.6 (19.5-29.8) 
 ≥40 Gy 1.54 (1.04-2.28) 1.85 (1.18-2.88) 2.33 (1.32-4.11) 2.20 (1.14-4.24) 32.4 (23.5-35.7) 
Histology      
 Nonseminoma 1 (ref) 1 (ref) 1 (ref) 1 (ref) 19.5 (12.9-26.9) 
 Seminoma  1.23 (1.02-1.50) 0.93 (0.71-1.23) 1.34 (1.00-1.80)ii 1.10 (0.71-1.69) 18.0 (12.6-25.1) 
Note: The multivariable models investigating treatment variables were adjusted for histology in addition to age at TC diagnosis. The 
multivariable models investigating histology were adjusted for treatment groups in addition to age at TC diagnosis. 
Abbreviations: HR, hazard ratio; TC, testicular cancer; SC, second cancer; y, years; 95% CI, 95% confidence interval; RT, radiotherapy; NA, 
not applicable; Gy, gray.  
 
 
i Numbers 1 to >4 refers to number of cisplatin-based chemotherapy cycles. Carboplatin adjuvant refers to carboplatin monotherapy in 
adjuvant setting for stage I seminoma.  
ii P-value= 0.054 
                                                          















Excluded (n=274, 4.3%) 
 Extragonadal localization (ICD-7 178.4) (n=180) 
 Localization ductus deferens or funicle (ICD-
7 178.3) (n=24) 
 Localization epididymis (ICD-7 178.2) (n=4) 
 Age < 16 years (n=66) 
   
  
Males diagnosed with germ cell TC in the NCR (coded 
with localization ICD-7 178.x) between 01/01/1980-
12/31/2009 (n=6354) 
Excluded (n=333 5.5%) 
 Previous diagnosis of non-TC cancer (n=58) 
 TC before 1980 (n=27) 
 Extragonadal localization (n=51) 
 Clinical data missing in medical records (n=55) 
 Other histology than GC cancer (n=99) 
 Treated abroad (n=11) 
 Clincial diagnosis only/histology not performed 
(n=11) 
 Other causes (n=2) 
 Synchronous non-TC diagnosis (n=19) 
 
 
Cohort for the analysis of mortality after TC = study 
population (n=5707, 90%) 
 
Dataset used as basis for information letter                
(n=6080, 95.7%) 
 Declined to participate (n=24, 0.39%) 
 
Dataset used as basis for collection of clinical data 
(n=6056, 95.3%) 
 
Excluded from the present study (n=16, 0.3%) due to the 
following events: 
 Post mortem diagnosis of TC (n=11)  
 Emigration before diagnosis of TC (n=5) 
Cohort of TCS with complete clinical data              
(n=5723, 90.1%) 
Abbreviations: TC, testicular cancer; NCR, the Norwegian Cancer Registry; ICD-7, International Classification of Diseases version 7, GC, 
germ cell; TCS, testicular cancer survivors. 
 






Supplemental Table 1. All Causes of Death in the Study Cohort According to Time Since TC Diagnosis 
Causes of Death All 1 y >1-10 y >10-20 
y 
>20-30 y >30 
y 
EU codea 
Total 846 73 251 227 218 77  
TC 181 61 98 13 7 2  
Total excluding TC 665 12 153 214 211 75  
Non-TC second cancers, total 257 1 34 90 97 35 2.1 excl. 
TC 
 Lip, oral cavity, pharynx 9 0 1 4 4 0 2.1.1 
 Oesophagus 7 0 1 3 3 0 2.1.2 
 Stomach 18 0 2 11 3 2 2.1.3 
 Colon, rectum and anus 29 0 3 8 15 3 2.1.4 
 Liver and intrahepatic bile ducts 5 0 0 2 2 1 2.1.5 
 Pancreas 33 0 6 8 13 6 2.1.6 
 Larynx 2 0 0 0 2 0 2.1.7 
 Trachea, bronchus and lung 49 0 3 17 24 5 2.1.8 
 Melanoma of skin 8 0 1 5 2 0 2.1.9 
 Breast 1 0 0 0 1 0 2.1.10 
 Prostate 14 0 1 5 4 4 2.1.14 
 Kidney 5 0 1 1 2 1 2.1.15 
 Bladder 16 0 1 1 8 6 2.1.16 
 Brain and CNS 10 0 3 6 1 0 2.1.17 
 Hodgkin disease and lymphomas 5 0 2 2 1 0 2.1.19 
 Leukemia 8 0 4 2 2 0 2.1.20 
 Other malignant hematological neoplasmsb 2 0 0 0 0 2 2.1.21 
 Other malignant neoplasms 36 1 5 15 10 5 2.1.22 
Non-cancer death, total 408 11 119 124 114 40  
 Infectious and parasitic diseases  15c 1 6 3 4 1 1. 
 Diseases of the blood and blood-forming organsd 2 0 0 1 0 1 3. 
 Endocrine, nutrional and metabolic diseases 12 0 0 6 4 2 4. 
 Mental and behavioural disorders  18 1 8 1 6 2 5. 
 Disease of the nervous system  20 0 11 3 5 1 6. 
 Cardiovascular disease 151 6 42 50 38 15 7. 
  Ischemic heart disease 90 4 26 29 23 8 7.1 
  Other heart diseases  31 1 7 11 9 3 7.2 
  Cerebrovascular diseases 17 1 8 6 1 1 7.3 
  Other circulatory  13 0 1 4 5 3 7.4  
 Diseases of the respiratory system 33 1 6 9 10 7 8. 
 Diseases of the digestive system  32 0 8 10 13 1 9. 
 Diseases of the musculoskeletal system 1 0 0 0 0 1 11. 
 Diseases of the genitourinary system 7 1 3 3 0 0 12. 
 Ill-defined 13 0 1 3 8 1 16. 
 Missinge 18       
 External causes 85 1 34 28 16 6 17. 
  Accidents 51 1 16 16 14 4 17.1 
  Suicide  33 0 17 12 2 2 17.2 
Note: Subgroups of causes of death are marked in cursive, they are also included in main groups as defined by the EU shortlist. 
Abbreviations: TC, testicular cancer; y, year. 
  
a Eurostat. European Shortlist of Causes of Death, May 2012. Available from: 
http://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_NOM_DTL&StrNom=COD_2012&StrLanguageCode=EN&IntPcKey=&StrLayoutCode=HIERARCHIC. 
 
b Other malignant neoplasms of lymphoid and haematopoietic tissue 
c Of which AIDS n=3 
d Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism 
e Missing death diagnosis was no longer given an R-diagnosis from 1996 and onwards 
                                                          
 
 
 
 
 
